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ABBREVIATIONS 
 
 
AKT RAC-α serine/threonine-protein kinase 
Abl Abelson proto-oncogene 
ALK Anaplastic lymphoma kinases 
AP-1 Transcription factor activator protein 1 
ATP Adenosine triphosphate 
BAFF B cell-activating factor 
BAFFR B cell-activating factor receptor 
Bcl Protein family which's founder was discovered at the chromosomal 
breakpoint of t(14;18) bearing human B-Cell Lymphomas 
Bcr Breakpoint cluster region 
BLC B lymphocyte chemoattractant 
BMimpF6 1-Butyl-3-methylimidazolium hexafluorophosphate 
CBS Bio-Structural Chemistry laboratory 
CDK4 Cyclin-dependent kinase 4 
cIAP Baculoviral Inhibitor of Apoptosis repeat-containing protein 
cKIT Citokine receptor encoded by the kit gene 
CML Chronic myelogenous (or myeloid) leukemia 
COX-2 Cyclooxygenase 2 
Cpd Compound 
DDR1 Discoidin domain receptor tyrosine kinase 1 
DEC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide  
DHMEQ Dehydroxymethylepoxyquinomicin 
DMARD Disease-modifying anti-rheumatic drug 
DNA Desoxyribonucleic acid 
EBV Epstein Barr virus 
EGFR Epidermal growth-factor receptor 
ELC Epstein-Barr virus induced molecule 1 ligand chemokine 
erk Extracellular signal-regulated kinases 
ESI Ionisation electro-spray 
Et Ethyl 
FADD Fas (TNFRSF6)-associated via death domain 
FLS Fibroblast-like synoviocyte 
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FRET Fluorescence resonance energy transfer 
GIST Gastrointestinal stromal tumor 
H Hydrogen 
HDAC Histone Deacetylase 
HEK Human embryonic kidney 
HeLa  Cell line was derived from cancer cells taken from Henrietta Lacks 
HER Human Epidermal growth factor Receptor 
HS Hypereosinophilic syndrome 
HOBt 1-Hydroxybenzotriazol 
HTLV Human T-cell lymphotrophic virus 
ICAM-1 Intracellular adhesion molecule-1 
IKK IκB kinase 
IL Interleukin 
ILR Interleukin receptor 
iNOS Inducible nitric oxyde synthase 
IRAK Interleukin receptor associated kinase 
IκB Inhibitor of NF-κB 
JNK c-Jun N-terminal kinase  
KA ent-kaurenoic acid 
LIGHT TNF superfamily member homologous to lymphotoxins 
LPS Lipopolysaccharides 
LRR Leucine rich region 
LTB  Lymphotoxin β 
LTβR Lymphotoxin β receptor 
MAP Mitogen activated protein 
Me Methyl 
MEK MAP-erk kinase 
MKK Mitogen-activated protein kinase kinase 
mTOR Mammalian Target of Rapamycin 
Myc Gene encoding for a transcription factor 
NDO Number of different orientations 
NEMO NF-κB essential modulator - also known as IκB kinase gamma (IKKγ) 
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NF-κB Nuclear Factor κB 
NIK NF-κB inducing kinase 
NLR NACHT-LRR 
NSAID Non-steroidal anti-inflammatory drug 
NSCLC Non-small cell lung cancer 
O Oxygen 
OH Hydroxy 
OMe Methoxy 
PAK p21 activated kinases 
PDB protein databank 
PDGFR Platelet-derived growth-factor receptor 
PDK 3-phosphoinositide dependent protein kinase-1 
Ph Phenyl 
PI3K phosphatidylinositol 3-kinase 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PIP3 Phosphatidylinositol-3,4,5-trisphosphate 
Pr Propyl 
PRR Pathogen-recognition receptors 
RA Rheumatoid arthritis 
RCC Renal cell carcinoma 
Rel Protein structurally related to the NF-κB family  
RHD Rel Homology Domain 
SLO Secondary lymphoid organ 
SRC Sarcoma (proto-oncogenic tyrosine kinases) 
TAK1 TGF-β Activated kinase 1 
Tec Tyrosine-protein kinase encoded by the tec gene 
TGF Transforming Growth Factor 
TLC Thin Lame Chromatography 
TLO Tertiary lymphoid organ 
TLR Toll-like receptor 
TMS Trimethylesilane 
TNF Tumor necrosis factor 
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TNFL Tumor necrosis factor ligand 
TNFR Tumor necrosis factor receptor 
TRADD TNFRSF1A-associated via death domain 
TRAF TNFR Associated Factor 
VEGFR Vascular endothelial growth-factor receptor 
VS Virtual screening 
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 AMINO ACIDS  
A Ala alanine 
 
M Met methionin
e 
 
C Cys cysteine 
 
N Asn asparagine 
 
D Asp aspartic acid 
 
P Pro proline 
 
E Glu glutamic 
acid 
 
Q Gln glutamine 
 
F Phe phenyl-
alanine 
 
R Arg arginine 
 
G Gly glycine 
 
S Ser serine 
 
H His histidine 
 
T Thr threonine 
 
I Ile isoleucine 
 
V Val valine 
 
L Leu leucine 
 
W Trp trypto-phane 
 
K Lys lysine 
 
Y Tyr tyrosine 
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1.  Rheumatoid Arthritis 
 
 Rheumatoid arthritis (RA) is a systemic autoimmune disease 
affecting around 1-2% of worldwide population with a men/woman ratio of 
2.5/1, and a worldwide geographical distribution.  Clinically, RA manifests 
as a symmetric arthritis associated with swelling and pain in multiple joints. 
It often initially occurs in the joints of the hand, wrists, and feet, but disease 
onset is insidious in most cases, and several months can elapse before 
ascertaining a firm diagnosis.1,2 An inflamed synovium is central to the 
pathophysiology of RA and the main histological changes are characterised 
by pronounced angiogenesis, cellular hyperplasia, inflammatory leucocytes 
influx and changes in the expression of cell-surface adhesion molecules. As 
the synovial lining becomes hyperplasic, the sublining undergoes striking 
alterations in cellular number and content (T cells, B cells, macrophages and 
plasma cells).1 A locally invasive synovial tissue (pannus) is then formed, 
growing into the synovium region and leading to the progressive destruction 
of cartilage and bone (Figure 1).3,4 
 
 Many cytokines such as tumor necrosis factor α (TNFα) and 
interleukin-1β (IL-1β) are abundant in RA synovium.5-7 Produced by 
macrophages and fibroblast-like synoviocytes (FLS), TNFα and IL-1β likely 
contribute to synovial inflammation by stimulating fibroblast proliferation 
and increasing production of various cytokines, chemokines as well as 
enzymes that result in irreversible joint destruction. In turn, these cytokines 
can activate macrophages in the environment and lead to continued cytokine 
production.  
 20 
 
Figure 1: Evolution of RA in knee joint8 
 
 Such conditions create a positive feedback mechanism between FLS 
and macrophages, perpetuating synovial inflammation.9 In the synovium, 
these inflammatory mediators activate multiple intracellular signal 
transduction and transcription factor pathways. Most of these signalling 
pathways lead to the activation of the transcription factor NF-κB, the 
transcription factor activator protein 1 (AP-1) and the mitogen activated 
1 
2 
3 
 21 
protein (MAP) kinases cascade which are especially central in the regulation 
of synovial inflammation.10 In 2002, the importance of NF-κB in constitutive 
TNFα production in RA was demonstrated, predicting that blocking NF-κB 
should be an effective therapeutic target for this pathology.11 
 
 
 
2.  Therapeutic principles 
 
Medications which are used to treat RA are divided into four main 
classes:  
1. non-steroidal anti-inflammatory drugs (NSAIDs) including 
cyclooxygenase-2 (COX-2) inhibitors; 
2. corticosteroids ;  
3. disease-modifying anti-rheumatic drugs (DMARDs);  
4. biologic agents.  
 
NSAIDs are particularly helpful during the first few weeks in which 
the patient develops symptoms.  These drugs provide partial relief of pain 
and stiffness until a definitive diagnosis of RA can be established.12 Both 
traditional NSAIDs and COX-2 inhibitors have been associated with various 
side effects (gastric and duodenal ulcers, increased fluid retention, 
exacerbation of hypertension, impairment of renal function in susceptible 
patients).13-16  
 
Corticosteroids are also potent suppressors of the inflammatory 
response in RA despite their dose-dependent side effects (skin thinning, 
cataracts, osteoporosis, hypertension and hyperlipidemia).12,17,18 Controversy 
continues about their therapeutical scheme in the treatment of RA. 
Nevertheless, some studies established that corticosteroids decrease the 
progression of RA.19,20 
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Considering that drugs should be used to slow down the damage 
caused by the disease rather than simply to control symptoms led to the 
introduction of various agents known as DMARDs.21  These drugs are 
defined as medications that delay or stop the progression of the disease.12  
Methotrexate emerged as the lead molecule of the antirheumatic arsenal 
(Figure 2).22  This antimetabolite and antifolate drug was shown to have a 
considerable protective effect in terms of joint destruction.23,24 It 
demonstrated efficacy, durability,  acceptable toxicity and low cost.12,25 An 
observational study has shown that patients with RA who have been treated 
with methotrexate have significantly lower mortality than untreated 
patients.26 Methotrexate became then the most widely used, alone or in 
combination with other DMARDs (like sulphasalazine or hydroxychloro-
quine).12,27  
 
 
Figure 2: Methotrexate, sulphasalazine and hydroxychloroquine (from left to right) 
 
But, as the last 20 years have seen an accumulation of insights into 
the pathogenetic pathways, new therapeutic targets have been identified.8 
One of the major advances in the treatment of RA occurred with biologic 
agents (also known as biologic DMARDs) produced through expression of 
recombinant DNA and modifying the immune response by blocking the 
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effect of the pro-inflammatory cytokines.28  In 1999, infliximab (a 
monoclonal antibody, figure 3) and etanercept (a fusion protein) were the 
first anti-TNFα registered and marketed. Then, several new biologic agents 
were designed to target specific cytokines like IL-1 and TNFα,29 or cell 
surface molecule like IL-1R,30 IL-6R,29,31 and CD20 (phosphoprotein 
expressed on the surface of all mature B-cells).32,33 Thousands of patients 
have then been treated with anti-TNFα, leading to the identification of 
multiple mechanisms of action for these medications.34 However, a wider 
use of TNFα antagonists resulted in reports of adverse effects including 
serious bacterial infections (i.e. tuberculosis),35-39 cancer,40 injection-site and 
infusion reactions (like headache or nausea),41 immune and autoimmune 
disease (because of a reduction of the antibodies formation),29,42 
demyelinating syndromes,43 and heart failure.44 
 
 
Figure 3:  infliximab-TNFα complex45  
 
Morevover, controversies are reported in RA management: should 
biologic agents be used as first-line therapy? Should glucocorticoid therapy 
be used in early RA? Should these drugs be switched or cycled? In what 
order? Nevertheless, majority of trials support the overall superiority of 
combination therapies.22 The most widely used treatment for RA is the 
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combination of an anti-TNFα and methotrexate,21 but such issues clearly 
indicate a strong need in new approaches in the treatment of RA. Moreover, 
if methotrexate is a cheap medication (3 €/month/patient in Belgium, in 
2009), anti-TNFα like infliximab or adalimumab are very expensive drugs 
(between 1100€ and 1200€/month/patient in Belgium, in 2009).46,47 This 
high cost illustrates the necessity of novel therapeutic strategies. Finally, 
cure remains an elusive goal and true remission is achieved by only a 
minority of patients. Destructive process cannot be stopped as well as repair 
of previous damage is unreached in most of patients. It remains a 
considerable unmet need in RA therapy. Fortunately, several alternative 
strategies are currently being investigated raising hope for a better future for 
patients with this disease. Modulation of the NF-κB alternative activation 
pathway is a promising approach considering results published by Dejardin 
et al.48 and Claudio et al.49 In the following section, the two main NF-κB 
activation pathways are described in order to clarify the interest of this new 
strategy. 
 
3.  NF-κB activation 
 
Initially identified in activated B cells, the transcription factor NF-
κB rapidly emerged as essential for both innate and adaptative immunity, 
cell survival, apoptosis and inflammation among others.50-53 Being activated 
in the RA synovium, this transcription factor controls the transcription of 
inflammatory genes implicated in RA, including TNFα, IL-1, IL-6, IL-8, 
COX-2, inducible nitric oxyde synthase (iNOS) and intracellular adhesion 
molecule-1 (ICAM-1).54 In mammals, the Rel/NF-κB family is comprised of 
p65 (Rel-A), c-Rel (Rel), Rel-B, p50 and p52. These structurally related 
proteins share extensive sequence similarities within their N-terminal Rel 
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Homology Domain (RHD) that enables them to dimerise, to translocate into 
the nucleus, and to bind to specific DNA sequences, named κB sites. Among 
the Rel/NF-κB family, only p65, c-Rel and Rel-B contain a C-terminal 
transcriptional activation domain. Therefore, they are able to directly 
activate the transcription. The two other members, p50 and p52, are 
synthesised as precursors called p105 and p100, respectively. Proteins p50 
and p52 can behave as transcriptional activators only upon dimerisation with 
p65, c-Rel, RelB or Bcl3.55  
 
It has been shown that two main pathways control the activation of 
NF-κB. The first one, named classical NF-κB pathway (or canonical), is 
triggered by inflammatory cytokines such as TNFα, IL-1, or by bacterial and 
viral proteins through pathogen-recognition receptors (PRR) like TLRs and 
NLRs (Figure 4).56 These inducers activate the recruitment of specific 
adaptor proteins to their cognate receptors, which enable the activation of a 
cascade of kinases. Among them, TGF-β activated kinase 1 (TAK1) plays a 
key role at the crossroad of the NF-κB and MAPK signalling pathways 
(Figure 4). TAK1 is part of the MAP kinase subfamily.57 However, some 
studies showed that IL-1β and TNFα signalling pathways are affected in 
TAK1 KO mice.58,59 TAK1 activates the IKK complex by phosphorylating 
the IKKβ subunit. Moreover, TAK1 acts on MKK6 to trigger the activation 
of p38 and JNK (Figure 4). Upon TAK1 activation, the activated IKK 
complex phosphorylates IκBα, the main inhibitor of the classical NF-κB 
pathway, releasing NF-κB (e.g; p50/p65), which finally, translocates into the 
nucleus.60 This pathway is activated within minutes and relies on the 
indispensable adaptor protein NEMO (or IKKγ), holding together IKKβ and 
IKKα to form the IKK complex. 
 
 
 26 
 
Figure 4: Classical (yellow) and alternative (orange) NF-κB activation pathways. 
 
The second NF-κB pathway, called alternative NF-κB pathway (or 
non-canonical), is induced by a subset of TNFL family members as well as 
by some viral proteins.61 This pathway is dependent on the stabilisation and 
activation of the kinase NIK. The half-life of this particular kinase is 
negatively controlled by TRAF2, TRAF3, c-IAP-1 and c-IAP-2.62,63 Upon 
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activation of receptors like CD40, BAFF or LTβR, the inhibitory function of 
TRAF2 and TRAF3 is alleviated. Then, stabilised NIK activates IKKα 
leading to the processing of p100 into p52 (Figure 4).48,49,64 The latter, in 
association with its main partner Rel-B, fulfils non-redundant biological 
functions such as secondary lymphoid organ (SLO) development and 
induction of specific chemokines involved in adaptative immunity.61 
 
 
 
4.  NF-κB alternative pathways as a therapeutic target 
 
 There is no doubt that cytokines inducing or produced by the NF-κB 
alternative pathway are involved in inflammatory disorders. LTβR was 
demonstrated as a master receptor involved in the development of secondary 
lymphoid organ (SLO), and molecular mechanisms controlling tertiary 
lymphoid organ (TLO) formation required LTβR as well.61 TLO are 
organized lymphocytic aggregates (B cell and T cell areas) forming at sites 
of chronic inflammation.65,66  Unlike SLO, TLO are not connected to afferent 
lymph vessels and are not encapsulated, which implies that they are directly 
exposed to stimulating antigens and pro-inflammatory cytokines. TLO arises 
typically in non-lymphoid locations but the identity of stromal cells initiating 
their development is unknown. Nevertheless, TLO formation was observed 
in several mouse models of chronic inflammatory pathologies but also in 
transgenic mice by ectopic expression of inducers or target genes of the 
alternative pathway.66 For instance, constitutive tissue specific expression of 
LTβ, BLC (B lymphocyte chemoattractant) or ELC (Epstein-Barr virus 
induced molecule 1 ligand chemokine) into pancreatic islets or kidney is 
sufficient to generate TLO.66  It is noteworthy that TLO has been detected in 
a significant percentage of patients suffering from several chronic 
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inflammatory diseases like RA, but also Sjogren’s syndrome, multiple 
sclerosis, ulcerative colitis or chronic hepatitis C.65  Thus, inhibition of 
LTβR function in SLO and/or TLO could be beneficial for the treatment of 
chronic inflammatory pathologies. Actually, administration of LTβR-Ig 
fusion proteins (acting as a decoy receptor for LTα1β2 and LIGHT) has 
been successfully used in a rodent disease model of collagen-induced 
arthritis or inflammatory bowel disease. This approach is under clinical 
investigation.67 
 
 Besides TLO formation, another hallmark of most autoimmune 
diseases is the exacerbated expression of the prosurvival BAFF. In the 
synovial fluid of patients with RA, a high concentration of this cytokine is 
observed and these conditions allow the survival of unwanted autoantibody 
producing B cells.68 Tremendous efforts have been accomplished for the 
development of biological antagonists of BAFF, such as anti-BAFF antibody 
or decoy receptors for BAFF.69 The rational of using specific inhibitors of 
NF-κB alternative pathway would be their property to inhibit simultaneously 
several TNFR mediating pathologic conditions, like LTβR and BAFFR. As 
NIK has been shown to be critical for antigen-mediated induction of bone 
erosion in several mouse models,70 this kinase certainly represents an 
attractive candidate. Thus, inactivation of NIK with chemical compounds 
could have the advantage to spread the inhibition at levels of multiple 
effectors of chronic inflammation.61 
 
 As the NF-κB transcriptional activation is associated with essential 
cell functions, aberrant NF-κB regulation is also observed in many cancers.71 
Various mouse models in which IKK/NF-κB activation has been blocked by 
molecular biology highlighted the key role of NF-κB as a crucial promoter 
of inflammation linked cancers.72-74 One of the most documented functions 
of NF-κB is its ability to promote cell survival through the induction of 
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target genes, the products of which inhibit the apoptotic machinery in both 
normal and malignant cells.75,76 NF-κB also prevent programmed necrosis by 
inducing genes encoding antioxidant proteins.76 As tumour cells frequently 
use NF-κB to achieve resistance to anticancer drugs and radiation therapy, 
inhibition of NF-κB activation emerge as a promising option to improve the 
efficacy of conventional anticancer therapies.71 Although, in this work, we 
focused on NF-κB related inflammatory disorders and the potential interest 
of NIK as therapeutic target. 
 
5.  NF-κB inducing kinase 
 
 First described in 1997, NIK (or MAP3K14) is a serine/threonine 
kinase belonging to the MAP3K family. 947 amino acids constitute this 
protein which contains a 256 residues kinase domain (from 400 to 655 - 
Figure 5).77 
 
 Upstream in the NF-κB activation cascade, members of the TRAF 
family interact with NIK as negative regulators (TRAF2 and TRAF3).78 
Interactions of the N-terminal domain of NIK with TRAF3 induce 
constitutive degradation of NIK by 19S proteasome, keeping alternative 
activation pathway under control.63 On the other side, interactions between 
NIK et IKKα was demonstrated. It occurs with the C-terminal  domain of 
NIK (residues 735 to 947) and induces IKKα phosphorylation on serine 176 
(Figure 5).79  
 
 Little information is reported in the literature concerning the ATP 
binding site of this kinase. Only three residues are described as essential for 
the activity of NIK: KK429-430 and T559 (Figure 5). On one hand, as the 
double mutant KK429-430AA disabled NIK, it was presumed that at least 
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one lysine induces the stabilisation of the phosphate transfer in the kinase 
pocket.77 On the other hand, T559, belonging to the activation loop of NIK, 
is reported as a phosphorylation site. As the phosphorylation of T559 
induces the amplification of the kinase activity of NIK, the T559A mutant 
reduces the IKKα phosphorylation by ΝΙΚ.80  
 
 
 
Figure 5: Primary structure of NIK 
 
   
 From a structural point of view, no data of the 3D-structure of NIK 
are available, as well as the molecular mechanism or the potential 
interactions of its kinase domain with ATP or IKKα. 
 
6.  Kinase ATP binding site 
 
 Protein kinases catalyse the transfer of the distal phosphate group 
from adenosine triphosphate (ATP) to the hydroxyl group of a serine, a 
threonine or a tyrosine residue of the kinase itself or another protein 
substrate. Phosphorylation can create new recognition sites for protein 
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binding or may alter the conformation of the phosphorylated enzyme and 
modify its activation state or function.81-83 Protein kinase enzymes play 
pivotal roles in signal transduction from the cell membrane to the nucleus 
and in the cell-cycle control.84 
 
 High structural similarities of kinase ATP binding sites lend itself to 
a description of key regions and interactions observed across the kinome 
(Figure 6).  Most of them have a common fold consisting of two lobes. The 
N-terminus lobe consists of five antiparallel β-strands and one α-helix. 
Conversely, the C-terminus lobe is highly helical (Figure 6).  
 
 
Figure 6:  3D structure of a kinase domain 85 
  
 
 The ATP binding site is a narrow hydrophobic pocket located 
between the two lobes which are linked by a flexible hinge region (Figures 6 
& 7). The top of the ATP binding site is formed by the G-loop, known as the 
glycine-rich loop for its highly conserved GXGXXG motif (Figure 7).  
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Figure 7: 3D ATP-binding site with G-loop (red), hinge region (pink), gatekeeper 
(magenta), activation loop (green) and salt bridge (blue) 
 
  
 Kinases have a second loop (called activation loop, figures 7 & 8) 
containing serine, threonine, or tyrosine residues, which may be 
phosphorylated. The N-terminal side of the activation loop is a highly 
conserved DFG triplet. The aspartate residue (D) is catalytically involved in 
the phosphate transfer, and typically engaged in a salt bridge interaction with 
a conserved lysine residue and an aspartate/glutamate residue (Figure 8). 
This activation loop occupies a part of the ATP binding site when these 
residues are not phosphorylated. Most of ATP-competitive inhibitors 
recognise the so-called "active conformation" of the kinase.86 But targeting 
this site with ligand-protein interactions is not the only way to enhance 
inhibitor selectivity. When the catalytic aspartate of the DFG triplet is in a 
rotated-out conformation (known as DFG-out), it rotates out of the ATP 
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binding pocket, and it is accompanied by a corresponding rotation of the 
adjacent phenylalanine (F) and glycine (G) residues.87 The phenylalanine 
movement reveals a large hydrophobic pocket which may be filled by 
complementary groups of the ligand. The marketed drug imatinib targets this 
DFG-out conformation, emphasising the potential importance of this 
conformational state in ligand design.88,89 
 
 
 
 
Figure 8: 2D representation of a typical kinase ATP-binding site.90 
  
 The gatekeeper (gk) is another important amino acid of the ATP 
binding site (Figure 8). The size and the volume of the side chain of this 
residue dictate the access to the hydrophobic pocket located behind the 
gatekeeper, thereby defining a potential inhibitor selectivity of the ATP site. 
The peptide bonds forming the key hydrogen bond acceptor motifs in the 
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hinge region are thusly referenced as gk+1 and gk+3,90 relative to the 
position of the gatekeeper:  
 
hinge residues = gk + 1 and gk + 3 
 
 Usually, the hinge region has one hydrogen as donor flanked by two 
oxygen regarded as acceptors. Interestingly, these atoms derived from the 
protein backbone and not from the side-chains of the residues gk+1 and 
gk+3. These residues recognise the ATP-purine moiety and stabilise the 
nucleotide into the pocket by two or three critical H-bonds. This region is 
also known to be targeted for the design of ATP-competitive inhibitors.90 
 
 Kinases are at the crossroad of controversies regarding their status as 
drug targets. As the cellular concentration of ATP is high, typically 1–5 
mM,91,92 it was thought that a high concentration of ATP-competitive 
inhibitor would be needed, bringing potential toxicity. Another concern is 
that all protein kinases share a common cofactor and a similar three-
dimensional structure of the catalytic site. These features increase the 
difficulties for the design of adequate and selective kinase inhibitors. But it 
can be seen that these have been successfully challenged. Currently, ten 
approved kinase inhibitors binding in the ATP binding site are marketed for 
the treatment of various diseases (Table 1).84,86,93 
 
 Being firstly discovered as a product of the bacterium Streptomyces 
hygroscopicus, the mTOR (mammalian target of rapamycin) inhibitors 
rapamycin (also known as sirolimus) and temsirolimus are macrolides with a 
high molecular weight (914 g/mole and 1030 g/mole respectively).94  They 
are not reported in table 1. The eight others inhibitors present ordinary 
structures and are indicated in the reported diseases (Table 1): 
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Table 1: Chemical structure and known kinase targets for clinically approved kinase 
inhibitors.93,94 
 
Structure Name Known 
targets 
Indication 
 
 
Imatinib 
(Glivec; 
Novartis) 
Bcr-
Abl,  
c- Abl, 
PDGFR,  
c-KIT, 
DDR1 
 
CML, 
GIST,  
HS 
 
 
Nilotinib 
(Tasigna; 
Novartis) 
Bcr- 
Abl,  
c- Abl, 
PDGFR,  
c-KIT, 
DDR1 
 
Imatinib-
resistant 
CML 
 
Erlotinib 
(Tarceva; 
OSIPharma 
/Genentech 
/Roche) 
 
EGFR,  
HER2 
 
NSCLC, 
pancreas 
cancer 
 
 
Gefitinib 
(Iressa; 
Astra 
Zeneca) 
 
EGFR, 
HER2, 
HER4 
 
NSCLC 
 
 
Sorafenib 
(Nexavar; 
Bayer 
/Onyx) 
 
c-KIT, 
PDGFR, 
VEGFR 
(b-raf) 
 
 
Renal 
cancer 
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Structure Name Known 
targets 
Indication 
 
 
Sunitinib 
(Sutent; 
Pfizer) 
 
c-KIT, 
PDGFR, 
VEGFR 
Renal 
cancer, 
imatinib-
refractory 
GIST 
 
 
Lapatinib 
(Tykerb; 
GSK) 
 
HER2 
 
Breast 
cancer 
 
 
Dasatinib 
(Sprycel; 
Bristol-
Myers 
Squibb) 
 
Bcr- 
Abl,  
SRC 
family, 
Tec 
family 
 
Imatinib-
resistant 
CML 
 
CML, chronic myelogenous leukaemia; DDR1, discoidin domain receptor tyrosine 
kinase 1;EGFR, epidermal growth-factor receptor; GIST, gastrointestinal stromal 
tumours; HES, hypereosinophilic syndrome; NSCLC, non-small cell lung cancer; 
PDGFR, platelet-derived growth-factor receptor; VEGFR, vascular endothelial 
growth-factor receptor. 
 
  
 
 Interestingly, while the initial research focused largely on the 
discovery of monospecific or highly selective kinase inhibitors for 
therapeutic use, the clinical experience, and a growing understanding of 
kinase biology show that molecules with a broader pattern of inhibitory 
activities can be even more effective.95-97 
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7.  NIK inhibitors  
 
 Surprisingly, despite a demonstrated high interest for the NF-κB 
alternative pathway, and particularly for NIK inhibition, only three series of 
molecules are described as NIK inhibitors in the literature: kaurenes 1-3, 
alkynyl alcohols 4 and pyrazolo[4,3-c]isoquinolines 5: 
 
7.1  Kaurenes  
 
 Kaurenes are tetracyclic diterpenes (Figure 9).  These asymmetric 
hydroxylated molecules derived from the ent-kaurenoic acid (KA), isolated 
from plants like Viguiera robusta.  In 2001, NIK was reported by Castrillo et 
al. as one of the potential target of compounds 1-3.98  
 
 
 
Figure 9 : Kaurene reported as potential NIK inhibitors 
   
 In the published results, the authors reported various assays based on 
LPS-activated cells treated with kaurene diterpenes. Unfortunately, as the 
alternative activation pathway was not yet described, the authors did not 
consider the two pathways distinctly. Their results suggest that kaurenes 
inhibit a step preceding IKKβ activation. Briefly, cells were then transfected 
with a Myc-NIK expression vector which, after overexpression, triggers 
IKKβ activation per se.77,99  In these conditions, the authors indicated that 
kaurenes inhibited the Myc-NIK-dependent activation of IKKβ in the 
absence of LPS stimulation. Although, some observations suggested that 
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IKKβ and NIK are involved in two distinct pathways.61 Anyway, NIK and 
IKKβ interdependence remains unclear.100 These conclusions are therefore 
not obvious and an enzymatic assay would clarify their assumptions. No 
further data on this series have been published. 
  
7.2  Patents on alkynyl-alcohols and pyrazolo[4,3-c]isoquinolines  
 
 On december 2009, a new series was published as NIK inhibitor.  
The corresponding patent was based on the alkynyl-alcohol 4 moiety (Figure 
10).101 Unfortunately, neither biological data nor structure-activity 
relationships related to this series were described in the original patent.  
 
 Up to 2009, the pyrazolo[4,3-c]isoquinoline template 5 was the only 
scaffold reported and claimed as NIK inhibitor (Figure 10). This series was 
submitted in 2002 and then published in 2005 by Aventis as a patent.102,103 
This patent reports: (...) pyrazoloisoquinolines derivatives are strong and 
very specific inhibitors of NIK (...). It is also claimed: a method of treating a 
disease condition associated with the increase activity of NIK comprising 
administering to a patient suffering from said disease condition a 
therapeutically effective amount of a compound of the formula 5 (Figure 10) 
or a stereoisomeric form or a pharmaceutically acceptable salt of this 
compound 5. 
 
Figure 10: Alkynyl-alcohol 4 and pyrazolo[4,3-c]isoquinolinyl 5 scaffolds 
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8. Objectives 
 
 As the intracellular signal transduction responsible for the survival 
of immunity cells is identified and associated with the early development of 
RA, it might be valuable to design a novel class of inhibitors targeting 
kinases at the crossroad of multiple pathways relevant to this pathology. As 
NIK definitely represents an attractive target, we aim, on one hand, to 
understand and characterise this protein and, on the other hand, to discover, 
design and synthesise new inhibitors. Being the strongest starting point to 
identify new inhibitors of NIK, we decided to clarify the inhibitory 
mechanism of pyrazolo[4,3-c]isoquinolines. The study of the interactions of 
these pyrazolo[4,3-c]isoquinolines with NIK was one of our main goals. To 
reach it, we will proceed according to the following steps: 
1. Molecular modelling and mutagenesis will be performed to study 
the kinase domain of NIK. 
2. The only scaffold described as NIK inhibitor, the pyrazolo[4,3-
c]isoquinoline scaffold 5 will be considered in a 3D-model of NIK 
to identify the main potential interactions between these inhibitors 
and their target. 
3. Novel pyrazolo[4,3-c]isoquinolines will be synthesised and their 
inhibitory potency and specificity will be evaluated on isolated 
NIK and in a cellular test. 
4. A virtual screening of molecular databases will be developed to 
identify an original scaffold for the design of NIK inhibitors. 
5. Various analogues of the most promising compounds will be 
synthesised to start a new and original series of NIK inhibitors. 
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1.  Molecular modelling 
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 To learn more about the ATP-binding site of NIK and to understand 
the enzymatic mechanism, a molecular modelling study was initiated in 
collaboration with the CBS laboratory of Professor J. Wouters.  This study 
enabled to identify the nature of amino acids located into the catalytic cavity 
and to understand the potential interactions that could exist between those 
residues and NIK ligands. Molecular modelling is then a tool to interpret 
activity results, to rationalise structure-activity relationships and to improve 
the affinity and selectivity of target modulators. Finally, molecular 
modelling is very helpful for designing novel structures and may therefore 
cooperate closely with organic synthesis.  Since no crystal structure or 3D-
model of NIK was available, we started to build a 3D model of NIK. 
 
 
1.1  Sequence homology 
 
 The first step of a homology modelling is the identification of a 
protein used as template. The 3D-structure of the template has to be 
available and its amino acids sequence must be as close as possible to the 
sequence of NIK. Such research is possible by means of a sequence 
alignment software (BLASTP) dealing with every protein available in the 
Protein DataBank (PDB).104,105 On the day of this experiment (October 9th, 
2006), the closest accessible crystallised kinase was PAK1 (p21 activated 
kinase 1; PDB code: 1YHW-A), the first reported protein of the aligned 
sequences list (Figure 11) : 
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Figure 11: Sequences alignment to NIK performed by BLASTP software. PAK1 is 
represented by the code 1YHW-A. A colour code represents the identity level of 
each aligned sequence and NIK. 
NIK 
NIK 
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PAK1 shares 30% sequence identity and up to 48% sequence 
homology (similar residues) with NIK (Figures 12 and 13).  As this value is 
satisfying enough to build a model, PAK1 was then chosen to be the pattern 
structure (template) to build the 3D kinase domain of NIK.  
 
 
 
 
 
 
 
Figure 12 : Unidimentional alignment of NIK (blue) and PAK1 (yellow, kinase 
domain only) 
 
 
 The proper alignment of PAK1 and NIK sequences by BLASTP is 
reported below (Figure 13): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Sequence aligning of NIK (Query) and PAK1 (Subject) by BLASTP 
 
PAK1 
NIK 
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1.2  3D-model building 
 
 As the target/template alignment step is known to be critical for the 
quality of a model, we used the automated homology program 
ESyPred3D.106 This performs a consensus alignment between the sequences 
of the target and the template. Then MODELLER generates the 3D 
coordinates.107  The final 3D model of NIK shows a classical kinase structure 
with the N-terminus side constituted by five anti-parallel β-strands, the C-
terminus side rich in α-helixes, and a cavity, in the middle of the protein, 
bordered by a flexible hinge region (Figure 14). 
 
Figure 14: 3D-model of NIK (kinase domain) 
 
 The catalytic pocket of NIK was refined by minimisation to take into 
account the protein flexibility. The position of the side-chains of the residues 
located 20 Å around L472 (the gk+3 hinge residue)a were minimised by 
means of the MINIMIZE module, as implemented in SYBYL 8.0.108 
                                                 
a
 Hinge residues, named gk+1 and gk+3 relatively to the gatekeeper position, are 
fundamental amino acids in kinase-ATP recognition and phosphorylation activity. 
L472 was identified as the gk+3 residue and was therefore considered as central in 
the ATP-binding site of NIK. More details about the hinge region of NIK are 
reported further in this chapter. 
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1.3  Validation and critics of the model 
 1.3.1.  Ramachandran plot  
 
 Ramachandran developed a plotting approach to summarise φ and ψ  
values of every amino acid residues in the protein structure (Figure 15).109  
 
Figure 15: φ and ψ dihedral angles of amino acid residues in the protein structure 
(where R is the side chain) 
 
The plot shows the possible conformations of φ and ψ angles for the 
polypeptide main chain (Figure 16). In the reported plot, red areas represent 
the most favourable angles values: 
- area A represents angles corresponding to an α−helix; 
- area B represents angles corresponding to a β−sheet; 
- area L represents angles corresponding to left-handed helix. 
 
 Yellow, beige, and white areas represent additionally 
authorised, generously authorised and forbidden values for torsion angle 
respectively (Figure 16).  Ramachandran plot of the model of NIK proved to 
be very satisfactory with 90.2% residues located in the most favoured 
regions, 7.3% in the allowed regions, only four residues (1.6%) in the 
generously allowed regions (φ and ψ torsion angles slightly larger than 
usual) and two residues in the disallowed regions (unfavourable φ and ψ  
torsion angles). It must be noticed that these six residues (Q484, T401, 
 50 
Y391, E395, D544 and S572) are located far from the active site and the 
hinge region. The torsion angles distribution is summarised in table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Ramachandran plot of the model of NIK 
 
 
 
Table 2: Summary of the Ramachandran plot distribution 
Color Area Residues  Residue % 
red most favourable 221 90.2% 
yellow additionally authorised 18 7.3% 
beige generously authorised 4 1.6% 
white forbidden 2 0.8% 
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This Ramachandran plot is the first validation of our newly 
developed homology model. 
 
 
 1.3.2. K430 orientation 
 
 Once the model was built, the residues reported as essentials for the 
kinase activity of NIK were analysed in a second validation study.  
Literature reports that the double mutant KK429-430AA of NIK is 
inactive.77  Nevertheless, an interaction between K430 and ATP (or any 
ligand in this pocket) was unfavourable. In the proposed model, the side-
chain of K430 points out of the cavity (Figure 17). Conversely, K429 is 
oriented to the pocket. This is in agreement with the previously published 
result (Figure 17). To confirm these positions, and as these mutations have 
always been studied simultaneously,77  the design of the single mutants 
K429A and K430A would be very helpful.  By this way, the specific role of 
each lysine could be clarified.  If K430 is not essential for the kinase activity 
(or if the activity of the K430A mutant is preserved in comparison to NIK 
wild type), the orientation of this side chain will be validated in the model of 
NIK. These results will be reported further (section II.2). 
 
Finally, T559 is located on the C-terminus side of the cavity at the 
end of the activation loop. The orientation of its side-chain allows a 
phosphate transfer on its hydroxyl function (Figure 17). 
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Figure 17: Model of NIK with residues KK430-429 and T559 (from left to right and 
underlined in orange) 
 
 
 
 1.3.3  Identification of the key residues of NIK 
 
 The 3D-structures of the kinase domains of NIK and PAK1 were 
then superimposed. As expected, the overall folding pattern (β-sheets, α-
helixes and main loops) was shown to be logically preserved  (Figure 18). 
The ATP-binding sites superimposition was analysed and the active site 
residues common to majority of kinases were recognised.   
  K430 
 K429 
T559 
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Figure 18: General view of the superimposition of PAK1 (green) and NIK (blue) 
 
 
First, in the NIK structure, M469, which corresponds to M344 in 
PAK1, was identified as the gatekeeper (gk) residue. Then, residues E470 
(gk+1) and L472 (gk+3) were logically located in the hinge region. As 
explained in the introduction, gk+1 and gk+3 residues are responsible for the 
stabilisation of the adenine moiety of the ATP. In PAK1, hinge residues 
gk+1 and gk+3 correspond to E345 and L347 respectively. In a co-crystal 
structure where 3-hydroxystaurosporine is soaked into PAK1 (PDB code: 
2HY8), both residues are involved in the stabilisation of the aromatic ring of 
3-hydroxystaurosporine (Figure 19). This observation assumes the key role 
of this region in the ATP-binding site, as explained previously. Finally, in 
the back of the NIK active site cavity, a salt bridge between residues K429 
and E440, corresponding to the salt bridge between R299 and E315 in 
PAK1, is also preserved (Figure 20). 
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Figure 19: Superimposition of NIK and PAK1 with co-crystallised 3-
hydroxystaurosporine 
 
Close to this ionic interaction, the highly conserved triplet DFG of 
the activation loop is found in the model of NIK from residue 534 to 536 
(Figure 20). This loop is very well overlaid on the template structure, and the 
triplet corresponds exactly to residues from D407 to G409 in PAK1. 
 
 Finally, the G-loop of PAK1 contains the amino acids 277 to 282 
with the sequence GQGASG. In this loop, the residues G277, Q278 and 
G279 belong to the β-sheet preceding the flexible loop. This G-loop, linking 
the anti-parallel β-sheets, is then shortened. This observation explains why 
this region is not perfectly superimposed to the model of NIK. In fact, none 
of the residues from 407 to 412 belonging to NIK are included into any β-
sheet in the model. Then, these residues form a longer and more flexible 
loop than in PAK1. 
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Figure 20: Main residues identified in the ATP-binding site of NIK 
 
Each key residue of the ATP-binding site is reported in table 3: 
 
Table 3 : Main residues of the ATP-binding site of NIK and PAK1 
Region PAK1 NIK 
gatekeeper M344 M469 
hinge region E345 and L347 E470 and L472 
salt bridge R299 and E315 K429 and E440 
activation loop triad 407-DFG-409 534-DFG-536 
G-loop 277-GQGASG-282 407-GRGSFG-412 
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In conclusion, a 3D-model of NIK was build, validated and studied 
with a rational approach.110 This tool is now available to reach 
various goals. In a first step, the kinase domain of NIK will be 
investigated deeper with the help of a mutagenesis study.  Then, 
various docking studies and virtual screening will be performed with 
this model in order to understand the required interactions for NIK 
inhibition and to identify new scaffolds. 
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2.  Mutagenesis 
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 To study into detail the kinase domain of NIK, the activity of various 
single mutants was considered. This study is directly derived from the 
molecular modelling. In this second step, the model of NIK can be validated 
or improved, residues interacting with ATP will be acknowledged and key 
regions for NIK inhibition will be identified. This study started with the 
selection of residues to be mutated. 
 
2.1  Selection of key amino acid residues 
 
To select the most interesting residues from the ATP-binding site of 
NIK, three filters were applied on the 253 residues kinase domain of NIK 
(Figure 21) as following: (i) a sequence alignment imitating the natural 
selection, (ii) an elimination based on the nature of the side chain, and (iii) 
an evaluation of the 3D situation. 
 
 
 
Figure 21: Kinase domain sequence of NIK (residues from 405 to 647) 
 
 
First step - This first filter, similar to a natural selection, was applied as 
following: an alignment of the kinase domain sequence of NIK was 
performed with the ten closest homologous proteins kinases reported in the 
literature so far (September 2007) by means of BLASTP.104 Every biological 
species were taken together and the considered sequences shared until 32% 
of homology with the sequence of NIK. Then, each residue of NIK not 
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found each alignment was eliminated. Amino acids recovered in each 
sequences and selected are reported in figure 22: 
 
 
 
Figure 22: Remaining residues after the first selection (natural selection) 
 
 
Second step - Then, the aliphatic residues were removed (G, A, V, L, and I).  
Side chains of such amino acids contribute to the structure, but gives weak 
interactions (<0.7 kcal/mole) with ligands in comparison to residues forming 
H-bond (<6 kcal/mole) or ionic interactions (<10 kcal/mol). After this 
second filtration, 53 residues were remaining (Figure 23): 
 
 
 
Figure 23: Remaining residues after the second filtration step (aliphatic side chains ) 
 
 
 
Third step - The previously described model of NIK finally stepped in as 
the third filter.  In this final selection, each of the 53 remaining residues was 
located into the 3D structure. By doing so, residues out of the ATP-binding 
site were discarded. Only 9 of the 253 initial amino acids remained as 
potential points of mutations (Figure 24): 
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Figure 24: Remaining residues after the third filtration step (3D location) 
 
 
Interestingly, T559, the phosphorylation site, and K429, forming the 
salt bridge with E440, are recovered in this selection. D534 and F535, 
forming the highly conserved DFG triplet, were selected as well.  In return, 
K430 was eliminated in the first phase. As explained below, the involvement 
of this lysine in the mechanism of the phosphate transfer remains unclear.  
K430A was then evaluated anyway with the eight following single mutants: 
K429A, D534A, F535A , F411A, F436A, H562A, E440A and E560A.  
 
2.2 Site directed mutations 
 
 The study of the NF-κB alternative activation pathway and the 
protein NIK is the result of a fruitful collaboration with the laboratory of 
Virology and Immunology (GIGA, University of Liège).  Each single mutant 
and measurement of its residual activity was entirely performed by this team.  
The selected residues were then mutated one by one and the mutants were 
evaluated for their ability to induce the alternative pathway.  Each selected 
residue was changed to alanine by site-directed mutagenesis from an 
expression vector encoding wild-type NIK.  The ability of each mutant to 
activate the NF-κB alternative pathway was evaluated by transient 
transfection assays in HEK293T cells (human embryonic kidney 293T cells).  
High expression of NIK induced a constitutive p100 processing in the 
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alternative pathway (see Introduction, Figure 4).  Cells were then lysed 40 
hours after transfection and the processing of p100 into p52 was analysed by 
Western-blot.111  Any loss of ability to activate this cascade would be 
detected by an increase of p100 concentration and a decrease of p52 
concentration when compared to the processing induced by NIK wild type 
(wt, Figure 25). 
  
 First, K430A undoubtedly induces the processing of p100 into p52 
(Figure 25).  This mutation does not affect the ability of NIK to induce the 
alternative pathway.  Therefore, K430 is not fundamental for the kinase 
activity of NIK and the orientation of its side-chain outside the cavity is 
confirmed.  Conversely, the mutation K429A was unable to induce the same 
processing. It was consequently demonstrated that K429 is the unique lysine 
interacting with ATP during the phosphate transfer. Moreover, this result is 
completely in agreement with the proposed model of NIK.   
 
   
 
 
 
 
 
 
 
Figure 25: NIK activity of each single mutant was measured by western-blotting 
subunits p100 and p52 (v = blank ; wt = wild type) 
  
 
 As previously suggested, the ammonium of K429 is forming an ionic 
interaction with the carbonate side chain of E440, in the model of NIK.  The 
mutant E440A prevents also the processing of p100, indicating the major 
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part of this salt bridge into the kinase mechanism (Figure 25). This result 
also confirms the proposed 3D model of NIK. 
  
 The D534A mutant displays an important activity defeat.  Belonging 
to the activation loop motif DFG, this aspartate is most probably involved in 
the phosphate transfer. Similarly, the F535A mutation affecting the DFG 
triad strongly reduces the processing of p100 into p52. This result indicates a 
significant inhibition of NIK as well (Figure 25). 
  
 On the C-terminus side of NIK, H562 is a residue close to the 
phosphorylation site T559.  The H562A mutant was also unable to induce 
the alternative pathway activation (Figure 25).  This result can be explained 
by the vicinity of this histidine and T559.  The imidazole scaffold of H562 is 
therefore expected to stabilise the transferred phosphate or the 
phosphorylated threonine. 
  
 Then, F436, located just above the ATP-binding site and the salt 
bridge formed by K429 and E440, seems also to play a decisive role in the 
activity of NIK since the mutant F436A does not induce the p100/p52 
processing (Figure 25). This result can be explained by the localisation of 
F436 on top of the specificity pocket, a central point of the ATP-binding site. 
  
 Finally, no variation of activity is observed with mutations F411A 
and E560A, indicating these residues are less important for the kinase 
activity (Figure 25). This information is interesting in the frame of a better 
understanding of NIK's mechanism. In fact, F411 could be suspected as a 
key residue for NIK as it belongs to the G-loop located on the roof of the 
enzymatic pocket.  Equally, E560, which is just nearby the phosphorylation 
site T559, could also be involved in the phosphate transfer. These 
experiments proved that it is not the case. 
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In conclusion, the mutagenesis results show that six of nine selected 
residues play a critical role into NIK activity:  F436, E440, D534, 
F535, H562 and obviously K429.112 So, the filtration strategy seems 
clearly relevant, as well as the model of NIK which proved to be 
reliable. This mutagenesis study validates the 3D-structure of NIK 
built by homology modelling. This model will be considered as the 
starting point for the molecular docking and virtual screening 
detailed further. 
 
 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.  Docking 
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 To appraise the reliability of our model, the binding of the 
previously reported pyrazolo[4,3-c]isoquinolines claimed as NIK inhibitors 
was studied within the active site. Staurosporine, reported as a pankinase 
inhibitor including NIK,113 was also investigated in our model. Pyrazolo[4,3-
c]isoquinolines 5a-s and staurosporine (Table 4) were docked inside the 
ATP-binding site of NIK using the automated GOLD program.114 For each 
molecule, 20 conformations were generated and evaluated following two 
parameters:  
1. the number of different orientations (NDO) adopted by one 
molecule inside the NIK binding cleft;  
2. the number of different orientations where the compound is 
found to be stabilised with at least one H-bond with the residue 
L472 in the hinge region (NDO L472).  
 
 As explained in the introduction, the hinge residues gk+1 and gk+3 
develop key interactions with adenine from ATP in the kinase pocket. The 
backbone of this region is clearly identified as the highest common region 
targeted by each ATP-competitive inhibitor. More precisely, the NH of 
gk+3, the central H-bond donor of the hinge region, is stabilising each 
known ATP-competitive kinase inhibitor. That is the reason why this residue 
was selected to study the ligand interactions. 
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Table 4: Structure and number of conformations adopted by pyrazolo[4,3-
c]isoquinolines 5a-s. NDO is the number of different orientations observed after 20 
dockings for 1 molecule; NDO L472 is the number of 
different orientations observed with an H-bond interaction  
with residue L472 
 
 
 
 
 
 
 
Docking 
Cpd R1 R2 R3 R4 R5 NDO 
 
NDO  
L472 
Staurosporine 1 1 
5a 
  
H H H 4 1 
5b 
 
 
H H H 6 2 
5c Me 
 
H H H 2 0 
5d Me 
 
H H H 2 0 
5e Me 
 
H H H 3 0 
 
 
pyrazolo[4,3-c]isoquinolines 5 
 
staurosporine 
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Docking 
Cpd R1 R2 R3 R4 R5 NDO 
 
NDO  
L472 
5f Me 
 
H H Me 1 0 
5g CF3 
 
H H H 2 0 
5h Me 
 
H H Me 2 1 
5i Me 
 
H CO2Me H 4 2 
5j Me 
 
H CO2Me H 3 2 
5k Me 
 
H H Me 3 0 
5l Me 
 
H NMe2 H 2 0 
5m Me 
 
CF3 H H 2 1 
5n Me 
 
CF3 H H 4 2 
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Docking 
Cpd R1 R2 R3 R4 R5 NDO 
 
NDO  
L472 
5o Me 
 
H H H 4 1 
5p Me 
 
H NMe2 H 3 2 
5q Me 
 
H H H 4 1 
5r Me 
 
H H H 1 0 
5s Me CH2OMe H H H 5 1 
 
 
  
 Interestingly, the staurosporine moiety fits perfectly the catalytic 
pocket of NIK (Figure 26), adopting a similar binding orientation as 
observed for 3-OH-staurosporine in PAK1 (Figure 19).   
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Figure 26: (a) All of the 20 conformations obtained for staurosporine into the 
modelled active site cavity of NIK and (b) view of staurosporine in the active site 
cavity NIK illustrated with the Connolly surface. 
 
a 
b 
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 All of the 20 conformations generated lie in a unique orientation 
with two H-bonds between the lactam ring of staurosporine and the NH and 
CO moieties of L472 and E470, respectively, stabilising the ligand (Figure 
26).  In addition, hydrophobic interactions with aliphatic residues L406, 
V414, A427, L522 and C533 also contribute to the stabilisation on both 
sides of the aromatic plane. Conversely, when pyrazolo[4,3-c]isoquinolines 
5a-s are docked inside the ATP-binding site of NIK, several different 
orientations (2 to 6) are observed for each compound (Table 4), except 5f 
and 5r for which a unique binding orientation of the pyrazolo[4,3-
c]isoquinoline motif is found.  But these two compounds do not interact with 
L472 through an H-bound as requested.  In addition, other pyrazolo[4,3-
c]isoquinolines (5c-5e, 5g, 5k, 5l) are not stabilised through H-bond 
interaction with the hinge region residue L472.  
 
 To see if a unique orientation of the pyrazolo[4,3-c]isoquinoline 
series 5 could be highlighted, another docking was considered. In this new 
study, compounds 5a-s were docked again inside the NIK binding cleft 
imposing a H-bond between the NH of L472 and one acceptor atom of the 
ligand.  By doing so, still two orientations were found, and are illustrated 
using compound 5d (Figure 27 for orientation 1, and figure 28 for 
orientation 2). In both orientations, the pyrazolo[4,3-c]isoquinoline scaffold 
is stabilised by two H-bonds in the hinge region, as expected following a 
constraint docking.  But none of these two orientations seems more plausible 
than the other, or would allow a better understanding of the structure-activity 
relationships in this series. Thus, this docking study does unfortunately not 
allow to highlight a unique, obvious orientation of compounds 5a-s into the 
NIK binding cavity.  
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Figure 27:  Orientation 1 of compound 5d docked in the modelled ATP-binding site 
of NIK when imposing a H-bond between the NH of L472.  View without (a) or  
with (b) Connolly surface. 
 
a 
b 
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Figure 28:  Orientation 2 of compound 5d docked in the modelled ATP-binding site 
of NIK when imposing a H-bond between the NH of L472.  View without (a) or 
with (b) Connolly surface. 
  
b 
a 
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These two docking studies led to the conclusion that no 
particular affinity can be predicted for the pyrazolo[4,3-
c]isoquinoline series.110 Actually, since this molecular template was 
claimed as potent and selective inhibitors of NIK,102,103 a main and 
obvious docking mode was expected. On the contrary, neither 
affinity or relationship activity can be explained, even when a H-
bond is imposed between the ligand and the key residure L472. 
Based on these observations, different hypothesis could be 
suggested:  
1. although staurosporine, a confirmed NIK inhibitor, fits 
perfectly its active site, the 3D-model of NIK is not reliable; 
2. the pyrazolo[4,3-c]isoquinolines 5a-s are effectively NIK 
inhibitors but through a different mechanism of inhibition, for 
instance through interactions with an allosteric site; 
3. the pyrazolo[4,3-c]isoquinolines 5a-s are not NIK 
inhibitors.  
 
 To assess one of these assumptions, some pyrazolo[4,3-
c]isoquinolines (5a-d) and analogous pyrazolo[3,4-c]isoquinolines 
were synthesised simultaneously with this docking study. Their NIK 
inhibitory potency was evaluated on isolated human recombinant 
enzyme as well as on Hela cells where the NF-κB alternative 
pathway was induced. 
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4.  Organic synthesis and commercial compounds 
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 In parallel to the docking study, pyrazolo[4,3-c]isoquinolines, plus 
some molecular analogs, were synthesised to evaluate their effective 
inhibition potency against NIK. Also, the purchase of commercially 
available molecules is reported.  Finally, all of these molecules were assayed 
on the enzyme NIK to evaluate their inhibitory potency. 
 
 
4.1  Synthesis of pyrazolo[4,3-c]isoquinoline  
 
 The pyrazolo[4,3-c]isoquinolines 5a-d are synthesised in four steps 
(Scheme 1).  
 
 
Scheme 1:  Synthesis of pyrazolo[4,3-c]isoquinolines 
 
 
 Starting from the commercially available diketones 6a-b, oximes 7a-
b are prepared with a high yield (91-97%) by reaction of sodium nitrite in 
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acidic conditions.115  Oximes 7a-b further react with hydrazine hydrate to 
form pyrazoles 8a-b.116  Then, benzoic acids 9a-b activated by HOBT/DEC 
are condensed on pyrazoles 8a-b to form the corresponding amides 10a-d. 
Finally, the desired pyrazolo[4,3-c]isoquinolines 5a-d (Table 5) are obtained 
according to the Pictet-Gams reaction in poor yields (2-13%).117  Chemical 
yield of this last step is very low due to the formation of several side 
products and a delicate purification (Scheme 1). 
 
 
4.2  Pyrazolo[3,4-c]isoquinolines synthesis 
  
 As poor yields and difficult purification were curbing the 
pyrazolo[4,3-c]isoquinolines synthesis, an analogous scaffold has been 
considered.  By choosing more reachable molecules, a largest series can be 
synthesised, leading to more interesting potential structure-activity 
relationships.  In the meantime, this new series is a way to step out of the 
Aventis patent. For all those reasons, the pyrazolo[3,4-c]isoquinoline 
scaffold was chosen. This molecular structure, very close to pyrazolo[4,3-
c]isoquinolines was previously patented by Exelixis as ALK (anaplastic 
lymphoma kinase) inhibitors.118 Pyrazolo[3,4-c]isoquinolines 11a-l are then 
synthesised in three steps, each of it being an opportunity to introduce new 
structural variations at the R6, R7 and R8 positions (Scheme 2). 
 
The esters 13a-c and benzylcyanide 12 react in basic conditions to 
form the nitrile derivatives 14a-c with various R6 substituents. These nitriles 
react further with R7-substituted hydrazines to form the aminopyrazoles 15a-
h. Finally, the benzoyl derivatives 16a-c react with the aminopyrazoles 15a-
h in acidic conditions to form the required pyrazolo[3,4-c]isoquinolines 11a-
l with a wide range of yield (1-60%).  
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Scheme 2:  Synthesis of pyrazolo[3,4-c]isoquinolines. 
 
 
In comparison to the synthesis of pyrazolo[4,3-c]isoquinolines, the 
cyclisation step generating pyrazolo[3,4-c]isoquinolines is a cleaner process 
which does not involve the same purification issues. 
 
Thirteen pyrazolo[3,4-c]isoquinolines were synthesised following 
this pathway (Table 5). 
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Table 5:  Synthesised pyrazolo[3,4-c]isoquinolines structures 
 
 
 
Compound R6 R7 R8 
11a Me Me H 
11b Me H H 
11c H H H 
11d Me Me OH 
11e H Me H 
11f Me H OH 
11g H H OH 
11h Et Me H 
11i Et H H 
11j Me H OMe 
11k Me 2-pyridinyl H 
11l Me Ph H 
 
 
 
4.3  Commercial compounds 
 Finally, a panel of commercially available kinase inhibitors or 
molecules closely related to the structure of pyrazolo[4,3-c]isoquinolines 
was selected. 
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 4.3.1  Fragments of  pyrazolo[4,3-c]isoquinolines 
 
To identify other pyrazoloisoquinolines as potential NIK inhibitors 
and with a view to develop SAR in this series, the pyrazolo[4,3-
c]isoquinolines scaffold was searched for into the ZINC database.119   
 
 
 
Figure 29:  Commercial molecules structurally related to the molecular template 5 
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 On 2,700,000 commercially available compounds, no pyrazolo[4,3-
c]iso-quinolines was regained in the database. Then the scaffold was splitted 
into pyrazolopyridine (Y) and isoquinoline (X) as starting structures to 
identify structurally related molecules. The compounds 17 to 22 were 
identified as commercially available and bought (Figure 29). 
 
 4.3.2  Kinase inhibitors 
 
 Another strategy to identify potential and novel NIK inhibitors was 
to search for molecules described as inhibitors of kinases structurally related 
to NIK.  As mentioned previously, NIK belongs to the MAP kinase family.  
Considering this approach, the following compounds were investigated 
(Figure 30): 
 
Figure 30:  Commercial molecules reported as kinase inhibitors in the literature. 
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Compound 24 is a selective p38 MAP kinase inhibitor with an ATP-
competitive mechanism.99,120 Compounds 25, 26 and 27 are MEK 
inhibitors,121-126 and staurosporine 28 is a multi-kinase inhibitor previously 
mentioned in the molecular modelling and docking studies.113,127 This 
molecule is the reference inhibitor for each enzymatic and cellular assay. 
 
 
 
 
 
 
  
 
 
At this point, we own a diversified collection of chemical 
compounds formed by pyrazolo[4,3-c]isoquinolines 5a-d claimed in 
a patent as NIK inhibitors,110 analogous pyrazolo[3,4-c]isoquinolines 
11a-l, fragments like pyrazolopyridine Y or isoquinolines X, and 
inhibitors of kinases described in the literature as active on kinase 
structurally close to NIK. A biological evaluation of all these 
molecules is now considered and the results are reported in the 
following section. 
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5.  Biological evaluation 
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5.1  Human recombinant NIK inhibition  
 
 A radiometric protein kinase assay, performed by ProQinase GmbH, 
Freiburg, Germany, measured the activity of NIK in presence of the potential 
inhibitors, at a single concentration of 10 µM. Briefly, NIK was expressed in 
Sf9 insect cells as human recombinant GST-fusion protein and purified by 
affinity chromatography using GSH-agarose.  The substrate, a recombinant 
protein kinase (RBER-CHKtide) was expressed in E.coli.  The assay cocktail 
was incubated at 30°C for 60 minutes with [γ-33P]-ATP (1 µM, pH 7.5).  
Incorporation of 33P was measured with a microplate scintillation counter.  
Staurosporine was chosen as reference.113,127 
 
 
 
Figure 31: ProQinase in vitro enzymatic assay 
 
 
 Inhibitory potency of each previously described molecule was then 
evaluated (Table 6). 
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Table 6:  Inhibition of NIK in presence of pyrazoloisoquinolines 5a-d and 11a-l 
(10µM).  Mean + SD (n = 3). 
                              
 
Molecule R1 R2 R6 R7 R8 
NIK inhibition 
(10µM) 
Staurosporine 28  72% 
5a Ph 
 
- - - 6% 
5b Ph 
 
- - - 0% 
5c Me 
 
- - - 18% 
5d Me 
 
- - - 2% 
11a - - Me Me H 2% 
11b - - Me H H 0% 
11c - - H H H 4% 
11d - - Me Me OH 8% 
11e - - H Me H 2% 
11f - - Me H OH 0% 
11g - - H H OH 0% 
11h - - Et Me H 0% 
11i - - Et H H 0% 
11j - - Me H OMe 0% 
11k - - Me 2-pyridyl H 9% 
1ll - - Me Ph H 0% 
 
 91 
 Although the inhibition of NIK in the presence of staurosporine was 
confirmed, none of the pyrazoloisoquinolines (10µM) significantly reduced 
the NIK activity (Table 6). This corroborates the modelling study and 
demonstrates that the pyrazolo[4,3-c]isoquinolines 5a-d are not NIK 
inhibitors.  Moreover, the pyrazolo[3,4-c]isoquinolines 11a-l do not inhibit 
NIK. Except staurosporine 28, none of the commercial molecules 
structurally close to pyrazolo[4,3-c]isoquinolines 17-22 or reported as kinase 
inhibitors 24-28 blocked the kinase activity of NIK.   
 
 At this point, the pyrazolo[4,3-c]isoquinoline scaffold patented by 
Aventis can not be considered as NIK inhibitor.  To confirm this scaffold 
can not inhibit other proteins of the NF-κB alternative pathway, their 
inhibition property was then investigated in a cellular assay where this 
alternative pathway was solely involved. 
 
 
5.2  NF-κB alternative pathway inhibition 
 
 The cellular assays regarding the alternative pathway were 
performed by Caroline Remouchamps and Corinne Ganeff under the 
supervision of Emmanuel Dejardin from the laboratory of Virology and 
Immunology (GIGA, University of Liège). Briefly, pyrazolo[4,3-
c]isoquinolines 5a-d were assayed using carcinoma Hela cells expressing 
LTβR.  The NF-κB alternative pathway was induced or not by an LTβR 
agonist antibody. After induction, NIK was overexpressed and the 
processing of p100 into p52 was triggered by phosphorylation of IKKα 
(Figure 32). Then, the p100/p52 ratio was finally analysed by Western blot, 
as reported on figure 33.  
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Figure 32: Alternative pathway activation assay 
 
 
 Staurosporine, which strongly inhibit isolated human recombinant 
NIK, also clearly blocks the p100/p52 processing (Figure 33).  Here again, 
none of the pyrazolo[4,3-c]isoquinolines 5a-d inhibited the NF-κB 
alternative pathway.  In fact, the processing of p100 into p52 was observed 
in the presence (+) and in the absence (-) of 5a-d whatever the concentration 
of the inhibitor (10, 20 or 50 µM).  On the contrary to the claims of the 
original patent, the pyrazolo[4,3-c]isoquinolines 5a-d cannot be considered 
neither as NIK inhibitor nor as blocker of the NF-κB alternative pathway.  
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Figure 33: Processing of p100 into p52 from Hela cells expressing LTβR stimu-
lated by an LTβR agonist antibody (AGO). Cells were incubated in absence or in 
presence of pyrazolo[4,3-c]isoquinolines 5a-d or with staurosporine.  DMSO used 
as cosolvent has no effect. 
 
5.3  Multikinase Assay 
 
 With the aim of identifying the putative target of the pyrazolo[4,3-
c]isoquinolines and pyrazolo[3,4-c]isoquinolines, a multikinase screening 
assay was performed. One compound of each series (5d and 11f) was 
selected to carry out this study. Their inhibitory protency (10 µM) was 
evaluated on a panel of 263 kinases (Millipore KinaseProfiler™, Table of 
results in the Appendix).  
 
 94 
 As a result, the inhibition of at least 50% was observed for 92 and 98 
kinases over the 263 assayed in presence of 5d or 11f, respectively.  Both 
scaffolds are clearly good kinase inhibitor templates. However, no kinase 
groups or families seems to be more affected than others. Both pyrazolo-
isoquinolines inhibit indiscriminately more than a third of our kinase panel. 
Nevertheless, among these, 5d particularly decreased (70%) the activity of 
TAK1, a TGF-β−activated kinase involved in the classical NF-κB pathway 
(see Introduction, figure 4).  To confirm this interesting result, an enzymatic 
assay on TAK1 was immediately performed with pyrazolo[4,3-
c]isoquinolines 5a-d.  
 
5.4  TAK1 inhibition 
 
 The TAK1 dose-inhibitory potency of compounds 5a-d was 
evaluated using a Lanthascreen® Eu Kinase Binding Assay (performed by 
Invitrogen Limited, Paisley, Scotland, United Kingdom).  Briefly, this assay 
is based on the detection of the binding of a “tracer” to a kinase by addition 
of a Eu-labeled anti-tag antibody.  The binding to a kinase of both tracer and 
antibody results in a high degree of FRET, whereas displacement of the 
tracer with a kinase inhibitor results in a loss of FRET (Figure 34). The 
results are reported in Table 7:  
 
Table 7: IC50 of pyrazolo[4,3-c]isoquinolines 5a-d against TAK1. 
Cpd TAK1 IC50 (µM) 
staurosporine 0.021 
5a NI (at 10µM) 
5b NI (at 150µM) 
5c 0.58 
5d 2.1 
NI = no inhibition at the reported maximum concentration 
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Figure 34: Schematic of LanthaScreenTM Eu Kinase Binding Assay 
 
 As expected, staurosporine 28, the reference inhibitor in this assay, 
strongly inhibits TAK1 with an IC50 of 0.021 µM. From the four compounds 
analysed, 5c and 5d, effectively inhibit TAK1 with an IC50 value of 0.58 and 
2.1 µM respectively, whereas no inhibition was observed at 10µM and 
150µM for 5a and 5b respectively.  
 
5.5  NF-κB classical pathway inhibition 
 To access the effective inhibition of TAK1 in the canonical 
activation pathway of NIK, a last assay was performed using Hela cells.  
Briefly, 5c (50 µM), the best TAK1 inhibitor (IC50 = 0.58 µM), was assayed 
on carcinoma Hela cells where the NF-κB classical pathway was induced by 
TNFα (100 U/mL). As readout, the TNFα and IL-6 mRNA levels were 
quantified (in presence or in absence of 5c) and normalised with respect to 
control conditions. As expected, TNFα doubles the relative TNFα mRNA-
level 1 h (x2.2) and 2 h (x1.9) following induction, whereas the induction in 
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presence of 5c is only x0.77 and x0.65 respectively (Figure 35). TNFα 
strongly increases the relative IL-6 mRNA-level 1 hour (x3.7) and 2 hours 
(x3.8) after induction. Conversely, the addition of 5c prevents an increase of 
the normalised IL-6 mRNA-levels which are x0.5 and x0.7 when measured 
1h and 2h after induction respectively. 
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Figure 35:  Normalised TNFα and IL-6 mRNA levels induced by TNFα (100 U/ml) 
in absence or in presence of TAK1 inhibitor 5c (50 µM). Measurements were 
conducted 1h and 2h following TNFα addition. TNFα and IL-6 mRNA levels prior 
to TNFα addition (CTRL) are considered as 1. Mean + sd. 
5c 
5c 
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5.6  Docking of pyrazolo[4,3-c]isoquinoline into TAK1  
 
 As the 3D-coordinates of TAK1 are available (PDB code 2EVA),128 
molecular interactions stabilising 5c and 5d inside the TAK1 cavity were 
analysed with a view to identify the structural elements required for their 
inhibitory potency. When 5c or 5d are docked inside the TAK1 binding 
cleft, all of the 20 conformations adopt a unique orientation corresponding to 
a deep insertion in the cavity of the pyrazolo[4,3-c]isoquinoline. The R1-
methyl points towards the entrance of the active site (Figure 36a). Both 
compounds are stabilised by: 
 1. two H-bonds with residues E105 and A107 in the hinge region; 
 2. hydrophobic interactions with residues V50, A61 and L163.   
So, 5c and 5d fit perfectly the TAK1 ATP-binding site (Figure 36). 
  
 Interestingly, the inactivity of compounds 5a and 5b might be 
explained by a steric clash between the phenyl group in position R1 of the 
pyrazolo[4,3-c]isoquinoline ring and the residue Y106 of TAK1 (Figure 
36c).  
 
 Thus, this study highlights the molecular interactions of 
pyrazolo[4,3-c]isoquinolines 5c-d with TAK1. When the R1-methyl is 
replaced by bulkier group such as a phenyl (5a-b), the steric hindrance 
certainly prevents its binding to TAK1 and suppresses their inhibitory 
potency against this kinase.   
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Figure 36:  Molecular interactions between TAK1 and (a) 5d (stick representation), 
(b) 5d and (c) 5a with sphere representation in the hinge region of TAK1. Pictures 
made using PYMOL.129 
 
a 
b c 
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5.7  TAK1 inhibition as a perspective 
 
 
 In conclusion, a multikinase screen revealed a good inhibitory 
potency of 5d for TAK1, a kinase involved in the classical NF-κB activation 
pathway. Then, a dose-response assay confirmed the inhibitory potency of 
5c-d against TAK1 with an IC50 of 0.58 and 2.1 µM respectively. Finally, a 
docking study of both compounds brought to light the molecular interactions 
of pyrazolo[4,3-c]isoquinolines 5c-d with TAK1.110 
 
 Regarding the interest for TAK1 inhibition, Tang et al. showed on 
one hand that conditional deletion of TAK1 in knockout mice leads to 
multiple organ defects, during development, and to death, after 8-10 
days,130,131 suggesting that TAK1 is essential for the development. On the 
other hand, a patent published in December 2009 described the interest of 
TAK1 inhibitors in the cancer treatment.132 In this context, the pyrazolo[4,3-
c]isoquinoline 5c appears clearly as a novel interesting TAK1 inhibitor.110 
  
 Molecular modelling can be used once more to develop stronger and 
more specific TAK1 inhibitors based on the pyrazolo[4,3-c]isoquinoline 
scaffold.  Orientation of the chemical structure 5d in the ATP-bonding site 
of TAK1 is illustrated in figure 37: 
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Figure 37:  2D representation of the pyrazolo[4,3-c]isoquinoline 5d in the ATP 
binding site of TAK1. 
 
 
 To improve the drug-enzyme interactions, the specificity pocket,90 or 
hydrophobic pocket II,86 located behind the gatekeeper (M104) could be 
targeted by adding a hydrophobic substituent on C8 of the 
pyrazoloisoquinoline (Figure 37). But the steric hindrance of the methionine 
side-chain is not propitious to favour the access to this pocket. To enhance 
inhibitor specificity, another substitution on C7 could be an interesting 
proposal to target the DFG-out conformation of the ATP-binding site, an 
inactive kinase conformation (Figure 37).86 This strategy has to consider a 
H-bond donor/acceptor link and an hydrophobic functional group targeting 
an allosteric site. For instance, imatinib is the most famous example 
considering this inhibition type.133 Another hydrophobic region is also often 
targeted in kinase inhibition. Called hydrophobic pocket I (Figure 37), this 
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site is smaller than the previous ones and is located just above the gk+3 
residue (A107). The methyl group of the pyrazole moiety is pointing right to 
this site. Substitution by ethyl, propyl or isopropyl could therefore be of 
interest. Finally, as far as a nucleophilic cysteine residue is found in the 
cavity, a covalent type inhibition could be considered. An electrophilic 
group on the scaffold could react with C174, at the lip of the ATP-binding 
site. Therefore, irreversible covalent bound is then a third way to target 
TAK1. These suggestions emerge as perspectives of this work. 
 
  
5.7 Conclusions  
 
 The initial goal of this work was to build a 3D-model of NIK and 
study a series of known pyrazolo[4,3-c]isoquinolines, claimed as NIK 
inhibitors,103 with a view to elucidate the required structural elements for 
NIK inhibition. In the absence of any experimental structural data on this 
enzyme, we built a 3D-model of NIK by using comparative modelling 
techniques. The binding of pyrazolo[4,3-c]isoquinolines claimed as NIK 
inhibitors was directly analysed in the putative active site.  Surprisingly, this 
study revealed a poor binding orientation of the template inside the ATP-
binding pocket of NIK. This suggested either a poor inhibitory potency or an 
alternative mechanism of inhibition. Based on the modelling results, we 
synthesised some pyrazolo[4,3-c]isoquinolines (5a-d) and studied their 
inhibitory potency in two tests involving NIK: (i) an isolated enzyme assay 
using human recombinant NIK, and (ii) a cellular assay where the alternative 
NF-κB pathway is only involved.  As a result, all synthesised molecules 
were completely deprived of any significant inhibition on both assays. On 
the contrary to the original patent, this confirmed these compounds were 
neither inhibitor of NIK, nor of the alternative NF-κB activation pathway. 
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By performing a multikinase screen using 5d as example, the effective target 
of these pyrazolo[4,3-c]isoquinolines in the NF-κB activation was 
elucidated.  
 
 In the original patent,103 the NIK inhibitory potency claimed by 
Flohr et al. was based on the ability of pyrazolo[4,3-c]isoquinolines 5 to 
prevent TNFα  and IL-6 release from human peripheral blood lymphocytes 
after stimulation by LPS or IL-1β. Such readout is inappropriate to 
discriminate the alternative from the classical activation pathway.  On the 
contrary, the present study demonstrated that pyrazolo[4,3-c]isoquinolines 
are not NIK inhibitors but are likely modulators of the classical NF-κB 
pathway through TAK1 inhibition. Then, these results allow to re-assess the 
inhibition mechanism in this series.110 
 
 As we aimed at designing inhibitors of the NF-κB alternative 
activation pathway, we focused again our efforts on NIK. By demonstrating 
a lack of inhibition potency of pyrazolo[4,3-c]isoquinolines against NIK, we 
validated our model, which predicted a poor affinity in this series. To 
identify novel inhibitors of this enzyme, two different virtual screenings 
(VS) based on this 3D-structure were performed and are reported in the next 
section. 
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6.  Virtual Screenings 
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 Virtual (database) screening (VS) is an increasingly important 
component of the computer-based search for novel lead compounds. Two 
fundamental different approaches are described in the literature. The first 
one is based on a VS by docking ligands into the enzymatic active site. This 
requires knowledge of the 3D-structure of the targeted protein binding site to 
filter chemical structures by their likelihood to bind to the target. A second 
approach is a VS where no data about the protein structure are 
necessary/available. In this case, one or more pharmacophores that are 
known to bind to the target are used as a structural query.134 Both screening 
procedures extract potential ligands from one or several databases according 
to appropriate criteria, in order to screen an ended number of relevant 
structures. 
 
 In the previous chapters, several results based on the 3D model of 
NIK were presented, including a mutagenesis study and a docking of 
molecules reported as NIK inhibitors. As all these investigations led to the 
validation of the 3D-model, we started a VS study based on a docking of 
compounds extracted from databases to discover potent NIK inhibitors.  
 
 
6.1  Fragment database screening 
 
 6.1.1 Fragment database 
 
 Various chemical libraries can be used to perform VS. In this work, 
the VS focused on small-size molecules. Various reasons triggered this 
choice:  
 1. Chemical space can be more efficiently probed by screening 
collections of small chemical entities rather than large molecules libraries.135 
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 2. Small molecules usually present a high ligand efficiency 
(LE).b,136,137  
 3. This approach increases the chance of hit discovery which can be 
presumably readily optimisable in further development. Such strategy offers 
an original and unique possibility to design new leads by fragment evolution 
or linking.138  
 
 A VS was then performed with an approach using a fragment 
chemical library. There is no single definition that can categorically 
distinguish between fragments and non-fragments, but there are general rules 
of thumb:139 
 1. Fragments are smaller than drug-like molecules, whether it is 
defined by MW or the number of heavy atoms (HA). 
 2. Fragments are less complex than drug-like molecules. 
 3. Fragments should be highly soluble. 
 4. Fragments should be devoid of undesirable chemical functiona-
lity, facilitating rapid development to more potent molecules. 
 
 The exact nature of a fragment library is very much depending on 
the screening protocol. In this study, the fragment database, built by Dr 
Raphaël Frederick,140 was based on molecular fragments belonging to a wide 
variety of pharmaceuticals. It contains approximately 400 fragments and all 
the combinations of these pieces can reconstitute 99% of the commercially 
available drugs.141,142   
                                                 
b
 The ligand efficiency (LE) is the ratio of the binding free energy (∆G) for a ligand 
and its molecular size measured by the number of heavy atoms (HA): 
 
LE = ∆G0/HA ≈ -RT ln(IC50)/HA ≈  -0.592 ln(IC50)/HA = LEexp 
 
LE is a useful metric for measuring the impact on activity of the addition of more 
molecular bulk. Molecules that achieve a given potency with fewer heavy atoms 
(HA) are by definition more efficient.  
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 6.1.1  Fragments screening 
 
 The selection of the fragments was performed in two steps, 
following the flowchart reported in figure 38:  
 
 
Figure 38: Fragments screening flowchart 
  
 First step: Using the automated software GOLD,114 each fragment 
was docked 3 times in the modelled ATP-binding site of NIK. All these 
structures were then visually analysed inside the NIK binding cleft. Only 
fragments interacting with hinge region were selected (Figure 38). From the 
resulting 413 docked small-size molecules, 62 structures effectively 
displayed the critical H-bond interaction with the backbone NH of L472.  
 
 Second step: The 62 fragments interacting with the hinge region 
were ranked following three different scoring functions: GOLDSCORE, 
CHEMSCORE and Astex Scoring Potential (ASP). The GOLDSCORE 
fitness function is made up of protein-ligand hydrogen bond energy, protein-
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ligand van der Waals (vdw) energy, ligand internal vdw energy and ligand 
torsional strain energy.114 CHEMSCORE estimates the total free energy 
change that occurs on ligand binding.143,144 And the ASP scoring function is 
based on force fields or on regression, where parameters are derived from a 
set of experimental binding affinities and structures.145 For each score, a 
theoretical ligand efficiency index (LEgoldscore, LEchemscore and LEasp)c was 
calculated.137,146 Subsequently, a consensus LE index (LEtotal) was obtained 
by meaning the three individual LE components. The 30 fragments 
possessing the best LEtotal were selected. Finally, the 22 compounds 
appearing as commercially available were purchased and evaluated for their 
NIK inhibitory potency (Figure 39).  
 
 6.1.2  NIK inhibition by fragments 
 
 Typically, fragments bind to a target with an affinity (KD) ranging 
from 100 to 10 mM. Detecting such a weak binding is a challenge for most 
biochemical and binding assays and routine fragment screening has relied on 
the development of a range of biophysical methods.147 Testing the 22 
molecular fragments in the same radioactive enzymatic assays was the only 
option at our disposal. The residual activity of NIK was measured in 
presence of the 22 fragments at a single concentration of 100 µM. Briefly, 
NIK, expressed in Sf9 insect cells as human recombinant GST-fusion 
protein, was purified by affinity chromatography using GSH-agarose. The 
substrate, a recombinant protein kinase (RBER-CHKtide) was also 
expressed in E.coli. The assay cocktails were incubated at 30°C for 60 
minutes with [γ-33P]-ATP (1 µM, pH = 7.5) and incorporation of 33P was 
measured with a microplate scintillation counter. The NIK inhibitory 
potency of the fragment library was assayed at 100µM (Figure 40). 
                                                 
c
 The theoretical ligand efficiency (LEscore) is obtained by dividing the affinity 
score value by the MW of the compound (LEscore = score / MW). 
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Figure 39:  Molecular fragment commercially available (black) or not (red) selected 
by virtual screening  
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Figure 40: Human recombinant NIK inhibition level by the selected 22 fragments 
(100 µM). Mean + SD (n = 3).  
 
 
 
 At this concentration, fragment F152 was the only chemical entity 
with an inhibitory potency against NIK over 20%. These results were 
considered as not strong enough to base the whole inhibitor design on them. 
It turned out that systems providing more sensitive and accurate binding 
measurements should have been complementarily used to succeed in this 
fragment screening. For example, the surface plasmon resonance or the 
nuclear magnetic resonance-based screening would be very appropriate to 
detect this fragments binding.148,149 Regrettably, both techniques require pure 
recombinant NIK availability. The production and purification of the kinase 
was considered in this project by collaborators from the University of Liège 
(ULg) with a view to crystallise it and work out enzymatic assays. But this 
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work was not achieved during this project, because of big stability issues 
with this kinase.   
 
 Nevertheless, it is interesting to observe that, by this fragment-based 
screening strategy, we selected molecules structurally related to the adenine. 
Adenine is the molecular moiety which interacts with the hinge region of the 
enzymatic pocket, this observation validates our VS approach.  
 
 
6.2  Commercial compound database screening  
 
 A second VS approach based on commercial compounds was carried 
on. Various chemical libraries like the NCI database (National Cancer 
Institute), the ACD (Available Chemical Directory) or ZINC library (over 8 
million commercially-available compounds)119 are available to perform VS. 
The latter, ZINC, was chosen, since it is free, web-accessible, offers ligands 
in a ready-to-dock 3D-format, and hits are purchasable for confirmatory 
evaluation. Using the same strategy than used for the fragment based design, 
this VS focused on small-size molecules. The VS flowchart is depicted in 
figure 41. 
 
 First step:  Lipinski-style rules typical for fragments were first 
applied to the ZINC library.150,151  The selected descriptors were molecular 
weight (150 < MW < 250), the hydrophobicity (logP ≤ 2.5) and the number 
of H-bond donors (DH ≤ 2) and acceptors (HA ≤  4) as the first filter. Then, 
all of the qualifying structures were downloaded from the ZINC website and 
transformed into a UNITY hit list file (SYBYL)108 for compatibility with our 
modelling system. This resulted in a fragment-like library of roughly 67,500 
structures (Figure 41). 
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Figure 41: Virtual screening flowchart 
  
 
 Second step:  The resulting molecules were then docked in the 
ATP-binding site of NIK using the automated GOLD program with 
parameters especially designed for a large database screening (7-8 fold 
acceleration).114 The ATP binding site of NIK was delimited by a 10Å-
sphere around staurosporine 28, chosen as reference. As previously 
described, three docking positions were generated for each compound. Their 
affinity with NIK was then assessed using the same scoring functions as 
previously described, namely GOLDSCORE, CHEMSCORE and ASP. For 
each score, a theoretical ligand efficiency index (LEscore) was 
calculated.137,146 Afterwards, the consensus LE index (LEtotal) was as well 
obtained by means of the three individual LE components. Then, 2000 
compounds possessing the best LEtotal value as well as the 100 highest 
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compounds in each individual LEscore were selected. This led to a set of 2250 
structures predicted to tightly bind NIK. 
 
 Third step:  All these structures were at this time visually analysed 
inside the NIK binding cleft, and those that did not interact in the hinge 
region were discarded (Figure 41). From the resulting 1019 compounds, 324 
structures effectively displayed the critical H-bond interaction with the 
backbone NH of L472, but only 224 of them were commercially available. 
 
 Fourth step:  From this last set, 49 compounds were chosen because 
of their structural diversity and their appropriate conformation inside the 
NIK binding cleft (Appendix 2 & 3). Briefly, the type of interaction of each 
of the 224 structures in the hinge region was analysed, and at least one 
structure per conformation was selected. Additional compounds were also 
chosen on the basis of their high LEtotal index. Compounds were ordered 
from different retailers (Chembridge, Enamine, ASDI, IBScreen, Maybridge, 
Vitas M, Alfa-Aesar, Key Organics, Oakwood, Acros, Sigma-Aldrich, 
Specs, Asinex and Apollo). 
 
 
6.3  NIK inhibition by screened commercial compounds  
 
 
 6.3.1  Enzymatic evaluation 
 
 The NIK inhibitory potency of the 49 selected compounds was first 
evaluated using the same radiometric protein kinase assay than used for the 
molecular fragments. The residual activity of NIK was measured in presence 
of each molecule at a single concentration of 50 µM. From the 49 structures 
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identified by VS, two molecules (29 and 30) displayed an interesting NIK 
inhibitory potency with around 60% NIK inhibition at 50 µM (Figure 42).  
 
 
Figure 42: Human recombinant NIK inhibition level by the selected 49 compounds 
(50 µM) reported with ZINC codes. Molecules 29 and 30 are the two best inhibitors 
and (*) denotes NIK inhibition < 0 %.  Staurosporine was used as reference. Mean + 
SD (n = 3).  
 
 
 
 At this stage, this corresponds to an enrichment rate of about 4%, 
still an excellent result taking into account the use of a homology model 
instead of experimental 3D-coordinates of NIK. The present study therefore 
highlights the excellent potential of VS for the discovery of novel hits. 
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 Compound 29 (Figure 42) is a 1,4-naphthoquinone substituted in the 
2- and 5-position by a methyl and a hydroxyl moiety, respectively. However, 
quinones are Michael acceptors and known as DNA-alkylating agents. They 
are also highly redox active molecules and can potentially lead to the 
formation of reactive oxygen species including superoxide, hydrogen 
peroxide and hydroxyl radicals. These species in turn can lead to oxidative 
stress and the formation of oxidised cellular macromolecules.152  So, despite 
the observed NIK inhibiton, 29 does not represent an interesting scaffold for 
future drug development.  
 
 On the contrary, compound 30, an 4H-isoquinoline-1,3-dione, 
represents an interesting hit for the discovery of new potent NIK inhibitors.  
 
 
6.3.2  Validation and optimisation of the 4H-isoquinoline-1,3-dione 
30 as NIK inhibitor 
 
 
 
 
Figure 43:  Structure of 4H-isoquinoline-1,3-dione 30 
  
 
 To validate the interest of the scaffold 30 against NIK (Figure 43), 
we started a research for molecules structurally related to this hit. Sixteen 
commercially available analogs of 30 were found and bought from retailers 
(Figure 44).153 Their NIK inhibitory potency was then determined at 50 µM 
(Figure 45). 
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Figure 44: Isoquinolinedione analogs 31 - 46 
 
 
 At 50 µM, five analogs 31, 32, 39, 40 and 46 were found to 
significantly inhibit NIK (>20% inhibition, Figure 45). Among them, 31 
(53% inhibition at 50 µM) and 40 (44% inhibition at 50 µM) are the most 
potent compounds. Compound 31, a 2H,4H,5H,7H-2,7-naphthyridine-
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1,3,6,8-tetrone scaffold, is structurally different from the original 
isoquinoline-1,3-dione template of 30 and therefore could constitute a novel 
interesting scaffold for the development of novel NIK inhibitor. 
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Figure 45: Inhibitory potency of isoquinolinedione 30 and analogous compounds 
(50 µM). Mean + SD (n = 3). 
  
 
 Compound 40 is an isoquinoline-1,3-dione ring substituted in the 4-
position by an ethoxymethylene group. Is it interesting to note that the 
substitution in this position seems tolerated but only with a rather small 
group. In fact, except compound 39 (25% inhibition at 50µM) substituted by 
a thiophenylmethylene moiety in this position, molecules 41, 42, 44 and 45, 
bearing a bulkier group, are completely inactive on NIK (inhibition <15% at 
50 µM, figure 45). Another hypothesis to explain the activity of 40-41 is the 
presence of a Michael acceptor exocyclic double bond which is not present 
in 41, 42, 44 and 45 (Figures 44 et 45). This reactive Michael acceptor might 
play a role in the binding of these derivatives.   
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 The dose-response inhibitory potency of the most potent compounds 
was performed. The required concentration (IC50) to reduce of 50% the NIK 
activity was evaluated for compounds 30, 31, 32, 39, 40 as well as 46, and 
compared to that of staurosporine 28, chosen as reference (Table 8). 
Although less potent than staurosporine, 30 remains the most interesting 
NIK inhibitor with an IC50 value of 51 µM. The 2,7-naphthyridine-1,3,6,8-
tetrone 31 is less potent with an IC50 of 90 µM. Compounds  32, 39, 40 and 
46 exhibit IC50 values >100µM.  
 
 As a parameter for assay quality, the Z´-factor was used for the low 
and high controls of each assay plate.154 Our criterion for repetition of an 
assayed plate is a Z´-factor lower than 0.4.155 In this experiment, Z´-factors 
did not drop below 0.77, indicating an excellent assay quality. As an 
additional control, a 1 % DMSO plate was included as an indicator for 
putative washing and/or pipetting variations. The calculated coefficient of 
variation was 5.01 %. 
  
 Interestingly, compounds 30 and 31 are characterised by a high 
ligand efficiency index (LEexp)d136 of 0.42 and 0.39, respectively whereas the 
LEexp of staurosporine is 0.22 only. So, the LEexp of 30 and 31 is above 0.3 
which is usually described as a minimum for further development,138 and 
thus corroborates their potency as novel NIK inhibitory scaffolds (Table 8).   
 
 
 
 
                                                 
d
 The experimental ligand efficiency index (LEexp) is the ratio of the coefficient 
RT ln(IC50) and the number of heavy atoms (HA) of the compound: 
 
LEexp = -0.592 ln(IC50)/HA 
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Table 8 : Concentration reducing of 50% of the NIK activity (IC50) and ligand 
efficiency index (LEexp) calculated from the IC50 and the number of HA 
 
Compound IC50 (µM) HA LEexp = -0.592 ln(IC50)/ HA  
Staurosporine 28 2.3 35 0.22 
30 51 14 0.42 
31 90 14 0.39 
32 >100 11 ND 
39 >100 18 ND 
40 >100 16 ND 
46 >100 14 ND 
HA = heavy atoms, LE = ligand efficiency, ND = not determined. 
 
 6.3.3  Molecular docking of 30 and 31 
 
 To understand how these two compounds 30 and 31 achieve their 
potency, we deeply investigated their binding conformation inside the NIK 
cavity. Both molecules were docked inside the NIK-binding site as 
previously described. In order to take into account the protein flexibility, the 
best conformation was further refined using the MINIMIZE module 
implemented in SYBYL 8.0 (Tripos force field and Gasteiger-Hückel 
charges). Key interactions stabilising the compounds 30 and 31 are depicted 
in figure 46.  
 
 Both inhibitors are deeply inserted in the NIK cavity. As expected, 
for each compound, one H-bond acceptor atom, i.e. the oxygen atom from 
the carbonyl in position 1, onto the ligand is H-bonded to the L472 backbone 
NH located in the NIK hinge region (ATP-binding site). Additionally, both 
compounds are also stabilised through a supplementary H-bond between one 
H-bond donor atom, i.e. the nitrogen atom in position 2, onto the ligand and 
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the L472 CO backbone. Except these two H-bonds, the NIK inhibitory 
potency could be attributed mainly to the close shape complementarities and 
van der Waals contacts between these two inhibitors and the NIK active site 
(Figure 46).  
 
Figure 46: Compounds 30 (a) and 31 (b) docked in the ATP binding site of NIK 
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6.4 NF-κB alternative pathway inhibition by screened commercial 
compounds 
 
 6.4.1  Biological evaluation 
 
 
 In parallel, the inhibitory potency of the 49 selected compounds was 
evaluated in the NF-κB alternative pathway. These experiments were also 
performed at the ULg (GIGA) by the group of Dr E. Dejardin.  Briefly, each 
compound was assayed using carcinoma Hela cells expressing LTβR. The 
NF-κB alternative pathway was induced (or not) by an LTβR agonist 
antibody. After induction, NIK was overexpressed and the processing of 
p100 into p52 was triggered by phosphorylation of IKKα. Then, the 
p100/p52 ratio was finally analysed by Western blot and staurosporine 28 
was used as reference. 
 
 Up to 50 µM, the compound 30 did not inhibit the alternative 
pathway. The Michael acceptor 29 displayed a strong cytotoxicity at 50µM 
and 10 µM. This is in accordance with the previously discussed properties of 
this quinone scaffold and its potential toxicity.152 No inhibition was there-
fore observed for 29.  
 
 However, an interesting result was observed with compound 47 that 
partially inhibited the alternative pathway at 50µM and 100µM (Figure 47). 
This inhibitory potency of 47 was unexpected, since no inhibition was 
observed with this compound in the radiometric assay, as previously 
reported (Figure 42,). To elucidate the inhibitory potency of the NF-κB 
alternative pathway, the biological properties of the pyrazole 47 were further 
investigated. 
 
 122 
         
 
Figure 47: Processing of p100 into p52 from Hela cells expressing LTβR stimulated 
by an LTβR agonist antibody.  Cells were incubated in absence or in presence of 47 
at 10, 50 and 100 µM.  DMSO, used as cosolvent, has no effect. 
 
   
 A cell viability assay estimating the ATP production was performed 
using a CellTiter-Glo® luminescent cell viability assay (Figure 48). 
Whatever the concentration applied, 47 did not impair the ATP production 
of the cultured Hela cells incubated for 6 hours. The inhibition of the 
p100/p52 processing observed in the assay involving the alternative pathway 
is therefore not caused by toxicity issues. 
 
 
Figure 48: Hela cells ATP production in presence of compound 47 incubated for 6 
hours at 10, 50 and 100µM. NT = not treated; DMSO was used as cosolvent 
 
  
 The inhibitory selectivity of 47 between both classical and 
alternative NF-κB activation pathways was also evaluated. In this assay, the 
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classical NF-κB activation pathway only was activated by TNFα (Figure 
49). To bear out an inhibition of this pathway by 47, the degradation of IκBα 
was analysed.  
 
Figure 49: Classical (yellow) and alternative (orange) NF-κB activation pathways 
 
 By this assay, it was demonstrated that the pyrazole 47 is not an 
inhibitor of the classical NF-κB activation pathway. As reported in figure 50, 
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when the classical pathway is activated by the agonist TNFα, the 
degradation of IκBα is complete with compound 47 (50µM) or without 
(DMSO). Conversely, when only the alternative pathway is activated by a 
LTβR agonist with the same incubation delays, 47 inhibits significantly the 
processing of p100 into p52 (Figure 50). 
 
 
 
 
 
Figure 50: NF-κB activation pathway selectivity for compound 47. NT = not 
treated; DMSO was used as cosolvent 
  
 
  
 Taking into account these results, a new hit displaying a significant 
and selective inhibition of the NF-κB alternative activation pathway was 
identified. Similarly to the previous scaffold 30, also discovered by VS, a 
validation and optimisation of this pyrazole 47 was considered. 
 
 125 
6.4.2  Validation of the 4-(2-chloroethyl)-3,5-dimethyl-1H-pyrazole 
47 as inhibitor of the NF-κB the alternative pathway 
 
 
 
 
Figure 51: Structure of 4-(2-chloroethyl)-3,5-dimethyl-1H-pyrazole 47 
 
  
 With a 2-chloroethyl function, the 3,5-dimethyl-1H-pyrazole 47 
appears as a potential alkylating agent (Figure 51). Such molecules are 
reported to be DNA cross-linking and may therefore be toxic for cells.156 
Their mode of action is characterised by an alkylation of a DNA base,157 
stopping the mitosis in the late G1 or S phase because of a destroyed 
DNA.156 Such mechanism being extremely unspecific, it seemed necessary 
to measure the relative importance of the halogen function in 47. For this 
reason, but also with a view to establish the first structure-activity 
relationships (SAR), various analogs of 47 were synthesised or purchased.  
 
 First, the 3,5-dimethyl-4-propyl-1H-pyrazole 48 was synthesised in 
order to evaluate the inhibition potency of the closest structure without any 
potential alkylating properties. This compound was prepared in two steps 
from the pentane-2,4-dione 49. The acid 3-position of the dione 49 was 
deprotonated by the 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and reacted 
with the iodopropane to form the 3-propyl-pentane-2,4-dione 50. Without 
intermediate purification, the dione 50 reacted with hydrazine hydrate to 
form the pyrazole 48 (Scheme 3). 
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Scheme 3 : Synthesis of 3,5-dimethyl-4-propyl-1H-pyrazole 48 
 
 In parallel, various structurally related compounds were searched in 
commercial databases. Eleven available molecules displaying a common 4-
(2-ethyl)-3,5-dimethyl-1H-pyrazole moiety were purchased. Every analogs 
were then evaluated in the NF-κB alternative activation pathway (Figure 51). 
 
 
Figure 51: Commercial compounds structurally related to 47 
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 First, compound 59 displayed an interesting inhibitory potency 
against the alternative pathway. Unfortunately, this inhibition is explained by 
an important toxicity for compound 59, expressed as a reduced cells ATP- 
production (Figures 52). 
 
 
 
Figure 52: Processing of p100 into p52 from Hela cells expressing LTβR stimulated 
by an LTβR agonist antibody (LIGHT). Cells were incubated in absence or in 
presence of compounds 58, 53 and 59 at 10µM and 50 µM. Only 59 displays a 
partial inhibitory potency at 50 µM. A cell viability assay, expressed as ATP 
production, shows an important toxicity for compound 59 at 100µM and 50µM. 
DMSO was used as cosolvent. 
 
 
 
 
 128 
 Conversely, analogs 51 and 52 inhibit the processing of p100, as 
reported in figure 53: 
 
 
 
Figure 53: Processing of p100 into p52 from Hela cells expressing LTβR stimulated 
by an LTβR agonist antibody (LIGHT).  Cells were incubated in absence or in 
presence of compounds 47, 51 and 52 at 10µM, 50 µM and 100 µM. 
 
 
 In comparison to the previously discovered fragment 47, 4-(2-
bromoethyl)-3,5-dimethyl-1H-pyrazole 51 is significantly more potent and 
inhibits partly the alternative pathway even at 10 µM (Figure 53). The 
inhibitory potency of the 4-(2-amino-ethyl)-3,5-dimethyl-1H-pyrazole 52 is 
however less interesting with a partial inhibition of the p100 processing only 
at 100µM. Cell viability assays was also performed to assess that the 
observed inhibition is not induced by toxicity issues. As a result, 51 impairs 
the ATP production at 100 µM only (Figure 54). 
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Figure 54: Cell viability assays, expressed as ATP production, for compounds 51 
and 52 at 100, 50 and 10 µM. DMSO was used as cosolvent. 
 
  
 
 Finally, in this series, two compounds displaying a good inhibitory 
potency against the alternative pathway were identified. Unfortunately, these 
two compounds 47 and 51 are both potential alkylating agents and this 
inhibition mechanism can not be excluded.  So, potential side-effects due to 
a lack of specificity are underlying any further development of this series. 
Nevertheless, it remains essential to assess its inhibition mechanism as well 
as its effective target in this pathway. To our knowledge, 4-(2-halogeno-
ethyl)-3,5-dimethyl-1H-pyrazoles are the first selective inhibitors of the NF-
κB alternative activation pathway. 
51 
52 
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6.5 Conclusion 
 
 
Figure 55: VS summary 
  
 
 At the end, it is interesting to turn back to the first reported 
structures identified by fragment screening. Even if the detection techniques 
were inappropriate for low affinities due to small molecules, the compounds 
selection was actually very coherent. Most of these fragments, reported in 
the figure 39, are structurally very close to at least one of these three 
scaffolds:  
1. adenine, the natural substrate of kinases (f201, f127, f152, f270, 
f396, f408, f190, f183, f302, f411, f400, f407, f409 and f311); 
2. isoquinolinedione 30, identified by VS as a putative NIK inhibitor 
(f212, f270, f231, f190, f302, f124, f311, and f106); 
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 3. pyrazole, as highlighted by VS with the series of compounds 47 
and 51 and inhibiting the alternative pathway (f068, f168, f169, 
f128, f392, f151, f403, f395 and f409). 
So, even in absence of outstanding results, the 3D-model used for high-
throughput docking is undoubtedly validated. 
 
 Thus, this VS study led to the discovery of two series of inhibitors 
(Figure 55). First, the 4H-isoquinoline-1,3-dione 30 exhibited an IC50 of 
51µM against NIK. As this hit was validated, it corresponds to an 
enrichment rate of about 2%. Although enrichment rates in the range of 10% 
to 30 % were previously reported by VS using experimentally determined 
3D structures, this is still an interesting rate taking into account (i) the use of 
an homology model but not experimental 3D-coordinates of NIK for the VS, 
and (ii) that the hit rate usually obtained by high-throughput screening is 
only 0.02% in most cases.158 The present study is therefore another example 
highlighting the potential of VS for the discovery of novel hits. Thanks to a 
structural research, the 2H,4H,5H,7H-2,7-naphtyridine-1,3,6,8-tetrone 31 
was also evaluated and displayed an IC50 of 90 µM. Both inhibitors 30 and 
31 displayed good LEexp comparing to staurosporine 28.159 
  
 The binding modes of both molecules within NIK were finally 
evaluated, and revealed essential features responsible for their NIK 
inhibition potency. Particularly, these compounds interact with the hinge 
region of NIK via a lactam moiety, similarly to staurosporine which is 
known to be an ATP-competitive pan-kinase inhibitor. Based on this 
observation, it could be hypothesised that these molecules inhibit NIK with a 
similar mechanism. 
 
 The isoquinolinyl scaffold of 30 was recently reported as a cyclin-
dependent kinase 4 (CDK4) inhibitor.160,161 So, the screening of a selection 
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of commercial compounds in the 3D-model of NIK led to the discovery of 
potent inhibitors previously validated on a structurally related target 
(CDK4), corroborating the relevance of our strategy as well as our tools. 
Moreover, despite a common structural moiety with this CDK4-inhibitor 
series, the fragment based approach allows us to avoid specificity issues. It 
remains therefore to develop these scaffolds 30 and 31 which are, to the best 
of our knowledge, the first validated NIK inhibitors (with the recently 
patented alkynyl-alcohol).101,110 
 
 Secondly, 4-(2-halogenoethyl)-3,5-dimethyl-1H-pyrazoles like com-
pounds 47 and 51 were identified as NF-κB alternative activation pathway 
inhibitors. Their mechanism of action remains to be clarified and, being 
potential alkylating agents, the specificity issues of this series must be 
considered in the scaffold optimisation. Fortunately, a first cell viability 
assay performed revealed the absence of cytotoxicity for molecular 
fragments 47 (at 100, 50 and 10 µM) and 51 (at 50 and 10 µM). On this 
account, these molecules are very promising in the field of the alternative 
pathway investigation.  
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Conclusion and perspectives 
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 In the field of inflammation, our research focused on the inhibition 
of the NF-κB alternative activation pathway, a new promising therapeutic 
strategy against pathologies like RA. In this protein cascade, NIK was 
considered as a promising target for drug design. The number of known 
inhibitors for this kinase being very limited, we studied this enzyme on 
different levels. 
 
 In the absence of any experimental structural data on NIK, we built 
and validated the first 3D-model of NIK using comparative modelling 
methods.  The ATP-binding site of NIK was then investigated deeper by 
means of a mutagenesis study leading to the identification of key amino 
acids. On one hand, some highly recovered residues were by this way 
recognised and located in the 3D-structure (K429 and T559). Their role in 
the phosphate transfer mechanism was confirmed by the effective inability 
of their mutant to activate the corresponding pathway. On the other hand, 
new residues identified by a four filters selection were also acknowledged as 
essential for the enzymatic activity of NIK (F436, D534, F535 and H562). In 
the meantime, K430 was also demonstrated to be unnecessary for its 
phosphorylation mechanism. 
 
 With a view to elucidate the required structural elements for NIK 
inhibition, we started a docking study of a series of pyrazolo[4,3-
c]isoquinolines, claimed as NIK inhibitors.103 The binding of these 
pyrazolo[4,3-c]isoquinolines was directly analysed in the putative active site 
of NIK, revealing a poor binding orientation of the template. Conversely, the 
docking of the pankinase inhibitor staurosporine 28 was consistent and 
reproducible. This suggested either a poor inhibitory potency or an 
alternative mechanism of inhibition for pyrazolo[4,3-c]isoquinolines (5a-s).   
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 Based on this docking study, some pyrazolo[4,3-c]isoquinolines (5a-
d) and some structurally related pyrazolo[3,4-c]isoquinolines (11a-l) were 
synthesised to evaluate their inhibitory potency in two different assays 
involving NIK. The first in vitro assay was performed with human 
recombinant NIK. The second one was a cellular assay where the alternative 
NF-κB pathway only was induced by a LTβR agonist. As a result, all 
synthesised molecules were completely deprived of any significant 
inhibition on both systems. Nevertheless, staurosporine 28, which was used 
as positive control, validated the tests. These compounds were then neither 
inhibitor of NIK, nor of the NF-κB alternative activation pathway, 
confirming the docking study and validating the 3D-model of NIK.  
  
 To elucidate the potential target of these pyrazolo[4,3-c]isoquino-
lines in the NF-κB activation, a multikinase screen was performed using 5d 
as example. This screening revealed interesting inhibition properties of 5d 
against TAK1, a kinase which is involved in the classical NF-κB activation 
pathway. This was further confirmed by the determination of the inhibitory 
potency (IC50) of 5c-d vs. TAK1. This study allowed then to re-assess the 
inhibition mechanism of this series and led to a reliable 3D-model of NIK, 
used to search for novel inhibitors by virtual screening (VS). 
 
 The last part of this work was based on two different VS strategies:   
a commercial compounds database screening and a molecular fragment 
database screening. Unfortunately, the fragments screening led to the 
identification of molecules with low affinities. It was due to the small-sized 
selected compounds and to experimental techniques being not adapted to 
detect such binding. Conversely, the commercial compounds database 
screening was successful. We proceeded to combine various filters including 
high-throughput docking, using the 3D-homology model and ranking 
through different scoring functions.  
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 From the 49 selected and assayed final compounds, two molecules 
exhibiting a NIK inhibitory potency of about 50% at 50 µM were identified 
(29 and 30). One of them (30) was characterised by an IC50 of 51µM.  
Structural analogs of the isoquinolinedione 30 were then searched, leading to 
the identification of 31 endowed with an inhibitory potency (IC50) around 90 
µM. The binding modes of these two molecules within NIK were evaluated, 
revealing features responsible for their NIK inhibition potency. These two 
chemical fragments are characterised by excellent experimental ligand 
efficiency (LEexp), thus making them very potent and interesting starting 
points for the development of new structures for NIK inhibition. 
 
 After the same VS study, compound 47 was identified as inhibitor of 
the NF-κB alternative activation pathway. Another compound (51), 
structurally close to 47, effectively inhibits this pathway as well, confirming 
the interest of this 4-(2-halogenoethyl)-3,5-dimethyl-1H-pyrazole scaffold. 
Unfortunately, a halogeno-ethyl group seems to be necessary for the activity 
of these pyrazoles 47 and 51. Though, such chemical structures are potential 
alkylating agents, leading to the fear of a lack of specificity in this series. 
Nevertheless, this scaffold remains very interesting for several reasons: 
 1. As far as we know, this is the only series effectively and 
selectively inhibiting the alternative pathway activation of NF-κB. 
 2. Up to now, the target remains uncertain and further developments 
could lead to the identification of (i) a new protagonist of the alternative 
pathway; (ii) a cytosolic form of NIK different from of the kinase expressed 
in insect cells as human recombinant GST-fusion protein (as used in the 
radiometric assay) or (iii) an non-competitive mechanism of inhibition of 
NIK, stabilising the phosphorylated form of the enzyme and leading to its 
degradation. These hypotheses could explain a lack of activity in the 
radiometric enzymatic assay with 47. 
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 3. Despite the potential alkylation mechanism of this series, this 
mode of action remains to be demonstrated. In case of inhibition of NIK 
(non-competitive or ATP-competitive inhibition, as suggested by the 
docking of 47 in the hinge region of NIK shown in figure 56) various 
pharmacomodulations around this scaffold could lead to bioisosteres of 47 
and 51. Such molecular analogs could then display the same (or better) 
inhibition properties without any potential alkylating group.  
 
 For all these reasons, the discovery of the 4-(2-halogenoethyl)-3,5-
dimethyl-1H-pyrazole series by VS is a critical step in the study of the 
alternative pathway. 
 
 
Figure 56: Docking of 47 on the ATP-binding cleft of NIK 
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  We had chosen a strategy based on small molecules identification 
and offering possibilities of designing new hits by growing the lead chemical 
structure. As we identified two scaffolds endowed with good affinities with 
the hinge region of NIK, two possibilities exist to amplify rationally the 
potency of these series: 
 1. Linking: This first strategy identifies new fragments (by VS for 
example) endowed with high affinities with other regions of the ATP-
binding site of NIK. Then every validated fragment is chemically linked to 
another to form a new original and specific inhibitor of NIK. 
 2. Evolution: This second strategy is based on a genetic algorithm  
working with a "trial and error approach" to increase the size and weight of 
the lead structure inside of the modeled binding cleft. 
 
 By building, validating and taking advantage of molecular modeling 
tools, we finally succeeded in discovering molecular fragments inhibiting 
NIK and the alternative pathway, both attractive targets for the treatment of 
RA.   
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Material and methods 
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1. Molecular modelling 
 
1.1  Homology modelling  
 
 The human M3K14 (NIK) sequence was obtained from the Swiss-
Prot database (primary accession number Q99558).  Sequence alignment 
was performed using BLASTp,104 through the Protein Data Bank 
(BLOSUM62 matrix).105 The human PAK1 protein (PDB code 1YHW_A) 
was selected as the most appropriate template. Then, a consensus amino acid 
alignment and the 3D construction of the model was performed by 
ESyPred3D.106 The quality of the model (including Ramachandran Plot) was 
analysed by means of PDBsum server.162 To take into account protein 
flexibility, the resulting model was minimised using the MINIMIZE module 
included in SYBYL 8.0 program.108  
 
1.2  Docking simulations 
 
 Every compound evaluated in a docking study were built using the 
SKETCH module, as implemented in SYBYL (version 8.0),108 and their 
geometry was optimised using MINIMIZE module. The minimisation 
process uses the POWELL method with the TRIPOS force field (dielectric 
constant 1r) to reach a final convergence of 0.01 kcal.mol-1. Docking 
simulation was then performed (i) into the homology model of the human 
kinase NIK or (ii) into the 3D-structure of the kinase domain of TAK1,128  
with the automated GOLD program. Concerning NIK, the active site was 
defined including all residues in a volume of 7-10Å around 3-OH-
staurosporine superimposed onto the model of NIK.  
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 A similar procedure was used to dock 5c-d inside the TAK1 binding 
cleft using the 3D-coordinates obtained from X-ray diffraction.128  In the 
case of TAK1, the active site was defined by a sphere of 15Å around residue 
A107 in the active site.  
 
2. Chemistry  
 
 Every reagents, products and solvents were purchased from ACROS 
ORGANICS, SIGMA-ALDRICH or MERCK EUROLAB. 
 
 1H NMR spectra were recorded at 20°C in CDCl3 or DMSO-d6 on a 
400 MHz Jeol Spectrometer (Jeol JNM EX-400). Chemical shifts are 
reported in δ ppm relative to tetramethylsilane (TMS) as a singlet at 0 ppm 
(δ). Thin-Layer Chromatography (TLC) was performed on aluminum 
supported 0.25 mm silica gel plates (Merck 5719, 250 meshes).  TLC plates 
were visualized under 254 nm and 320 nm UV light.  Elemental analyses (C, 
H, N) were performed on a Thermo Finnigan FlashEA 1112 apparatus.  
Mass spectra were recorded on an 1100 series MSD Trap spectrometer 
equipped with an electrospray ionisation (ESI) source. Flash chromato-
graphy purifications were performed on a Biotage SP1 Purification System 
using silica or C18 Biotage FLASH+® Cartridges. Microwave assisted 
reactions were performed using an Initiator 16 Single-mode Microwave 
system producing a 2.450 GHz controlled irradiation (Biotage AB, Uppsala).  
The temperature was measured with an IR sensor on the outside of the 
reaction vial.  
  
 Elemental micro analyses (C, H, N, S) were performed on a 
Thermo Finnigan FlashEA 1112 elemental analyser. 
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 Purity of compounds 5a-d was also confirmed by LC with an 
Agilent 1100 series system. System control, data collection and data 
processing were accomplished with the ChemStation software (Agilent 
Technologies, Santa Clara). The mobile phase contained acetonitrile and 
acetic acid (0.1%). Compounds were detected and their purity was calculated 
using a UV detector (wavelength λ = 240 nm). Two different methods were 
used to analyse the reported compounds.  Method 1: injection volume = 3 µL 
in acetonitrile; gradient elution from 5% to 95% of acetonitrile over 2.4 min, 
then 95% acetonitrile until 3.6 min; analytical column C8 Zorbax Eclipse 
Plus (4.6 mm x 50 mm, 1.8 µm particle size); flow rate = 1.25 mL.min-1; 
temperature = 40°C. Method 2: injection volume = 5 µL in acetonitrile; 
gradient elution from 5% to 95% of acetonitrile over 4.5 min, then 95% 
acetonitrile until 8.0 min; analytical column C18 Zorbax SB column (3.0 
mm x 100 mm, 3.5 µm particle diameter); flow rate = 0.5 mL.min-1; 
temperature = 40°C.  Retention times were reported as Rt1 and Rt2 for these 
two methods respectively. 
 
1-Phenylbutane-1,2,3-trione-2-oxime 7a - The titled compound is 
commercially available. 
 
1,3-Diphenyl-propane-1,2,3-trione 2-oxime 7b - 240 mg (3.46 mmol) of 
sodium nitrite were dissolved in water (2 mL), and added dropwise to a 
solution of 130 mg (0.58 mmol) of dibenzoylmethane 6b diluted into acetic 
acid (10 mL). At room temperature, the solution was stirred for 1 hour.  The 
reaction mixture was extracted three times with diethyl ether (20 mL). The 
organic layers were combined and washed with a saturated aqueous solution 
of sodium bicarbonate (30 mL). Solvents were evaporated under reduced 
pressure, and the crude product purified by flash chromatography to give the 
title compound (Silica column; eluant AcOEt:cyclohexane with a gradient 
from 8% to 30% of AcOEt over 30 min; flow rate 40 mL/min). Yield: 81%. 
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1H RMN (CDCl3, 400 MHz): δ = 7.48-7.54 (m, 4H, Harom), 7.63 (m, 2H, 
Harom), 7.92 (d, J = 7.2 Hz, 2H, Harom), 8.10 (d, J = 7.2 Hz, 2H, Harom), 8.33 
(s, 1H, OH). Anal. Calcul. for C15H11NO3: C, 71.14; H, 4.38; N, 5.53. Found: 
C, 71.29; H, 4.62; N, 5.23. MS (ESI+) m/z 254.0 [M+H]+, 276.1 [M+Na]+ 
 
4-Amino-3-methyl-5-phenyl-1H-pyrazole 8a - At 0°C, hydrazine hydrate 
(0.18 mL, 3.70 mmol) was added dropwise to a solution of commercially 
available 1-phenylbutane-1,2,3-trione-2-oxime 7a (0,37 mmol) in ethanol (4 
mL). Then, the mixture was stirred for 7 hours at room temperature. Solvents 
were removed under reduced pressure and the crude product diluted in ethyl 
acetate (10 mL). The solution was acidified by HCl 3N (15 mL) and the 
organic layer discarded. The aqueous layer was neutralised by NaOH 1 N 
(50 mL) and extracted with ethyl acetate (3 x 20 mL). The organic layers 
were combined, dried on magnesium sulfate, and the solvent evaporated 
under reduced pressure. The crude product was purified by flash 
chromatography (Silica column; eluant: AcOEt:cyclohexane from 20% à 
100% of AcOEt over 45 min; flow rate: 40 mL.min-1). Yield: 86%. 1H 
RMN (CDCl3, 400 MHz): δ = 2.37 (s, 3H, CH3), 7.31 (t, J = 7.6 Hz, 1H, 
Harom), 7.42 (t, J = 7.6 Hz, 2H, Harom), 7.61 (d, J = 7.6 Hz, 2H, Harom). Anal. 
Calcul. for C10H11N3: C, 69.34; H, 6.40; N, 24.26. Found: C, 69.30; H, 6.14; 
N, 23.56. MS (ESI+) m/z 174.1 [M+H]+ 
 
4-Amino-3,5-diphenyl-1H-pyrazole 8b – The title compound was 
synthesised from 1,3-diphenyl-propane-1,2,3-trione 2-oxime 7b and 
hydrazine hydrate with the same procedure than that used for 8a. Yield: 
88%. 1H RMN (CDCl3, 400 MHz): δ = 7.25 (t, J = 7.4 Hz, 2H, Harom), 7.48 
(t, J = 7.4 Hz, 4H, Harom), 7.68 (d, J = 7.4 Hz, 4H, Harom). Anal. Calcul. for 
C15H13N3: C, 76.57; H, 5.57; N, 17.86. Found: C, 76.27; H, 5.65; N, 17.62. 
MS (ESI+) m/z 236.2 [M+H]+ 
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4-Benzamido-3,5-diphenyl-1H-pyrazole 10a - Benzoic acid 9a (92.6 
mmol), hydroxybenzotriazole (HOBt; 185 mmol) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (DEC; 79.5 mmol) were added 
to 4-amino-3,5-diphenyl-1H-pyrazole 8b (92.6 mmol) diluted in 
dichloromethane (30 mL). Two drops of BMimpF6 (1-butyl-3-
methylimidazolium hexafluorophosphate) were added, and the mixture was 
heated in the microwave oven for 1 hour (70°C). Then, water (20 mL) was 
added and the mixture extracted by ethyl acetate (3 x 20 mL) The organic 
layers were combined, dried on magnesium sulfate, and the solvent 
evaporated under reduced pressure. The crude product was purified by flash 
chromatography (Silica column; Eluant: AcOEt:cyclohexane from 20% to 
71% of AcOEt over 40 min; flowrate: 40 mL.min-1). Yield: 60%.1H 
RMN (CDCl3, 400 MHz): δ =  7.28-7.46 (m, 6H, Harom), 7.49 (t, J = 7.3 Hz, 
2H, Harom), 7.56 (t, J = 7.3 Hz, 1H, Harom), 7.64 (d, J = 6.3 Hz, 2H, Harom), 
7.72 (d, J = 6.3 Hz, 2H, Harom), 7.92 (d, J = 7.3 Hz, 2H, Harom), 9.96 (s, 1H, 
HNamide). Anal. Calcul. for C22H17N3O·H2O: C, 73.93; H, 5.36; N, 11.76. 
Found: C, 74.03; H, 5.13; N, 11.42. MS (ESI+) m/z 340.2 [M+H]+, 362.2 
[M+Na]+  
 
4-(3-Methoxybenzamido)-3,5-diphenyl-1H-pyrazole 10b - The title 
compound was synthesised from 3-methoxybenzoic acid 9b and 4-amino-
3,5-diphenyl-1H-pyrazole 8b as starting material, and according to the same 
procedure than that described for 10a. Yield: 60%. 1H RMN (DMSO- d6, 
400 MHz): δ = 3.77 (s, 3H, OCH3), 7.12 (d, J = 8.2 Hz,  1H, Harom), 7.26-
7.45 (m, 8H, Harom), 7.52 (d, J = 7.3 Hz, 1H, Harom), 7.64 (d, J = 7.3 Hz, 2H, 
Harom), 7.72 (d, J = 7.3  Hz, 2H, Harom), 9.94 (s, 1H, HN). Anal. Calcul. for 
C23H17N3O: C, 78.61; H, 4.88; N, 11.96; C, 78.04; H, 5.19; N, 11.58. MS 
(ESI+) m/z 369.2 [M+H]+, 391.3 [M+Na]+ 
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4-(3-Methoxybenzamido)-3-methyl-5-phenyl-1H-pyrazole 10c - The title 
compound was synthesised from 3-methoxybenzoic acid 9b and 4-amino-3-
methyl-5-phenyl-1H-pyrazole 8a as starting material, and according to the 
same procedure than that described for 10a.  Yield: 57%. 1H RMN (DMSO-
d6, 400 MHz): δ = 2.08 (s, 3H, CH3), 3.78 (s, 3H, OCH3), 7.12 (d, J = 8.2 
Hz,  1H, Harom), 7.22-7.41 (m, 4H, Harom), 7.49 (s, 1H, Harom), 7.54 (d, J = 7.5 
Hz, 1H, Harom), 7.6-7.7 (m, 2H, Harom), 9.69 (s, 1H, HN). Anal. Calcul. for 
C18H17N3O2: C, 70,34; H, 5,58; N, 13,67. Found: C, 70,51; H, 5,35; N, 
13,36. MS (ESI+) m/z 308.2 [M+H]+. 
 
4-Benzamido-3-methyl-5-phenyl-1H-pyrazole 10d - The title compound 
was synthesised from benzoic acid 9a and 4-amino-3-methyl-5-phenyl-1H-
pyrazole 8a as starting material, and according to the same procedure than 
that described for 10a. Yield: 75%. 1H RMN (CDCl3, 400 MHz): δ = 2.26 (s, 
3H, CH3), 7.34-7.51 (m, 6H, Harom), 7.61 (d, J = 8.2 Hz, 2H, Harom), 7.71 (d, J 
= 7.5 Hz, 1H, Harom), 7.83 (d, J = 8.2 Hz, 1H, Harom). Anal. Calcul. for 
C17H15N3O .1/2 H2O: C, 71.31; H, 5.63; N, 14.68. Found: C, 72.07; H, 5.33; 
N, 14.53. MS (ESI+) m/z 278.1 [M+H]+ 
 
3,5-Diphenyl-1H-pyrazolo[4,3-c]isoquinoline 5a – 4-Benzamido-3,5-
diphenyle-1H-pyrazole 10a (0.36 mmol) and phosphorus pentoxyde (3.60 
mmol) were suspended in dry chlorobenzene (10 mL) containing N,N-
diethylaniline (0.36 mmol). Under argon atmosphere, the mixture was 
warmed up to 120°C and phosphorus oxychloride (0.54 mmol) was added 
dropwise. The temperature was maintained for 24 hours. At the end, a 
saturated solution of sodium bicarbonate (10 mL) was carefully added, and 
the mixture was extracted by dichloromethane (3 x 20 mL). The organic 
layers were combined, dried on magnesium sulfate and the solvents was 
evaporated under reduced pressure. The crude product was purified by 
preparative HPLC (C18 column and isocratic mobile phase MeCN:AcOH 
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0,1% 50:50) to give the title compound 5a. Yield: 2%. m/z 340.2 [M+H]+, 
362.2 [M+Na]+. 1H RMN (CDCl3, 400 MHz): δ = 7.35 (t, J = 7.5, 1H, Harom), 
7.46-7.71 (m, 9H, Harom), 7.97 (t, J = 8.2 Hz, 1H, Harom), 8.04 (d, J = 7.5 Hz, 
1H, Harom), 8.51 (d, J = Hz, 2H, Harom). Rt1 = 3.35 min; Rt2 = 7.49 min. MS 
(ESI+) m/z 352.2 [M+H]+. 
 
5-(3-Methoxyphenyl)-3-phenyl-1H-pyrazolo[4,3-c]isoquinoline 5b - The 
title compound was synthesised from 4-(3-methoxybenzamido)-3,5-
diphenyl-1H-pyrazole 10b as starting material and according to the 
procedure described for compound 5a. Yield: 7%. 1H RMN (CDCl3, 400 
MHz): δ = 3.81(s, 3H, OCH3), 7.11 (dd, J1 = 2.2 Hz, J2 = 8.1Hz, 1H, Harom), 
7.20-7.24 (m, 1H, Harom), 7.21 (d, J = 2.2 Hz, 1H, Harom), 7.35 (t, J = 7.3 Hz, 
1H, Harom), 7.46-7.50 (m, 3H, Harom), 7.70 (t, J = 7.7 Hz, 1H, Harom), 7.95 (t, J 
= 7.7 Hz, 1H, Harom) 8.06 (d, J = 8.4 Hz, 1H, Harom), 8.52-8.50 (m, 3H, Harom). 
Rt1 = 3.30 min; Rt2 = 7.38 min. MS (ESI+) m/z 352.2 [M+H]+. 
 
5-(3-Methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-c]isoquinoline 5c - The 
title compound was obtained from 4-(3-methoxybenzamido)-3-methyl-5-
phenyl-1H-pyrazole 10c as starting material and according to the procedure 
described for compound 5a. Yield: 6%. 1H  RMN (CDCl3, 400 MHz): δ = 
2.76 (s, 3H, CH3), 3.87 (s, 3H, OCH3), 7.03 (d, J
 
= 10.8 Hz, 1H, Harom), 
7.21-7.28 (m, 2H, Harom),  7.44 (t, J = 12.1 Hz, 1H, Harom), 7.59 (t, J = 10.8 
Hz, 1H, Harom), 7.81 (t, J = 10.8 Hz, 1H, Harom), 8.13 (d, J = 12.1 Hz, 1H, 
Harom), 8.22 (d, J = 12.1 Hz, 1H, Harom). Rt1 = 2.78 min; Rt2 = 6.15 min. MS 
(ESI+) m/z 289.3 [M+H]+. 
 
3-Methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline 5d - The title 
compound was synthesised from 4-benzamido-3-methyl-5-phenyl-1H-
pyrazole 10d as starting material and according to the procedure described 
for compound 5a. Yield: 13%. 1H RMN (CDCl3, 400 MHz): δ = 2.76 (s, 3H, 
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CH3), 7.51-7.60 (m, 4H, Harom), 7.68 (d, J = 7.5 Hz, 2H, Harom), 7.78 (t, J = 
7.5 Hz, 1H, Harom), 8.10 (d, J = 8.5 Hz, 1H, Harom), 8.22 (d, J = 7.5 Hz, 1H, 
Harom). Rt1 = 2.78 min; Rt2 = 6.15 min. MS (ESI+) m/z 260.1 [M+H]+. 
 
3-Oxo-2-phenyl-propionitrile 14a - The benzylcyanide 12 (87,2 mmol) was 
added to the ethyl formiate ester 13a (104,6 mmol) and the mixture was 
stirred at room temperature. A solution of sodium ethanolate in ethanol 21% 
(165,6 mmol) was then added and the reaction was stirred for one minute at 
room temperature. The organic layer was extracted with dichloromethane (3 
x 20 mL), acidified (HCl 3N, 4 mL), washed with a saturated solution of 
sodium bicarbonate (10 mL) and dried on magnesium sulfate. Solvants were 
finally removed under reduced pressure and the product was purified by 
crystallisation of methanol (4 mL). Yield: 44%. Anal. Calcul. for C9H7NO: 
C, 74.47; H, 4.86; N, 9.65. Found: C, 75.53; H, 4.54; N, 9.33. MS (ESI+) 
m/z 146.2 [M+H]+. 
 
3-Oxo-2-phenyl-butyronitrile 14b - The title compound is commercially 
available  
 
3-Oxo-2-phenyl-pentanenitrile 14c - The title compound was prepared 
from ethyl propionate ester 13c and benzylcyanide 12 as starting material 
and according to the procedure described for compound 14a. Yield: 44% 1H 
RMN (DMSO-d6, 400 MHz): δ = 1.21 (t, J = 7.6 Hz, 3H, CH3), 2.57 (q, J = 
7.6 Hz, 2H, CH2), 7.17 (t, J = 7.4 Hz, 1H, Harom), 7.32 (t, J = 7.4 Hz, 2H, 
Harom), 7.58 (d, J = 7.4 Hz, 2H, Harom), 11.00 (s, 0.1H, CHCN), 11.52 (s, 
0.9H, CHCN). Anal. Calcul. for C11H11NO: C, 76,28; H, 6,40; N, 8,09. 
Found: C, 77.02; H, 6,33; N, 8,37. 
 
2,5-Dimethyl-4-phenyl-2H-pyrazol-3-ylamine 15a - 3-Oxo-2-phenyl-
butyronitrile 14b (2,0 g) was diluted in ethanol (8 mL). Methylhydrazine 
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(13,8 mmol) was then added at room temperature. The reaction was  
vigorously stirred under micro waves at 100°C during 20 minutes. The 
reaction was followed by TLC (AcOEt: cyclohexane 1:1). Solvents and 
hydrazine excess were the removed from the reaction mixture under reduced 
pressure. The crude product was diluted into ethyle acetate (5 mL) and 
acidified with HCl 3N (5 mL). Organic layer is discarded and aquous layer 
was neutralised by NaOH 1N (15 mL) and extracted with AcOEt (3 x 20 
mL). The organic layers are combined and dried on Na2SO4. Finally, 
solvents were removed under reduced pressure. Crude product was purified 
by flash chromatography (normal phase on silica cartridge; mobile 
phase:AcOEt:cyclohexane with a gradient from 5% to 90% of AcOEt; 
duration: 30 min.). Yield: 60%. Anal. Calcul. for C11H13N3: C, 70,56; H, 
7,00; N, 22,44. Found: C, 72,00; H, 6,78; N, 22,26. 
 
3-Amino-5-methyl-4-phenyl-2H-pyrazole 15b - The title compound was 
prepared from 3-oxo-2-phenyl-butyronitrile 14b and hydrazine hydrate 
according to the procedure described for compound 15a. Yield: 42%. 1H  
RMN (CDCl3, 400 MHz): δ = 2.31 (s, 3H, CH3), 3.76 (s, 2H, NH2), 7.26 (t, 
J = 7.3 Hz,  1H, Harom), 7.35 (d, J = 7.3 Hz, 2H, Harom),  7.41 (t, J = 7.3 Hz, 
2H, Harom). Anal. Calcul. for C10H11N3: C, C, 69,34; H, 6,40; N, 24,26. 
Found: C, 70.69; H, 6.22; N, 24.12.  
 
3-Amino-4-phenyl-2H-pyrazole 15c - The title compound was prepared 
from 3-oxo-2-phenyl-propionitrile 14a and hydrazine hydrate according to 
the procedure described for compound 15a. Yield: 37%. 1H  RMN (CDCl3, 
400 MHz): δ = 3.65 (s, 2H, NH2), 7.24-7.75 (m, 5H, Harom). MS (ESI+) m/z 
160.1 [M+H]+. 
 
3-Amino-2-methyl-4-phenyl-2H-pyrazole 15d - The title compound was 
prepared from 3-oxo-2-phenyl-propionitrile 14a and methylhydrazine 
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according to the procedure described for compound 15a. Yield: 63% Anal. 
Calcul. for C16H15N3 : C, 78.74; H, 5.05; N, 16,02. Found: C, 78.74; H, 5.21; 
N, 15.31. MS (ESI+) m/z 260.1 [M+H]+. 
 
3-Amino-5-ethyl-2-methyl-4-phenyl-2H-pyrazole 15e - The title 
compound was prepared from 3-oxo-2-phenyl-pentanenitrile 14c and 
methylhydrazine according to the procedure described for compound 15a. 
Yield: 25%  1H  RMN (CDCl3, 400 MHz): δ = 1.15 (t, J = 7.6 Hz,  3H, CH3), 
2.64 (q, J = 7.6 Hz, 2H, CH2), 3.54 (s, 2H, NH2) 3.67 (s, 3H, CH3), 7.23-7.28 
(m, 3H, Harom), 7.40 (t, J = 7.7 Hz, 2H, Harom). MS (ESI+) m/z 202.1 
[M+H]+. 
 
3-Amino-5-ethyl-4-phenyl-2H-pyrazole 15f - The title compound was 
prepared from 3-oxo-2-phenyl-pentanenitrile 14c and hydrazine hydrate 
according to the procedure described for compound 15a. Yield: 37%. 1H  
RMN (CDCl3, 400 MHz): δ = 1.15 (t, J = 7.7 Hz, 3H, CH3), 2.62 (q, J = 7.7 
Hz, 2H, CH2), 3.72 (s, 2H, NH2), 7.27 (t, J = 7.1 Hz, 1H, Harom), 7.34 (d, J = 
7.1 Hz, 2H, Harom), 7.40 (t, J = 7.1 Hz, 2H, Harom). 
 
3-Amino-5-methyl-4-phenyl-2-pyridin-2-yl-2H-pyrazole 15g - The title 
compound was prepared from 3-oxo-2-phenyl-butyronitrile 14b and 2-
pyridylhydrazine according to the procedure described for compound 15a. 
Yield: 99%. 1H  RMN (CDCl3, 400 MHz): δ = 2.14 (s, 3H, CH3), 3.26 (s, 
2H, NH2), 6.63 (d, J = 25.2 Hz, 2H, Harom), 7.14 (d, J = 25.2 Hz, 2H, Harom), 
7.31-7.35 (m, 3H, Harom), 7.80-7.85 (m, 2H, Harom). Anal. Calcul. for 
C15H14N4: C, 71,98; H, 5,64; N, 22,38. Found: C, 72.57; H, 5,60; N, 22,83. 
MS (ESI+) m/z 252.1 [M+H]+. 
 
3-Amino-5-methyl-2,4-diphenyl-2H-pyrazole 15h - The title compound 
was prepared from 3-oxo-2-phenyl-butyronitrile 14b and phenylhydrazine 
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according to the procedure described for compound 15a. Yield: 80%. Anal. 
Calcul. for C16H15N3 : C, 77,08; H, 6,06; N, 16,85. Found: C, 77,79; H, 6,06; 
N, 16,73. 1H  RMN (DMSO-d6, 400 MHz): δ = 2.14 (s, 3H, CH3), 5.05 (s, 
2H, NH2), 7.20 (t, J = 7.2 Hz, 1H, Harom), 7.27-7.41 (m, 5H, Harom), 7.46 (t, J 
= 8.0 Hz, 2H, Harom), 7.58 (d, J = 8.0 Hz, 2H, Harom). Anal. Calcul. for 
C15H14N4: C, 71,98; H, 5,64; N, 22,38. Found: C, 72.57; H, 5,60; N, 22,83. 
MS (ESI+) m/z 251.1 [M+H]+. 
  
1,3-Dimethyl-5-phenyl-3H-pyrazolo[3,4-c]isoquinoline 11a - Benzal-
dehyde 16a (1,48mmol) is added to 3-amino-2,5-dimethyl-4-phenyl-2H-
pyrazole 15a (1,34 mmol) diluted in methanesulfonic acid (2 mL) with 2 
drops of BMimpF6. The reaction mixture is stirred under micro waves at 
150°C for 15 minutes. The reaction is followed by TLC (AcOEt:cyclohexane 
1:1). The mixture was then neutralised by addition of sodium hydroxide 1N 
(3 mL), extracted with ethyl acetate (3 x 10 mL) and dried on magnesium 
sulfate. Solvents were evaporated under reduced pressure and the crude 
product was purified by flash chromatography (inverse phase on C18 
cartridge; mobile phase: water/MeCN with a gradient from 5% to 90% of 
MeCN for 30min). Yield: 18%. 1H  RMN (CDCl3, 400 MHz): δ = 2.88 (s, 
3H, CH3), 4.19 (s, 3H, NCH3), 7.44 (t, J
 
= 7.9 Hz, 1H, Harom), 7.52-7.85 (m, 
3H, Harom), 7.71 (d, J = 7.8 Hz, 2H, Harom), 7.80 (t, J = 7.9 Hz, 1H, Harom), 
8.12 (d, J
 
= 7.9 Hz, 1H, Harom), 8.33 (d, J = 7.9 Hz, 1H, Harom). MS (ESI+) 
m/z 274.2 [M+H]+. 
 
1-Methyl-5-phenyl-3H-pyrazolo[3,4-c]isoquinoline 11b - The title 
compound was prepared from 3-amino-5-methyl-4-phenyl-2H-pyrazole 15b 
and benzaldehyde 16a according to the procedure described for compound 
11a. Yield: 6%. 1H  RMN (CDCl3, 400 MHz): δ = 2.91 (s, 3H, CH3), 7.46-
7.56 (m, 4H, Harom), 7.70 (d, J = 7.8 Hz, 2H, Harom), 7.83 (t, J = 7.9 Hz, 1H, 
Harom), 8.16 (d, J = 7.9 Hz, 1H, Harom), 8.36 (d, J = 7.9 Hz, 1H, Harom). Anal. 
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Calcul. for C17H13N3: C, 78,74; H, 5,05; N, 16,20. Found: C, 77.85; H, 5.09; 
N, 15.86.  
 
5-Phenyl-3H-pyrazolo[3,4-c]isoquinoline 11c - The title compound was 
prepared from 3-amino-4-phenyl-2H-pyrazole 15c and benzaldehyde 16a 
according to the procedure described for compound 11a. Yield: 55%. 1H  
RMN (CDCl3, 400 MHz): δ = 7.50 (t, J = 8.5 Hz, 1H, Harom), 7.54-7.60 (m, 
3H, Harom), 7.73 (d, J = 8.1 Hz, 2H, Harom), 7.83 (t, J = 8.1 Hz, 1H, Harom), 
8.16 (d, J
 
= 8.1 Hz, 1H, Harom), 8.29 (d, J = 8.1 Hz, 1H, Harom), 8.45 (s, 1H, 
H1-pyrazole), 11.19 (s, 1H, NH). 
  
5-(3-Hydroxyphenyl)-1,3-dimethyl-3H-pyrazolo[3,4-c]isoquinoline 11d - 
The title compound was prepared from 3-amino-2,5-dimethyl-4-phenyl-2H-
pyrazole 15a and 3-hydroxybenzaldehyde 16b according to the procedure 
described for compound 11a. Yield: 7%.  1H RMN (DMSO-d6, 400 MHz): δ 
= 2.76 (s, 3H, CH3), 4.03 (s, 3H, NCH3), 6.92 (d, J
 
= 7.4 Hz, 1H, Harom), 
7.02 (s, 1H, Harom), 7.03 (d, J = 7.4 Hz, 1H, Harom), 7.34 (t, J = 7.8 Hz, 1H, 
Harom), 7.52 (t, J = 7.8 Hz, 1H, Harom),  7.88 (t, J = 7.4 Hz, 1H, Harom), 8.04 (d, 
J
 
= 7.8 Hz, 1H, Harom), 8.34 (d, J = 7.8 Hz, 1H, Harom), 9.68 (s, 1H, OH). 
Anal. Calcul. for C18H15N3O: C, 74,72; H, 5,23; N, 14,52. Found: C, 72.51; 
H, 5,01; N, 13.11. 
 
3-Methyl-5-phenyl-3H-pyrazolo[3,4-c]isoquinoline 11e - The title 
compound was prepared from 3-amino-2-methyl-4-phenyl-2H-pyrazole 15d 
and benzaldehyde 16a according to the procedure described for compound 
11a. Yield: 4%. 1H  RMN (CDCl3, 400 MHz): δ = 4.26 (s, 3H, NCH3), 7.44 
(t, J
 
= 7.9 Hz, 1H, Harom), 7.52-7.61 (m, 3H, Harom), 7.72 (d, J = 8.1 Hz, 2H, 
Harom), 7.79 (t, J = 7.9 Hz, 1H, Harom), 8.11 (d, J = 7.9 Hz, 1H, Harom), 8.24 (d, 
J
 
= 7.9 Hz, 1H, Harom), 8.37 (s, 1H, H1-pyrazole). 
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5-(3-Hydroxyphenyl)-1-methyl-3H-pyrazolo[3,4-c]isoquinoline 11f - The 
title compound was prepared from 3-amino-5-methyl-4-phenyl-2H-pyrazole 
15b and 3-hydroxybenzaldehyde 16b according to the procedure described 
for compound 11a. Yield: 3%. 1H RMN (DMSO-d6, 400 MHz): δ = 2.77 (s, 
3H, CH3), 6.91 (d, J
 
= 7.4 Hz, 1H, Harom), 7.01 (s, 1H, Harom), 7.02 (d, J = 7.4 
Hz, 1H, Harom), 7.34 (t, J = 7.8 Hz, 1H, Harom), 7.52 (t, J = 7.8 Hz, 1H, Harom),  
7.87 (t, J
 
= 7.4 Hz, 1H, Harom), 8.05 (d, J = 7.8 Hz, 1H, Harom), 8.35 (d, J = 7.8 
Hz, 1H, Harom), 9.66 (s, 1H, OH). Anal. Calcul. for C16H11N3O: C, 73,55; H, 
4,24; N, 16,08. Found: 72.94; H, 4.60; N, 14.20. 
  
5-(3-Hydroxyphenyl)-3H-pyrazolo[3,4-c]isoquinoline 11g - The title 
compound was prepared from 3-amino-4-phenyl-2H-pyrazole 15c and 3-
hydroxybenzaldehyde 16b according to the procedure described for 
compound 11a. Yield: 4%. 1H RMN (DMSO-d6, 400 MHz): δ = 6.92 (d, J = 
7.4 Hz, 1H, Harom), 7.05 (s, 1H, Harom), 7.06 (d, J = 7.4 Hz, 1H, Harom), 7.34 (t, 
J
 
= 7.8 Hz, 1H, Harom), 7.52 (t, J = 7.8 Hz, 1H, Harom), 7.85 (t, J = 7.4 Hz, 1H, 
Harom), 8.25 (d, J = 7.8 Hz, 1H, Harom), 8.41 (d, J = 7.8 Hz, 1H, Harom), 8.59 (s, 
1H, NH),  9.67 (s, 1H, OH). Anal. Calcul. for C16H11N3O: C, 73,55; H, 4,24; 
N, 16,08; O, 6,12. Found: 73,55; H, 4,07; N, 15.60. 
  
1-Ethyl-3-methyl-5-phenyl-3H-pyrazolo[3,4-c]isoquinoline 11h - The title 
compound was prepared from 3-amino-5-ethyl-2-methyl-4-phenyl-2H-
pyrazole 15e and benzaldehyde 16a according to the procedure described for 
compound 11a. Yield: 14%. 1H  RMN (CDCl3, 400 MHz): δ = 1.51 (t, J = 
7.4 Hz, 3H, CH3), 3.29 (q, J = 7.4 Hz, 2H, CH2 ), 4.20 (s, 3H, NCH3), 7.44 (t, 
J
 
= 7.8 Hz, 1H, Harom), 7.52-7.57 (m, 3H, Harom), 7.71 (d, J = 6.4 Hz, 2H, 
Harom), 7.81 (t, J = 7.8 Hz, 1H, Harom), 8.12 (d, J = 7.8 Hz, 1H, Harom), 8.29 (d, 
J
 
= 7.8 Hz, 1H, Harom). Anal. Calcul. for C19H17N3: C, 79.41; H, 5.96; N, 
14.62. Found: C, 79.24; H, 5.86; N, 14.08. 
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1-Ethyl-5-phenyl-3H-pyrazolo[3,4-c]isoquinoline 11i - The title 
compound was prepared from 3-amino-5-ethyl-4-phenyl-2H-pyrazole 15f 
and benzaldehyde 16a according to the procedure described for compound 
11a. Yield: 9%. 1H  RMN (CDCl3, 400 MHz): δ = 1.51 (t, J = 7.7 Hz, 3H, 
CH3), 3.32 (q, J = 7.7 Hz, 2H, CH2 ), 7.47-7.57 (m, 4H, Harom), 7.69 (d, J = 
6.6 Hz, 2H, Harom), 7.81 (t, J = 7.6 Hz, 1H, Harom), 8.16 (d, J = 7.6 Hz, 1H, 
Harom), 8.33 (d, J = 7.6 Hz, 1H, Harom). 
 
5-(3-Methoxy-phenyl)-1-methyl-3H-pyrazolo[3,4-c]isoquinoline 11j - 
The title compound was prepared from 3-amino-5-methyl-4-phenyl-2H-
pyrazole 15b and 3-methoxybenzaldehyde 16c according to the procedure 
described for compound 11a. Yield: 1%.1H RMN (CDCl3, 400 MHz): δ = 
2.91 (s, 3H, CH3), 3.88 (s, 3H, OCH3), 7.07 (dd, J1 = 8.5 Hz, J2 = 2.1 Hz, 1H, 
Harom), 7.23-7.27 (m, 2H, Harom), 7.44-7.50 (m, 2H, Harom), 7.83 (t, J = 7.7 Hz, 
1H, Harom), 8.18 (d, J = 8.2 Hz, 1Harom), 8.36 (d, J = 8.2 Hz, 1Harom), 10.69 (s, 
1H, NH). 
 
1-Methyl-5-phenyl-3-pyridin-2-yl-3H-pyrazolo[3,4-c]isoquinoline 11k - 
The title compound was prepared from 3-amino-5-methyl-4-phenyl-2-
pyridin-2-yl-2H-pyrazole 15g and benzaldehyde 16a according to the 
procedure described for compound 11a. Yield: 60%.  1H RMN (CDCl3, 400 
MHz): δ = 3.04 (s, 3H, CH3), 7.07 (dd, J1 = 6.9 Hz, J2 = 5.0 Hz, 1H, Harom), 
7.25-7.59 (m, 4H, Harom), 7.78 (d, J = 7.6 Hz, 2H, Harom), 7.87 (q, J = 8.2 Hz, 
2H, Harom), 8.24 (d, J = 8.2 Hz, 1H, Harom), 8.44 (d, J = 8.2 Hz, 1H, Harom), 
8.66 (d, J = 5.0 Hz, 1H, Harom), 8.74 (d, J =8.2 Hz, 1H, Harom). Anal. Calcul. 
for C22H16N4: C, 78.55; H, 4.79; N, 16.66. Found: C, 78.49; H, 4.89; N, 
16.01.  
 
1-Methyl-3,5-diphenyl-3H-pyrazolo[3,4-c]isoquinoline 11l - The title 
compound was prepared from 3-amino-5-methyl-2,4-diphenyl-2H-pyrazole 
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15h and benzaldehyde 16a according to the procedure described for 
compound 11a. Yield:  11%. 1H RMN (CDCl3, 400 MHz): δ = 2.99 (s, 3H, 
CH3), 7.47-7.57 (m, 7H, Harom), 7.77 (d, J = 7.8 Hz, 2H, Harom), 7.85 (t, J = 
7.8 Hz, 1H, Harom), 8.22 (d, J = 8.5 Hz, 1H, Harom), 8.34 (d, J = 8.5 Hz, 2H, 
Harom), 8.41 (d, J = 8.5 Hz, 1H, Harom). Anal. Calcul. for C23H17N3: C, 82.36; 
H, 5.11; N, 12.53. Found: C, 82.48; H, 5.27; N, 11.95. 
 
3,5-Dimethyl-4-propyl-1H-pyrazole 48 - 1,8-Diazabicyclo[5.4.0]undec-7-
ene (97.4 mmol) was added to a solution of 2,4-pentanedione (97.4 mmol) in 
tert-butyl methyl ether (25 mL) and toluene (10 mL). Iodopropane (97.4 
mmol) was added and the mixture was stirred at room temperature for 5 
hours. Solvents were removed under reduced pressure and the crude product 
was diluted into EtOH (25 mL). Then, the hydrazine hydrate (97.4 mmol) 
was added and the reaction mixture was stirred overnight at room 
temperature. Solvents were evaporated under reduced pressure. The organic 
layer was separated by AcOEt (3x 100 mL) after acidification (pH = 5) by a 
formic acid solution 1N (60 mL), dried on Na2SO4 and solvents were 
removed under reduced pressure. The title compound product crystallised 
from the crude residue (yellow oil) to give 240mg of 3,5-dimethyl-4-propyl-
1H-pyrazole 48 isolated by filtration. Yield: 2%. 1H  RMN (CDCl3, 400 
MHz): δ = 0.87 (t, J
 
= 7.4 Hz, 3H, CH3), 1.45 (q, J = 7.4 Hz, 2H, CH2 ), 2.20 
(s, 6H, (CH3)2), 2.30 (t, J = 7.4 Hz, 3H, CH2), 9.93 (s, 1H, NH). Anal. 
Calcul. for C19H17N3: C, 69.52; H, 10.21; N, 20.27. Found: C, 69.83; H, 
10.04; N, 19.94.  
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3. Biology 
 
3.1  NIK enzymatic assay  
 
 
 This experiment was performed by ProQinase using the 
33PanQinase® technology (Figure 57). Inhibitory potency of staurosporine 
28 and molecules selected by VS were evaluated on human recombinant 
NIK. DMSO was used as cosolvent and its final concentration was 1%. NIK 
was expressed in Sf9 insect cells as human recombinant GST-fusion protein. 
The kinase was purified by affinity chromatography using GSH-agarose. 
The purity of the kinase was checked by SDS-PAGE/silver staining and the 
identity was verified by mass spectroscopy. The NIK activity was measured 
as the incorporation on an artificial substrate of 33P produced by hydrolysis 
of [γ-33P]-ATP.  
 
 The substrate (RBER-CHKtide) was an artificial fusion protein 
expressed in E.coli. It was consisting of a N-terminal GST-tag separated by a 
thrombin cleavage site from a fragment of the human retinoblastoma protein 
RB1, amino acids S773-K928 followed by 11 arginine residues (ER) and a 
peptide sequence: KKKVRSGLYRSPSMPENLNRPR (CHKtide). 
 
 
 
Figure 57: ProQinase in vitro enzymatic assay 
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 All kinase assays were performed in 96-well FlashPlatesTM from 
Perkin Elmer (Boston, MA, USA) in a 50 µl reaction volume. The reaction 
cocktail was pipetted in 4 steps in the following order: (i) 20 µl of assay 
buffer; (ii) 5 µl of ATP solution (in H2O); (iii)5 µl of test compound (in 10 
% DMSO); (iv) 10 µl of substrate / 10 µl of enzyme solution (premixed). 
The assay for NIK contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 
3 mM MnCl2, 3 µM Na-orthovanadate, 1.2 mM DTT, 50 µg/ml PEG20000, 
1 µM [γ-33P]-ATP (approx. 5 x 1005 cpm per well). The reaction cocktails 
were incubated at 30°C for 60 minutes. The reaction was stopped with 50 µl 
of 2 % (v/v) H3PO4, plates were aspirated and washed two times with 200 µl 
0.9 % (w/v) NaCl. Incorporation of 33Pi was determined with a microplate 
scintillation counter (Microbeta, Wallac). 
 The median value of the counts of each assay plate (n=8) was 
defined as "low control". This value reflects unspecific binding of 
radioactivity to the plate in the absence of a protein kinase but in the 
presence of the substrate. The median value of the counts of each assay plate 
(n=8) was taken as the "high control", i.e. full activity in the absence of any 
inhibitor. The difference between high and low control was taken as 100% 
activity. As part of the data evaluation the low control value from a 
particular plate was subtracted from the high control value as well as from 
all compound values of the corresponding plate. The residual activity (RA, 
in %) for each well was calculated by using the following formula:  
RA (%) = 100 X [(cpm of compound – low control) / (high control – low control)] 
 
3.2  NF-κB alternative pathway cellular assay  
 
 Human LTβR-positive HeLa cells were used to evaluate the NIK 
inhibitory potency expressed as the inhibition of the processing of p100 into 
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p52 (Figure 58). Briefly, HeLa cells were cultured in DMEM with 10% FBS 
and plated in 6 well plates until they reach 80% of confluence.  
 
 
 
Figure 58: Alternative pathway activation assay 
 
 
 The cells were washed twice with PBS and incubated for 2 hours 
with Opimem-1 containing 10, 20 or 50 µM of inhibitor 
(pyrazoloisoquinolines or commercial compounds selected by the virtual 
screen). DMSO was used as cosolvent at a maximal concentration of 0.5% 
(v/v). At this concentration, DMSO has no effect. Then, an antibody acting 
as agonist of human LTβR (R&D Systems, Inc. / LIGHT) was added for 5 
hours. Afterwards, the cells were washed twice with PBS and lysed in SDS 
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0.5% containing a cocktail of protease and phosphatase inhibitors (Complete 
and PhosStop, Roche). Protein extracts were quantified (Micro BCA protein 
kit assay, Pierce) and equal amounts of protein (15 µg) were loaded on SDS-
PAGE for analysing the processing of p100 into p52. For detecting p100 and 
p52, an antibody anti-human p52 (Upstate Cell Signaling 05-361) was used 
and a goat anti-mouse HRP (DAKO) was used as secondary antibody prior 
to measurement of chemiluminescence using the ECL kit from Pierce. 
 
 
3.3  Multikinase assay  
 
 This radiometric assay was performed by Millipore using the Kinase 
Profiler™ technology (Figure 59). Full protocols are available on the repor-
ted Millipore webpage.e, 163 
 
 
 
Figure 59: Millipore multikinase assay 
 
                                                 
e
 http://direct.millipore.com/techpublications/tech1/cd1000enus.  
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3.4  TAK1 enzymatic Assay  
 
 
 This experiment was performed by Invitrogen using LanthaScreen® 
Kinase Binding Assay technology (Figure 60).  
 Figure 60: Schematic of LanthaScreenTM Eu Kinase Binding Assay 
 
 
 The tested compounds were screened in 1% DMSO as final 
concentration. Three-fold serial dilutions were conducted from the starting 
concentration. All kinase/Antibody mixtures were diluted to a 2X working 
concentration in the appropriate kinase buffer. The 4X AlexaFluor® (AF) 
labelled tracer was prepared in kinase buffer and the read out was on 
fluorescence plate reader. The AF/Europium emission ratio (665 nm and 615 
nm respectively) were finally calculated. 
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3.5  NF-κB classical pathway cellular assay 
 
 
 HeLa cells were cultured in DMEM with 10% FBS and plated in 6-
well plates until they reach 80% of confluence. The cells were washed twice 
with PBS and incubated for 2 hours with Opimem-1 containing 50 µM of 
inhibitor or DMSO alone. Then, TNF-α (Pepro Tech Inc.) was added at 100 
U/mL for 0, 1 or 2 hours. Total RNA samples were isolated with the Tripure 
reagent (Roche Molecular Biochemicals). One microgram of RNA was 
submitted to reverse transcription using M-MLV reverse transcriptase and 
random primers (Invitrogen) in a total volume of 20 µL. Two microliters of 
cDNA were submitted to real-time PCR using TaqMan 7000 SDS (Applied 
Biosystems) and SYBR Green detection (Eurogentec). The results were 
normalised with the 18S transcript. PCR was performed with the following 
primers for the following human transcript :  
 
il-6 : FW 5’-CCAGGAGCCCAGCTATGAAC-3’ 
and RV 5’-CCCAGGGAGAAGGCAACTG-3’, 
TNFα : FW 5’-GGAGAAGGGTGACCGACTCA-3’  
and RV 5’-TGCCCAGACTCGGCAAAG-3’, 
18S : FW 5’-AACTTTCGATGGTAGTCGCCG-3’  
and RV 5’- CCTTGGATGTGGTAGCCGTTT -3’. 
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3.6  Cell viability assay 
 
 
 HeLa cells were cultured in DMEM with 10% FBS and plated in 96 
well plates until they reach 80% of confluence. The cells were washed twice 
with PBS and incubated for 6 hours with Opimem-1 containing 100, 50, 10 
µM of inhibitors or DMSO alone. Cell viability assay was performed using 
CellTiter-Glo® luminescent cell viability assay (Promega) that determine the 
number of viable cells in culture. Detection was based on the luciferase 
reaction to measure the amount of ATP from viable cells. Briefly a volume 
of CellTiter-Glo® reagent equal to the volume of cell culture medium was 
added to each well and mixed for 2 minutes to induce cell lysis. The plate 
was incubated for 10 minutes at room temperature to stabilise the 
luminescent signal and, then, each well content was transferred in an 
opaque-walled multiwell. The luminescent signal was recorded using a 96 
microplate luminometer. 
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Appendix 1: Multikinase screening residual activities (%) for compounds 5d 
and 11f  with the 263 reported kinases 
 
Kinase 5d 11f 
Abl(h) 94 1 
Abl(m) 66 2 
Abl (H396P) (h) 62 2 
Abl (M351T)(h) 54 8 
Abl (Q252H) (h) 59 1 
Abl(T315I)(h) 50 53 
Abl(Y253F)(h) 67 3 
ACK1(h) 18 9 
ALK(h) 51 32 
ALK4(h) 105 69 
Arg(h) 89 1 
AMPK(r) 39 78 
Arg(m) 80 3 
ARK5(h) 3 72 
ASK1(h) 0 68 
Aurora-A(h) 8 52 
Axl(h) 51 94 
Blk(m) 67 21 
Bmx(h) 22 19 
BRK(h) 89 -2 
BrSK1(h) 31 16 
BrSK2(h) 26 39 
BTK(h) 40 30 
BTK(R28H)(h) 95 108 
CaMKI(h) 66 104 
CaMKIIβ(h) 52 56 
CaMKIIγ(h) 25 62 
CaMKIδ(h) 100 92 
CaMKIIδ(h) 11 42 
CaMKIV(h) 88 114 
CDK1/cyclinB(h) 44 109 
CDK2/cyclinA(h) 40 93 
CDK2/cyclinE(h) 29 90 
CDK3/cyclinE(h) 19 85 
CDK5/p25(h) 17 49 
CDK5/p35(h) 19 57 
CDK7/cyclinH/MAT1(h) 72 96 
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CDK9/cyclin T1(h) 54 47 
CHK1(h) 6 88 
CHK2(h) 18 92 
CHK2(I157T)(h) 23 87 
CHK2(R145W)(h) 22 95 
CK1γ1(h) 80 86 
CK1γ2(h) 57 74 
CK1γ3(h) 78 63 
CK1δ(h) 81 49 
CK1(y) 57 31 
CK2(h) 96 94 
CK2α2(h) 90 104 
CLK2(h) 18 20 
CLK3(h) 67 86 
cKit(h) 71 15 
cKit(D816V)(h) 100 56 
cKit(D816H)(h) 12 5 
cKit(V560G)(h) 9 4 
cKit(V654A)(h) 9 15 
CSK(h) 112 69 
c-RAF(h) 84 1 
cSRC(h) 78 17 
DAPK1(h) 82 81 
DAPK2(h) 76 57 
DCAMKL2(h) 105 84 
DDR2(h) 91 40 
DMPK(h) 96 105 
DRAK1(h) 32 70 
DYRK2(h) 53 52 
eEF-2K(h) 122 113 
EGFR(h) 110 22 
EGFR(L858R)(h) 50 8 
EGFR(L861Q)(h) 66 6 
EGFR(T790M)(h) 30 78 
EGFR(T790M,L858R)(h) 17 53 
EphA1(h) 23 -1 
EphA2(h) 79 0 
EphA3(h) 86 5 
EphA4(h) 89 2 
EphA5(h) 83 -1 
EphA7(h) 60 89 
EphA8(h) 82 1 
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EphB2(h) 86 1 
EphB1(h) 77 1 
EphB3(h) 80 2 
EphB4(h) 86 0 
ErbB4(h) 91 66 
FAK(h) 8 91 
Fer(h) 5 91 
Fes(h) 11 59 
FGFR1(h) 12 9 
FGFR1(V561M)(h) 10 66 
FGFR2(h) 40 43 
FGFR2(N549H)(h) 16 14 
FGFR3(h) 27 44 
FGFR4(h) 99 90 
Fgr(h) 58 2 
Flt1(h) 18 12 
Flt3(D835Y)(h) 0 30 
Flt3(h) 6 76 
Flt4(h) -2 7 
Fms(h) 5 11 
Fyn(h) 61 4 
GCK(h) 7 25 
GRK5(h) 66 100 
GRK6(h) 68 83 
GRK7(h) 43 102 
GSK3α(h) 47 14 
GSK3β(h) 70 19 
Haspin(h) 83 37 
Hck(h) 71 6 
HIPK1(h) 105 95 
HIPK2(h) 67 80 
HIPK3(h) 80 99 
IGF-1R(h) 62 132 
IGF-1R(h), activated 71 91 
IKKα(h) 86 84 
IKKβ(h) 55 21 
IR(h) 55 97 
IR(h), activated 62 93 
IRR(h) 83 97 
IRAK1(h) 50 94 
IRAK4(h) 51 90 
Itk(h) 53 124 
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JAK2(h) 24 79 
JAK3(h) 39 110 
JNK1α1(h) 61 90 
JNK2α2(h) 65 99 
JNK3(h) 15 61 
KDR(h) 8 21 
Lck(h) 31 4 
LIMK1(h) 26 17 
LKB1(h) 85 5 
LOK(h) 15 18 
Lyn(h) 96 3 
Lyn(m) 85 1 
MAPK1(h) 56 67 
MAPK2(h) 63 106 
MAPK2(m) 34 72 
MAPKAP-K2(h) 114 115 
MAPKAP-K3(h) 105 98 
MEK1(h) 68 99 
MARK1(h) 54 76 
MELK(h) 12 49 
Mer(h) 5 75 
Met(h) 79 77 
MINK(h) 74 66 
MKK4(m) 46 58 
MKK6(h) 106 -6 
MKK7β(h) 52 80 
MLCK(h) 64 11 
MLK1(h) 2 28 
Mnk2(h) 14 68 
MRCKα(h) 102 104 
MRCKβ(h) 109 110 
MSK1(h) 76 81 
MSK2(h) 29 61 
MSSK1(h) 78 83 
MST1(h) 13 93 
MST2(h) 23 89 
MST3(h) 95 36 
mTOR(h) 103 106 
mTOR/FKBP12(h) 95 103 
MuSK(h) 76 105 
NEK2(h) 104 120 
NEK3(h) 97 83 
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NEK6(h) 99 108 
NEK7(h) 96 106 
NEK11(h) 111 17 
NLK(h) 83 27 
p70S6K(h) 68 76 
PAK2(h) 92 98 
PAK3(h) 81 91 
PAK4(h) 60 103 
PAK5(h) 59 99 
PAK6(h) 48 89 
PAR-1Bα(h) 59 73 
PASK(h) 96 80 
PDGFRα(h) 93 61 
PDGFRα(D842V)(h) 24 7 
PDGFRα(V561D)(h) 11 0 
PDGFRβ(h) 119 113 
PDK1(h) 11 95 
PhKγ2(h) 72 115 
Pim-1(h) 62 37 
Pim-2(h) 73 35 
Pim-3(h) 89 90 
PKA(h) 109 61 
PKBα(h) 106 90 
PKBβ(h) 110 107 
PKBγ(h) 90 41 
PKCα(h) 99 99 
PKCβI(h) 85 75 
PKCβII(h) 98 109 
PKCγ(h) 68 90 
PKCδ(h) 66 14 
PKCε(h) 91 86 
PKCη(h) 95 16 
PKCι(h) 103 86 
PKCµ(h) 43 66 
PKCθ(h) 91 26 
PKCζ(h) 98 21 
PKD2(h) 82 85 
PKG1α(h) 99 96 
PKG1β(h) 89 80 
Plk1(h) 88 93 
Plk3(h) 120 123 
PRAK(h) 96 103 
PRK2(h) 65 31 
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PrKX(h) 87 73 
PTK5(h) 82 6 
Pyk2(h) 46 59 
Ret(h) -1 7 
Ret (V804L)(h) 1 75 
Ret(V804M)(h) 2 65 
RIPK2(h) 80 0 
ROCK-I(h) 79 97 
ROCK-II(h) 70 88 
ROCK-II(r) 68 84 
Ron(h) 99 68 
Ros(h) 96 96 
Rse(h) 116 86 
Rsk1(h) 13 76 
Rsk1(r) 16 90 
Rsk2(h) 5 67 
Rsk3(h) 3 47 
Rsk4(h) 9 69 
SAPK2a(h) 103 58 
SAPK2a(T106M)(h) 94 112 
SAPK2b(h) 104 28 
SAPK3(h) 102 94 
SAPK4(h) 96 93 
SGK(h) 76 88 
SGK2(h) 83 10 
SGK3(h) 107 108 
SIK(h) 41 17 
Snk(h) 69 60 
Src(1-530)(h) 46 4 
Src(T341M)(h) 27 82 
SRPK1(h) 90 94 
SRPK2(h) 98 95 
STK33(h) 59 65 
Syk(h) 69 99 
TAK1(h) 30 80 
TAO1(h) 36 45 
TAO2(h) 66 50 
TAO3(h) 49 69 
TBK1(h) 28 86 
Tec(h) activated 41 29 
Tie2(h) 98 69 
Tie2(R849W)(h) 71 76 
Tie2(Y897S)(h) 79 61 
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TLK2(h) 54 107 
TrkA(h) 5 71 
TrkB(h) 6 96 
TSSK1(h) 38 106 
TSSK2(h) 73 103 
Txk(h) 45 6 
ULK2(h) 45 86 
ULK3(h) 40 55 
WNK2(h) 84 50 
WNK3(h) 67 45 
VRK2(h) 64 54 
Yes(h) 69 0 
ZAP-70(h) 101 102 
ZIPK(h) 81 97 
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Appendix 3: ZINC database screening (part 2) 
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Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-kB activation
Je´re´mie Mortier a,1, Raphae¨l Frederick a,1, Corinne Ganeff b, Caroline Remouchamps b, Patrice Talaga c,
Lionel Pochet a, Johan Wouters a, Jacques Piette b, Emmanuel Dejardin b, Bernard Masereel a,*
aDrug Design & Discovery Center, University of Namur, FUNDP, 61 Rue de Bruxelles, 5000 Namur Belgium
b Laboratory of Virology and Immunology, GIGA Research, University of Lie`ge, Belgium
cUCB SA Belgium
1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
affecting around 1–2% of worldwide population. Patients with RA
have an increased risk of early death. This pathology is mainly
characterized by an uncontrolled proliferation and accumulation
of inflammatory cells within the synovial fluids, causing cartilage
and bone resorption. Many cell types contribute to the pathogen-
esis ranging from lymphocytes to stroma cells [1]. These cells
express a panel of inflammatory mediators that activate multiple
signaling pathways. Most of these signaling pathways lead to the
activation of the transcription factor NF-kB and MAPK cascade.
It was recently shown that two main pathways control the
activation of NF-kB. The first one, named classical NF-kB pathway,
is triggered by inflammatory cytokines such as TNFa or IL-1, or by
bacterial and viral proteins through pathogen-recognition recep-
tors (PRR) like TLRs and NLRs [2]. These inducers trigger the
recruitment of specific adaptor proteins to their cognate receptors,
which enable the activation of a cascade of kinases. Among them,
TGF-b activated kinase 1 (TAK1) plays a key role at the crossroad of
the NF-kB and MAPK signaling pathways (Fig. 1). TAK1 was first
discovered as a TGF-b activated kinase and is part of the MAP
kinase subfamily [3]. However, recent studies showed that IL-1b
and TNFa signaling pathways are affected in TAK1 KO mice [4,5].
TAK1 activates the IKK complex by phosphorylating the subunit
IKKb and acts on MKK6 to trigger the activation of p38 and JNK
(Fig. 1). Upon TAK1 activation, the IKK complex phosphorylates
IkBa, the main inhibitor of the classical NF-kB pathway, releasing
NF-kB (e.g.; p50/p65), which finally, translocates into the nucleus
[6]. This pathway is activated within minutes and relies on the
indispensable adaptor protein NEMO, or IKKg, holding together
IKKb and IKKa to form the IKK complex.
The second NF-kB pathway, called alternative NF-kB pathway,
is induced by a subset of TNFL family members as well as by some
viral proteins [7]. This pathway is dependent on the stabilization
and activation of the kinase NIK. The half-life of this particular
kinase is negatively controlled by TRAF-2, TRAF-3, c-IAP-1 and c-
IAP-2 [8,9]. Upon activation of receptors like CD40, BAFF or LTbR,
the inhibitory function of TRAF-2 and -3 is alleviated. Then,
stabilized NIK activates IKKa leading to the processing of p100 into
p52 [10–12]. The latter, in association with its main partner Rel-B,
fulfils non-redundant biological functions such as secondary
lymphoid organ development and induction of specific chemo-
kines involved in adaptive immunity [7].
Because a wide variety of pro-inflammatory cytokines play a
role in the development of RA, it might be valuable to design a
novel class of inhibitors targeting proteins at the crossroad of
multiple pathways relevant to this pathology. Among the potential
proteins, NIK certainly represents an attractive candidate since it is
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involved downstream of many TNFR like CD40, RANK or LTbR
involved in the pathogenesis of RA.
According to our knowledge, presently only one series of
compounds has been claimed as NIK inhibitors. These are
characterized by a pyrazolo[4,3-c]isoquinoline ring substituted
in position 1, 3, 5, 7 and 9 (Fig. 2) [13]. Most of the chemical
modifications around the pyrazolo[4,3-c]isoquinoline template
involved the introduction of bulky, lipophilic groups such as
phenyl, trifluoromethylphenyl, pyridine or pentafluorophenyl in
the 5-position and introduction of small lipophilic groups like a
methyl or a trifluoromethyl in the 1- and 5-positions. Unfortu-
nately, poor information was given in the original patent relating
to their biological evaluation. For instance, the claimed NIK
inhibitory potency is only based on a whole cellular assay in
presence of some derivatives. No data on isolated NIK enzyme are
available.
At a structural point of view, the 3D-structure of NIK has not yet
been elucidated. The NIK amino acid sequence is comprised of 947
residues with a kinase domain containing 256 residues (400 to
655). Thus, the absence of any 3D-structure of this enzyme
hindered the discovery of novel NIK inhibitors.
In this work, we aimed to build a 3D-model of NIK and to study
the binding of the reported pyrazolo[4,3-c]isoquinolines with a
view to highlight the structural elements responsible for their
inhibitory potency. This would help us to subsequently search for
novel and more potent inhibitors of this enzyme using the
gathered information.
However, in the course of this work, we unexpectedly found
that the pyrazolo[4,3-c]isoquinolines initially reported as NIK
inhibitors were neither inhibitors of this enzyme nor of the
alternative NF-kB pathway, but were in fact inhibitors of another
kinase, the TGF-b activated kinase 1 (TAK1) which is involved in
the classical NF-kB pathway. This was confirmed by the re-
synthesis and the enzymatic evaluation of representative pyr-
azolo[4,3-c]isoquinolines. These results strongly suggesting a
completely different mechanism of action for the pyrazolo[4,3-
c]isoquinolines in modulating the NF-kB pathway, and allow to
review the state-of-the-art of NIK inhibitors and should without
any doubt be of value for scientists working in this field.
2. Material and methods
2.1. Homology modeling
The human M3K14 (NIK) sequence was obtained from the
Swiss-Prot database (primary accession number Q99558). Se-
quence alignment was performed using BLASTP [14], through the
Protein Data Bank (BLOSUM62matrix) [15]. The human PAK1 (PDB
code 1YHW_A)was selected as themost appropriate template, and
amino acid sequences were then aligned by means of the
ESyPred3D program [16]. Quality of the model has been analysed
by means of PDBsum server, and the Ramachandran plot is
available in supporting information [17]. To take into account
protein flexibility, the resulting model was minimized using the
MINIMIZE module included in SYBYL 8.0 program [18].
2.2. Docking simulations
Compounds 6a–s were built using the SKETCH module, as
implemented in SYBYL (version 8.0) [18], and their geometry was
optimized usingMINIMIZEmodule. The minimization process uses
POWELLmethod with the TRIPOS force field (dielectric constant 1r)
to reach a final convergence of 0.01 kcal molÿ1. Docking simulation
was then performed into the homologymodel of the human kinase
NIKwith the automatedGOLD program. The active sitewas defined
including all residues in a volume of 7 A˚ around 3-OH-stauros-
porine superimposed onto the model of NIK.
A similar procedure was used to dock 6d inside the TAK1
binding cleft using the 3D-coordinates obtained from X-ray
diffractions [19]. In the case of TAK1, the active site was defined
by a sphere of 15 A˚ around residue A107 in the active site.
2.3. Chemistry
1HNMR spectra were recorded at 20 8C in CDCl3 or DMSO-d6 on
a 400 MHz Jeol Spectrometer (Jeol JNM EX-400). Chemical shifts
are reported in d ppm relative to tetramethylsilane (TMS) as a
singlet at 0 ppm (d). Thin-layer chromatography (TLC) was
performed on aluminum supported 0.25 mm silica gel plates
(Merck 5719, 250 meshes). TLC plates were visualized under
254 nm and 320 nm UV light. Elemental analyses (C, H, N) were
performed on a Thermo Finnigan FlashEA 1112 apparatus. Mass
spectra were recorded on an 1100 series MSD Trap spectrometer
equipped with an electrospray ionization (ESI) source. Flash
chromatography purifications were performed on a Biotage SP1
Purification System using silica or C18 Biotage FLASH+1 Car-
tridges. Microwave assisted reactions were performed using an
Initiator 16 Single-mode Microwave system producing a
2.450 GHz controlled irradiation (Biotage AB, Uppsala). The
Fig. 1. Classical (yellow) and alternative (orange) NF-kB activation pathways.
Fig. 2. Chemical structure of the pyrazolo[4,3-c]isoquinoline scaffold reported by
Flohr as NIK inhibitors [13].
J. Mortier et al. / Biochemical Pharmacology xxx (2010) xxx–xxx2
G Model
BCP-10430; No of Pages 11
Please cite this article in press as: Mortier J, et al. Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-kB activation. Biochem
Pharmacol (2010), doi:10.1016/j.bcp.2010.01.007
temperature was measured with an IR sensor on the outside of the
reaction vial.
The purity of compounds 6a–d was also verified by LC on an
Agilent 1100 series system. System control, data collection and data
processingwere accomplishedusingChemStation software (Agilent
Technologies, Santa Clara). Themobile phase contained acetonitrile
and acetic acid (0.1%). Compounds were detected and their purity
was calculated using a UV detector (wavelength: 240 nm). Two
different methods were used to analyse the reported compounds.
Method 1: injection volume = 3mL in acetonitrile; gradient elution
from 5% to 95% of acetonitrile over 2.4 min, then 95% acetonitrile
until 3.6 min; analytical column C8 Zorbax Eclipse Plus
(4.6 mm 50 mm, 1.8mmparticle size); flowrate = 1.25 mLminÿ1;
1; temperature = 40 8C. Method 2: injection volume = 5mL in
acetonitrile; gradient elution from 5% to 95% of acetonitrile over
4.5 min, then 95% acetonitrile until 8.0 min; analytical column C18
Zorbax SB column (3.0 mm 100 mm, 3.5mm particle size);
flowrate = 0.5 mLminÿ1; temperature = 40 8C. Retention times
were reported as Rt1 and Rt2 for these two methods respectively.
2.3.1. 1,3-Diphenyl-propane-1,2,3-trione 2-oxime 2b
240 mg (3.46 mmol) of sodium nitrite were dissolved in water
(2 mL) and added dropwise to a solution of 130 mg (0.58 mmol) of
dibenzoylmethane 1b diluted into acetic acid (10 mL). At room
temperature, the solution was stirred for 1 h. The reaction mixture
was extracted three times with diethyl ether (20 mL). The organic
layers were combined and washed with a saturated aqueous
solution of sodium bicarbonate (30 mL). Solvents were evaporated
under reduced pressure, and the crude product purified by flash
chromatography to give the title compound (Silica column; Eluant
AcOEt: cyclohexane with gradient from 8% to 30% of AcOEt over
30 min; Flowrate 40 mL minÿ1). Yield: 81%. 1H RMN (DMSO-d6,
400 MHz): d = 7.52–7.58 (m, 4H, Harom), 7.68 (t, 2H, Harom), 7.82 (d,
2H, Harom), 7.99 (d, 2H, Harom). Anal. Calcul. for C15H11NO3: C,
71.14; H, 4.38; N, 5.53. Found: C, 71.29; H, 4.62; N, 5.23.m/z 254.0
[M + H]+, 276.1 [M + Na]+
2.3.2. 4-Amino-3-methyl-5-phenyl-1H-pyrazole 3a
At 0 8C, hydrazine hydrate (0.18 mL, 3.70 mmol) was added
dropwise to a solution of 1-phenylbutane-1,2,3-trione-2-oxime 2a
(0,37 mmol) in ethanol (4 mL). Then, the mixture was stirred for
7 h at room temperature. Solvents were removed under reduced
pressure and the crude product diluted in ethyl acetate (10 mL).
The solution was acidified by HCl 3N (15 mL) and the organic layer
discarded. The aqueous layer was neutralized by NaOH 1N (50 mL)
and extracted with ethyl acetate (3  20 mL). The organic layers
were combined, dried, and the solvent evaporated under reduced
pressure. The crude product was purified by flash chromatography
(Silica column; eluant: AcOEt:cyclohexane from 20% to 100% of
AcOEt over 45 min; flowrate: 40 mL minÿ1). Yield: 86%. 1H RMN
(CDCl3, 400 MHz): d = 2.37 (s, 3H, CH3), 7.31 (t, 1H, Harom), 7.42 (t,
2H, Harom), 7.61 (d, 2H, Harom). Anal. Calcul. for C10H11N3: C, 69.34;
H, 6.40; N, 24.26. Found: C, 69.30; H, 6.14; N, 23.56. m/z 174.1
[M + H]+.
2.3.3. 4-Amino-3,5-diphenyl-1H-pyrazole 3b
The title compound was synthesized with the same procedure
than that used for 3a. Yield: 88%. 1H RMN (CDCl3, 400 MHz):
d = 7.25 (t, 2H, Harom), 7.48 (t, 4H, Harom), 7.68 (d, 4H, Harom). Anal.
Calcul. for C15H13N3: C, 76.57; H, 5.57; N, 17.86. Found: C, 76.27; H,
5.65; N, 17.62. m/z 236.2 [M + H]+.
2.3.4. 4-Benzamido-3,5-diphenyl-1H-pyrazole 5a
Benzoic acid 4a (92.6 mmol), hydroxybenzotriazole (HOBt;
185 mmol) and N-(3-dimethylaminopropyl)-N0-ethylcarbodii-
mide (DEC; 79.5 mmol) were added to 4-amino-3,5-diphenyl-
1H-pyrazole 3b (92.6 mmol) diluted in dichloromethane
(30 mL). Two drops of BMimpF6 were added, and the mixture
was heated in the microwave oven for 1 h (70 8C). Then, water
(20 mL) was added and the mixture extracted by ethyl acetate
(3  20 mL). The organic layers were combined, dried, and the
solvent evaporated under reduced pressure. The crude product
was purified by flash chromatography (Silica column; Eluant:
AcOEt:cyclohexane from 20% to 71% of AcOEt over 40 min;
flowrate: 40 mL minÿ1). Yield: 60% 1H RMN (CDCl3, 400 MHz):
d = 7.28–7.46 (m, 6H, Harom), 7.49 (t, J = 7.3 Hz, 2H, Harom), 7.56
(t, J = 7.3 Hz, 1H, Harom), 7.64 (d, J = 6.3 Hz, 2H, Harom), 7.72 (d,
J = 6.3 Hz, 2H, Harom), 7.92 (d, J = 7.3 Hz, 2H, Harom), 9.96 (s, 1H,
HNamide). Anal. Calcul. for C22H17N3OH2O: C, 73.93; H, 5.36; N,
11.76. Found: C, 74.03; H, 5.13; N, 11.42. m/z 340.2 [M + H]+,
362.2 [M + Na]+.
2.3.5. 4-(3-Methoxybenzamido)-3,5-diphenyl-1H-pyrazole 5b
The title compound was synthesized from 3-methoxybenzoic
acid 4b and 4-amino-3,5-diphenyl-1H-pyrazole 3b as starting
material, and according to the same procedure than that described
for 5a. Yield: 60%. 1H RMN (DMSO-d6, 400 MHz): d = 3.77 (s, 3H,
OCH3), 7.12 (d, J = 8.2 Hz, 1H, Harom), 7.26–7.45 (m, 8H, Harom), 7.52
(d, J = 7.3 Hz, 1H, Harom), 7.64 (d, J = 7.3 Hz, 2H, Harom), 7.72 (d,
J = 7.3 Hz, 2H, Harom), 9.94 (s, 1H, HN). Anal. Calcul. for C23H17N3O:
C, 78.61; H, 4.88; N, 11.96; C, 78.04; H, 5.19; N, 11.58. m/z 369.2
[M + H]+, 391.3 [M + Na]+.
2.3.6. 4-(3-Methoxybenzamido)3-methyl-5-phenyl-1H-pyrazole 5c
The title compound was synthesized from 3-methoxybenzoic
acid 4b and 4-amino-3-methyl-5-phenyl-1H-pyrazole 3a as
starting material, and according to the same procedure than that
described for 5a. Yield: 57%. 1HRMN (DMSO-d6, 400 MHz): d = 2.08
(s, 3H, CH3), 3.78 (s, 3H, OCH3), 7.12 (d, J = 8.2 Hz, 1H, Harom), 7.22–
7.41 (m, 4H, Harom), 7.49 (s, 1H, Harom), 7.54 (d, J = 7.5 Hz, 1H,
Harom), 7.6–7.7 (m, 2H, Harom), 9.69 (s, 1H, HN). Anal. Calcul. for
C18H17N3O2: C, 70,34; H, 5,58; N, 13,67. Found: C, 70,51; H, 5,35; N,
13,36. m/z 308.2 [M + H]+.
2.3.7. 4-Benzamido-3-methyl-5-phenyl-1H-pyrazole 5d
The title compound was synthesized from benzoic acid 4a and
4-amino-3-methyl-5-phenyl-1H-pyrazole 3a as starting material,
and according to the same procedure than that described for 5a.
Yield: 75%. 1H RMN (CDCl3, 400 MHz): d = 2.26 (s, 3H, CH3), 7.34–
7.51 (m, 6H, Harom), 7.61 (d, J = 8.2 Hz, 2H, Harom), 7.71 (d, J = 7.5 Hz,
1H, Harom), 7.83 (d, J = 8.2 Hz, 1H, Harom). Anal. Calcul. for
C17H15N3O1/2H2O: C, 71.31; H, 5.63; N, 14.68. Found: C, 72.07;
H, 5.33; N, 14.53. m/z 278.1 [M + H]+.
2.3.8. 3,5-Diphenyl-1H-pyrazolo[4,3-c]isoquinoline 6a
4-Benzamido-3,5-diphenyl-1H-pyrazole 5a (0.36 mmol) and
phosphorus pentoxyde (3.60 mmol) were suspended in dry
chlorobenzene (10 mL) and N,N-diethylaniline (0.36 mmol). Under
argon atmosphere, the mixture was warmed up to 120 8C and
phosphorus oxychloride (0.54 mmol) was added dropwise. The
temperature was maintained for 24 h. At the end, a saturated
solution of sodium bicarbonate (10 mL) was carefully added, and
the mixture was extracted by dichloromethane (3  20 mL). The
organic layerswere combined, dried onmagnesium sulfate and the
solvent was evaporated under reduced pressure. The crude
product was purified by preparative HPLC (C18 column and
isocratic mobile phase MeCN: AcOH 0.1% 50:50) to give the title
compound 6a. Yield: 2%. m/z 340.2 [M + H]+, 362.2 [M + Na]+. 1H
RMN (CDCl3, 400 MHz): d = 7.35 (t, J = 7.5, 1H, Harom), 7.46–7.71
(m, 9H, Harom), 7.97 (t, J = 8.2 Hz, 1H, Harom), 8.04 (d, J = 7.5 Hz, 1H,
Harom), 8.51 (d, J = Hz, 2H, Harom). Rt1 = 3.35 min; Rt2 = 7.49 minm/z
352.2 [M + H]+.
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2.3.9. 5-(3-Methoxyphenyl)-3-phenyl-1H-pyrazolo[4,3-
c]isoquinoline 6b
The title compound was synthesized from 4-(3-methoxyben-
zamido)-3,5-diphenyl-1H-pyrazole 5b as starting material and
according to the procedure described for compound 6a. Yield: 7%.
1H RMN (CDCl3, 400 MHz): d = 3.81(s, 3H, OCH3), 7.11 (dd,
J1 = 2.2 Hz, J2 = 8.1 Hz, 1H, Harom), 7.20–7.24 (m, 1H, Harom), 7.21
(d, J1 = 2.2 Hz, 1H, Harom), 7.35 (t, J = 7.3 Hz, 1H, Harom), 7.46–7.50
(m, 3H, Harom), 7.70 (t, J = 7.7 Hz, 1H, Harom), 7.95 (t, J = 7.7 Hz, 1H,
Harom) 8.06 (d, J = 8.4 Hz, 1H, Harom), 8.52–8.50 (m, 3H, Harom).
Rt1 = 3.30 min; Rt2 = 7.38 min m/z 352.2 [M + H]
+.
2.3.10. 5-(3-Methoxyphenyl)-3-methyl-1H-pyrazolo[4,3-
c]isoquinoline 6c
The title compound was obtained from 4-(3-methoxybenza-
mido)-3-methyl-5-phenyl-1H-pyrazole 5c as startingmaterial and
according to the procedure described for compound 6a. Yield: 6%.
1HRMN (CDCl3, 400 MHz): d = 2.76 (s, 3H, CH3), 3.87 (s, 3H, OCH3),
7.03 (d, J = 10.8 Hz, 1H, Harom), 7.21–7.28 (m, 2H, Harom), 7.44 (t,
J = 12.1 Hz, 1H, Harom), 7.59 (t, J = 10.8 Hz, 1H, Harom), 7.81 (t,
J = 10.8 Hz, 1H, Harom), 8.13 (d, J = 12.1 Hz, 1H, Harom), 8.22 (d,
J = 12.1 Hz, 1H, Harom). Rt1 = 2.78 min; Rt2 = 6.15 min. m/z 289.3
[M + H]+.
2.3.11. 3-Methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline 6d
The title compound was synthesized from 4-benzamido-3-
methyl-5-phenyl-1H-pyrazole 5d as starting material and accord-
ing to the procedure described for compound 6a. Yield: 13%. 1H
RMN (CDCl3, 400 MHz): d = 2.76 (s, 3H, CH3), 7.51–7.60 (m, 4H,
Harom), 7.68 (d, J = 7.5 Hz, 2H, Harom), 7.78 (t, J = 7.5 Hz, 1H, Harom),
8.10 (d, J = 8.5 Hz, 1H, Harom), 8.22 (d, J = 7.5 Hz, 1H, Harom).
Rt1 = 2.78 min; Rt2 = 6.15 min. m/z 260.1 [M + H]
+.
2.4. NIK enzymatic assay
This experiment was performed by ProQinase using 33PanQi-
nase1 technology [31]. Inhibitory potency of staurosporine and
molecules 6a–d were evaluated on human recombinant NIK.
DMSO was used as cosolvent and its final concentration was 1%.
NIK was expressed in Sf9 insect cells as human recombinant GST-
fusion protein. The kinase was purified by affinity chromatography
using GSH-agarose. The purity of the kinase was checked by SDS-
PAGE/silver staining and the identity was verified by mass
spectroscopy. The NIK activity was measured as the incorporation
on an artificial substrate of 33P produced by hydrolysis of [g-33P]-
ATP. The substrate (RBER-CHKtide) was an artificial fusion protein
expressed in Escherichia coli. It was consisting of a N-terminal GST-
tag separated by a thrombin cleavage site from a fragment of the
human retinoblastoma protein RB1, amino acids S773–K928
followed by 11 Arg residues (ER) and a peptide sequence
KKKVRSGLYRSPSMPENLNRPR (CHKtide).
2.5. Alternative pathway assay
Human LTbR-positive HeLa cells have been used to evaluate the
NIK inhibitory potency expressed as the inhibition of the
processing of p100 into p52. Briefly, HeLa cells were cultured in
DMEM with 10% FBS and plated in 6 well plates until they reach
80% of confluence. The cells were washed twice with PBS and
incubated for 2 h with Opimem-1 containing 10, 20 or 50 mM of
inhibitors. DMSO was used as cosolvent at a maximal concentra-
tion of 0.5% (v/v). At this concentration, DMSO has no effect. Then,
an antibody acting as agonist of human LTbR (R&D Systems, Inc.)
was added for 5 h. Afterwards, the cells were washed twice with
PBS and lysed in SDS 0.5% containing a cocktail of protease and
phosphatase inhibitors (Complete and PhosStop, Roche). Protein
extracts were quantified (Micro BCA protein kit assay, Pierce) and
equal amounts of protein (15mg) were loaded on SDS-PAGE for
analyzing the processing of p100 into p52. For detecting p100 and
p52, an antibody anti-human p52 (Upstate Cell Signaling 05-361)
was used and a goat anti-mouse HRP (DAKO) was used as
secondary antibody prior to measurement of the signal by
chemiluminescence using the ECL kit from Pierce.
2.6. Multikinase assay
KinaseProfilerTM is a millipore technology using standard
protocole.
2.7. TAK1 enzymatic assay
This experiment was performed by Invitrogen using LanthaSc-
reen1 Kinase Binding Assay technology [32]. The test compounds
were screened in 1% DMSO as final concentration. 3-fold serial
dilutions were conducted from the starting concentration. All
kinase/antibody mixtures were diluted to a 2 working concen-
tration in the appropriate kinase buffer. The 4 AlexaFluor1
labeled tracer was prepared in kinase buffer and the read out was
on fluorescence plate reader.
2.8. Classical pathway assay
HeLa cells were cultured in DMEMwith 10% FBS and plated in 6
well plates until they reach 80% of confluence. The cells were
washed twice with PBS and incubated for 2 h with Opimem-1
containing 50 mM of inhibitor or DMSO alone. Then, TNF-a (Pepro
Tech Inc.) was added at 100 U/mL for 0, 1 or 2 h. Total RNA samples
were isolated with the Tripure reagent (Roche Molecular
Biochemicals). One microgram of RNA was submitted to reverse
transcription using M-MLV reverse transcriptase and random
primers (Invitrogen) in a total volume of 20 mL. Two microliters of
cDNA were submitted to real-time PCR using TaqMan 7000 SDS
(Applied Biosystems) and SYBR Green detection (Eurogentec). The
results were normalized with the 18S transcript. PCR was
performed with the following primers for the following human
transcript: il-6: FW 50-CCAGGAGCCCAGCTATGAAC-30 and RV 50-
CCCAGGGAGAAGGCAACTG-30, TNFa: FW 50-GGAGAAGGGTGACC-
GACTCA-30 and RV 50-TGCCCAGACTCGGCAAAG-30 and 18S: FW 50-
AACTTTCGATGGTAGTCGCCG-30 and RV 50-CCTTGGATGTGG-
TAGCCGTTT-30.
3. Results
3.1. Building of a 3D-model of NIK
Since no experimentally-derived structural data for NIK were
reported to date, a molecular model of this enzyme was first
developed using comparative modeling. This technique comprises
four main steps: (i) identification of a template, i.e. a protein of
known 3D-structure that shares sequence homology with the
target protein, (ii) alignment of the sequences of the target and
template, (iii) building and optimization of the 3D-model and
finally, (iv) quality assessment of the resulting structure. Following
a BLASTP alignment, we identified the protein PAK1 (p21 activated
kinase 1; PDB code: 1YHW_A) [20] as the best template. This
protein shares 30% sequence identity and up to 48% sequence
homology (similar residues) with NIK. As the target/template
alignment step is known to be critical to the quality of the models,
we used the automated homology program ESyPred3D [16]. This
performs a consensus alignment between the sequences of the
target, the template and other homologous proteins with the help
of several different alignment algorithms and then usesMODELLER
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[21] to generate the 3D-coordinates. The overall quality of the
resulting models was finally evaluated using different methods.
Ramachandran plots (available as Supporting Information) proved
to be very satisfactory with 90.2% residues located in the most
favored regions, 7.3% in the allowed regions, only four residues
(1.6%) in the generously allowed regions (Phi and Psi torsion angles
slightly larger than usual) and two residues in the disallowed
regions (unfavorable Phi and Psi torsion angles). It should be noted
that these six residues (Q484, T401, Y391, E395, D544 and S572)
are located far from the active site and the hinge region.
A superimposition of NIK with PAK1 (Fig. 3) shows that the
overall folding pattern (b-sheets, helices and main loops) is well
preserved. The ATP-binding site region is also highly preserved.
First, active site residues common to all serine–threonine kinases
were identified. In the NIK structure, M469, which corresponds to
M344 in PAK1, was identified as the gatekeeper (gk) residue. It is
one of the essential residues in the ATP-binding site. Indeed, the
nature of the gatekeeper (size and volume of the side-chain) is
variable from one kinase to another, thus dictating the access to a
specific pocket of the ATP-binding site (specificity pocket). Then,
residues E470 (gk + 1) and L472 (gk + 3) which correspond to
residues E345 and L347 in PAK1, were respectively identified in the
hinge region [22]. These two residues are responsible for the
stabilization of the adenine moiety of ATP. In the co-crystal
structure of the complex between PAK1 and 3-OH-staurosporine
(PDB code 2HY8), both residues are involved in the stabilization of
the aromatic ring of 3-OH-staurosporine. Finally, in the back of the
active site cavity, a salt bridge between residues K429 and E440
corresponding to the salt bridge between R299 and E315 in PAK1 is
also highly preserved.
The catalytic pocket of NIK was refined by minimization to take
into account the protein flexibility. The position of the side-chains
of the residues located 20 A˚ around L472wereminimized bymean
of the MINIMIZE module as implemented in SYBYL 8.0 [18].
To appraise the reliability of our model, the binding of the
previously reported pyrazolo[4,3-c]isoquinolines was studied
within the modeled active site. Staurosporine, which is known
as a pankinase inhibitor including NIK [24] was also studied in our
model. At a structural point of view, staurosporine is far from the
template of the synthesized pyrazolo[4,3-c]isoquinolines.
3.2. Docking of pyrazolo[4,3-c]isoquinolines into the 3D-model of NIK
The pyrazolo[4,3-c]isoquinolines 6a–s (Table 1) and stauros-
porine were docked inside the ATP-binding site of NIK using the
automated GOLD program [25]. For each molecule, 20 conforma-
tions were generated and further evaluated following two
parameters: (i) the number of different orientations adopted by
one molecule inside the NIK binding cleft and (ii) the number of
different orientations where the compound is found to be
stabilized with at least one H-bond with the residue L472 in the
hinge region.
Interestingly, staurosporine fits perfectly the catalytic pocket,
adopting a similar binding orientation as observed for 3-OH-
staurosporine in PAK1 (Fig. 3). All of the 20 conformations
generated lie in the same orientation with two H-bonds between
the lactam ring of staurosporine and the NH and CO moieties of
L472 and E470, respectively, stabilizing the moiety (Fig. 4a and b).
In addition, hydrophobic interactions with aliphatic residues L406,
V414, A427, L522 and C533 (not shown here for clarity) also
contribute to the stabilization on both sides of the aromatic plane.
Conversely,when pyrazolo[4,3-c]isoquinolines 6a–s are docked
inside the ATP-binding site of NIK, several different orientations
(2–6) were observed for each compound (Table 1), except for 6f
and 6r for which a unique binding orientation of the pyrazolo[4,3-
c]isoquinoline motif was found. But these two compounds did not
interact with L472 through an H-bound as requested. In addition,
in some cases, the inhibitor is not stabilized through H-bond
interaction(s) with the hinge region residue L472. This interaction
was however shown to be critical for kinase inhibition [22]. To see
if an unique orientation could be highlighted, compounds 6a–s
were docked again inside the NIK binding cleft imposing a H-bond
between the NH of L472 and one acceptor atom of the ligand. By
doing so, two orientations (orientation 1 and orientation 2) were
found as illustrated in Fig. 4 using compound 6d as an example
(Fig. 4c and d for orientation 1, and Fig. 4e and f for orientation 2).
Although in both orientations the pyrazolo[4,3-c]isoquinoline
scaffold is well stabilized by two H-bonds in the hinge region (as
expected following a constraint docking), none of these two
orientations seemsmore plausible than the other or would allow a
better understanding of the structure–activity relationships in this
series. Thus, this docking study does not allow to highlight an
unique, obvious orientation of compounds 6a–s into the NIK
binding cavity.
Based on these observations, different hypothesis could be
suggested: (i) although staurosporine, a true NIK inhibitor
(discussed later), fits perfectly its active site, the 3D-model of
NIK is not reliable, (ii) the pyrazolo[4,3-c]isoquinolines 6a–s are
effectively NIK inhibitors but through a different mechanism of
inhibition, for instance through interaction with an allosteric site
or (iii) the pyrazolo[4,3-c]isoquinolines are devoid of NIK
inhibitory potency. To assess this assumption, some representative
pyrazolo[4,3-c]isoquinolines (6a–d) were synthesized and their
NIK inhibitory potency evaluated on isolated human recombinant
Fig. 3. (a) Superimposition of PAK1 (cyan) with 3-OH-staurosporine (yellow) and NIK (blue) and (b) view of NIK with main active site residues in cyan. Pictures made using
PYMOL [23].
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Table 1
Structure and docking results for the pyrazolo[4,3-c]isoquinolines 6a–s.
Cmpd R1 R2 R3 R4 R5 Docking
Number of
different
orientations
Number of different
orientations with
H-bond with L472
Staurosporine 1 1
6a H H H 4 1
6b
H H H 6 2
6c Me H H H 2 0
6d Me H H H 2 0
6e Me H H H 3 0
6f Me H H Me 1 0
6g CF3 H H H 2 0
6h Me H H Me 2 1
6i Me H COOMe H 4 2
6j Me H COOMe H 3 2
6k Me H H Me 3 0
6l Me H NMe2 H 2 0
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enzyme as well as on HeLa cells where the NF-kB alternative
pathway was induced.
3.3. Chemistry
The pyrazolo[4,3-c]isoquinolines 6a–dwere synthesized in four
steps (Scheme 1). Starting from the commercially available
diketones 1a–b, oximes 2a–b were prepared with a high yield
by reaction of sodium nitrite in acidic conditions [26]. The oximes
2a–b further reactedwith hydrazine hydrate to formpyrazoles 3a–
b [26,27]. Then, benzoic acids 4a–b activated by HOBT/DEC were
condensed on pyrazoles 3a–b to form the corresponding amides
5a–d. Finally, the desired pyrazolo[4,3-c]isoquinolines 6a–d
(Table 1) were obtained according to the Pictet-Gams reaction
in poor yields due to the formation of several side products during
the reaction (Scheme 1) [28].
3.4. Biological evaluation
The NIK inhibitory potency of the prepared pyrazolo[4,3-
c]isoquinolines (6a–d) was evaluated in two enzymatic systems (i)
isolated human recombinant NIK and (ii) culturedHeLa cellswhere
the alternative NF-kB pathway was induced by an LTbR agonist
antibody.
3.4.1. Human recombinant NIK inhibition
A radiometric protein kinase assay was used to measure the
residual activity of NIK in presence of the synthesized inhibitors at
a single concentration of 10 mM. Briefly, NIK was expressed in Sf9
insect cells as human recombinant GST-fusion protein and purified
by affinity chromatography using GSH-agarose. The substrate, a
recombinant protein kinase (RBER-CHKtide) was also expressed in
E.coli. The assay cocktails were incubated at 30 8C for 60 min with
[g-33P]-ATP (1mM, pH 7.5). Incorporation of 33P was measured
with a microplate scintillation counter. Staurosporine was chosen
as Ref. [24].
Although the inhibition of NIK in the presence of staurosporine
was >70%, none of the pyrazoloisoquinolines 6a–d significantly
reduced NIK activity at 10 mM (Table 2). This corroborates the
modeling study and demonstrates that the pyrazolo[4,3-c]iso-
quinolines 6a–d are not NIK inhibitors.
To confirm that thesemolecules could not inhibit other proteins
of the NF-kB alternative pathway, their inhibition property was
then investigated in a cellular assaywhere the alternative pathway
is solely involved.
3.4.2. NF-kB alternative pathway inhibition
Briefly, pyrazolo[4,3-c]isoquinolines 6a–d were assayed using
carcinoma HeLa cells expressing LTbR. The NF-kB alternative
pathway was induced or not by an LTbR agonist antibody. After
induction, NIK was overexpressed and the processing of p100 into
p52 was triggered by phosphorylation of IKKa (Fig. 1). The p100/
p52 ratio was finally analysed by Western blot. DMSO, used as
cosolvent, has no effect. The results are reported on Fig. 5.
Staurosporine which strongly inhibit isolated human recombi-
nant NIK also blocks this pathway (Fig. 5). Here again, none of the
pyrazolo[4,3-c]isoquinolines 6a–d inhibited the NF-kB alternative
pathway. In fact, the processing of p100 into p52 was observed in
Table 1 (Continued )
Cmpd R1 R2 R3 R4 R5 Docking
Number of
different
orientations
Number of different
orientations with
H-bond with L472
6m Me CF3 H H 2 1
6n Me CF3 H H 4 2
6o Me H H H 4 1
6p Me H NMe2 H 3 2
6q Me H H H 4 1
6r Me H H H 1 0
6s Me CH2OMe H H H 5 1
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the presence (+) and in the absence (ÿ) of 6a–d whatever the
concentration of the inhibitor used (10, 20 or 50 mM). On the
contrary to the claims of the original patent, the pyrazolo[4,3-
c]isoquinolines 6a–d cannot be considered as NIK inhibitors
neither as blockers of the NF-kB alternative pathway.
3.4.3. Multikinase assay
With the aim to identify the putative target of the
pyrazolo[4,3-c]isoquinolines, a multikinase screening assay
was performed. The pyrazolo[4,3-c]isoquinoline 6d was selected
to carry out this study. The inhibitory properties of 6d were thus
evaluated on a panel of 263 kinases (Millipore KinaseProfilerTM)
at 10 mM.
As a result, an inhibition of at least 50% was observed for 92
kinases over the 263 kinases assayed (data not shown). Interest-
ingly, among these, 6d particularly decreased (70%) the activity of
TAK1, the TGF-b-activated kinasewhich is involved in the classical
NF-kB pathway (see Fig. 1).
3.4.4. TAK1 inhibition
Following this result, the TAK1 dose-inhibitory potency of
compounds 6a–d were evaluated using an Invitrogen Lanthasc-
reen1 Eu Kinase Binding Assay [32]. Briefly, this assay is based on
the detection of the binding of a ‘‘tracer’’ to a kinase by addition of a
Eu-labeled anti-tag antibody. Binding of the tracer and antibody to
a kinase results in a high degree of FRET, whereas displacement of
the tracer with a kinase inhibitor results in a loss of FRET. The
results are reported in Table 3.
As expected, staurosporine, the reference inhibitor in this assay,
strongly inhibits TAK1 with an IC50 of 0.021 mM. From the four
compounds analysed, only two, 6c and 6d, effectively inhibit TAK1
with an IC50 value of 0.58 and 2.1mM, respectively, whereas no
inhibition was observed at maximum solubility for 6a and 6b.
As the 3D-coordinates of TAK1 were recently available (PDB
code 2EVA), [19] the molecular interactions stabilizing 6c and 6d
inside the TAK1 cavity were analysed with a view to identify the
structural elements required for their inhibitory potency.
Fig. 4. (a) All of the 20 conformations obtained for staurosporine; (b) view of staurosporine in the active site cavity of NIK illustrated with the Connolly surface; (c and d) view
of 6d in the orientation 1 and (e and f) view of 6d in the orientation 2 inside the NIK binding cleft. Pictures made using PYMOL [23].
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Scheme 1. Synthesis of pyrazolo[4,3-c]isoquinolines.
Table 2
Inhibition of NIK in presence of pyrazolo[4,3-c]isoquinolines 6a–d at 10mM. Results
are mean of 3 experiments.
Cmpd NIK inhibition
Staurosporine 72%
6a 6%
6b 0%
6c 18%
6d 2%
Fig. 5. Processing of p100 into p52 from HeLa cells expressing LTbR stimulated by an LTbR agonist antibody (AGO). Cells were incubated in absence or in presence of
pyrazolo[4,3-c]isoquinolines 6a–d or with staurosporine. DMSO has no effect.
Table 3
IC50 of pyrazolo[4,3-c]isoquinolines 6a–d against TAK1 (N.I =no inhibition at
maximum solubility).
Cmpd TAK1 IC50 (mM)
Staurosporine 0.021
6a N.I.
6b N.I.
6c 0.58
6d 2.1
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When 6c or 6d are docked inside the TAK1 binding cleft, all of
the 20 conformations adopt the same orientation with the
pyrazolo[4,3-c]isoquinoline deeply inserted in the cavity and the
R1-methyl (see Fig. 1) pointing towards the entrance of the active
site (Fig. 6a). Both compounds are stabilized by (i) two H-bonds
with residues E105 and A107 in the hinge region and (ii)
hydrophobic interactions with residues V50, A61 and L163
(Fig. 6a and b). Indeed, 6c and 6d fits perfectly the TAK1 ATP-
binding site.
Interestingly, the inactivity of compounds 6a and 6b might be
explained by a steric clash between the phenyl group in position R1
of the pyrazolo[4,3-c]isoquinoline ring and the residue Y106 of
TAK1 (Fig. 6c).
This study thus suggest that pyrazolo[4,3-c]isoquinoline are
TAK1 inhibitors, at least when they are substituted in position R1
by a methyl group (6c–s). When this methyl is replaced by bulkier
group such as a phenyl (6a–b), the steric hindrance certainly
prevents the compounds to bind TAK1.
3.4.5. NF-kB classical pathway inhibition
Briefly,6c (50mM), thebestTAK1 inhibitor (IC50 = 0.58mM),was
assayed using carcinoma HeLa cells stimulated by TNFa. The NF-kB
classical pathwaywas induced by TNFa (100 U/mL), then the levels
of TNFa and IL-6 mRNA-levels were quantified in presence or in
absence of 6c. As expected (Fig. 7), TNFa doubles the relative TNFa
mRNA-level 1 h (2.2-fold) and 2 h (1.9-fold) following induction,
whereas the induction in presence of 6c is only 0.77-fold and 0.65-
fold respectively. TNFa strongly increases the relative IL-6 mRNA-
level 1 h (3.7-fold) and 2 h (3.8-fold) after TNFa-induction. On the
contrary, the addition of 6c prevents an increase of the normalized
IL-6 mRNA-levels which are 0.5-fold and 0.7-fold when measured
1 h and 2 h after induction respectively.
4. Discussion and conclusions
The initial goal of this work was to build a 3D-model of NIK to
studya seriesofknownpyrazolo[4,3-c]isoquinolines, claimedasNIK
inhibitors, [13] with a view to elucidate the required structural
elements for NIK inhibition. In the absence of any experimental
structural data on this enzyme,we built a 3D-model of NIK by using
comparative modeling techniques. The binding of known pyra-
zolo[4,3-c]isoquinolineswas directly analysed in the putative active
site. Surprisingly, this study revealed a poor binding orientation of
the template inside the ATP-binding pocket of NIK. This suggested
either a poor inhibitory potency or an alternative mechanism of
inhibition. Based on the modeling results, we synthesized some
pyrazolo[4,3-c]isoquinolines and characterized their inhibitory
activity in two tests involving NIK: (i) an isolated enzyme assay
using human recombinant NIK and (ii) a cellular assay where the
alternative NF-kB pathway only was involved. As a result, all
synthesized molecules were completely deprived of any significant
inhibition on both systems. On the contrary to the original patent,
this confirmed these compounds were neither inhibitor of NIK nor
even of the alternative NF-kB activation pathway. To elucidate the
potential target of these pyrazolo[4,3-c]isoquinolines, in modulat-
ing the NF-kB pathway, a multikinase screen was performed using
6d as example. This screening revealed interesting inhibition
properties of 6d for TAK1, a kinase which is involved in the classical
NF-kB activation pathway. This was further confirmed by determi-
nation of the inhibition (IC50) of 6a–d vs. TAK1. By preventing the
increase of the TNFa and IL-6 mRNA-levels induced by TNFa, the
best TAK1 inhibitor6c (IC50 = 0.58mM)confirmed its ability toblock
the classical NF-kB pathway.
Indeed, in the original patent, [13] the NIK inhibitory
potency claimed by Flohr was based on the ability of
Fig. 6.Molecular interactions between (a) 6dwith stick representation, (b) 6d and (c) 6awith sphere representation in the hinge region of TAK1. Pictures made using PYMOL
[23].
Fig. 7. Normalized TNFa and IL-6 mRNA-levels induced by TNFa (100 U/mL) in absence or in presence of TAK1 inhibitor 6c (50mM). Measurements were conducted 1 h and
2 h following TNFa addition. TNFa and IL-6 mRNA-levels prior to TNFa addition (CTRL) are considered as 1. Mean  s.d.
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pyrazolo[4,3-c]isoquinolines to prevent TNFa and IL-6 release
from human peripheral blood lymphocytes after stimulation by
LPS or IL1b. On the contrary, the present study demonstrated that
pyrazolo[4,3-c]isoquinolines are not NIK inhibitors but are likely
modulators of the classical NF-kB pathway through TAK1
inhibition. These results are of particular importance as they
allow to re-assess the mechanism of inhibition in this series.
Moreover it should be noted that recent results from Tang et al.
showed that conditional deletion of TAK1 in knockout mice led to
multiple organ defects during development and to death after 8–
10 days [29,30]. This suggests that inhibition of TAK1 is certainly
not advantageous.
Finally, this study led to a reliable 3D-model of NIK that could
be used to search for novel inhibitors of this enzyme.
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